{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_0", "document_index": 23, "latency_s": 2.0395601999916835, "prompt_toks": 51652, "completion_toks": 57}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    Codeine\n\nPubChem CID\n\n5284371\n\nStructure\n\nCodeine_small.png\n\nCodeine_3D_Structure.png\n\nCodeine__Crystal_Structure.png\n\nChemical Safety\n\nCorrosive\n\nIrritant\n\nHealth Hazard\n\nLaboratory Chemical Safety Summary (LCSS) Datasheet\n\nMolecular Formula\n\nC18H21NO3\n\nSynonyms\n\ncodeine\n\nMethylmorphine\n\nCodeine anhydrous\n\nCodicept\n\nCoducept\n\nMolecular Weight\n\n299.4 g/mol\n\nComputed by PubChem 2.2 (PubChem release 2024.11.20)\n\nDates\n\nCreate:\n\n2004-09-16\n\nModify:\n\n2025-04-19\n\nDescription\n\nCodeine appears as colorless to white crystalline solid or white powder. Sublimes at 284 °F. Odorless. Bitter taste. pH (saturated aqueous solution) 9.8. (NTP, 1992)\n\nNational Toxicology Program, Institute of Environmental Health Sciences, National Institutes of Health (NTP). 1992. National Toxicology Program Chemical Repository Database. Research Triangle Park, North Carolina.\n\n\n                    Context: \n                    This excerpt provides essential chemical data on codeine, including its CID, molecular formula, weight, safety classifications, physical appearance, and origin of the description, aligning with the comprehensive chemical, safety, and identification information section of the full PubChem compound profile for effective search and retrieval.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_1", "document_index": 23, "latency_s": 1.6224714999989374, "prompt_toks": 51671, "completion_toks": 72}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    Codeine is a morphinane alkaloid found in the opium poppy, Papaver somniferum var. album; has analgesic, anti-tussive and anti-diarrhoeal properties. It has a role as an opioid analgesic, an antitussive, an opioid receptor agonist, a prodrug, a xenobiotic, an environmental contaminant and a drug allergen. It is an organic heteropentacyclic compound and a morphinane alkaloid. It is functionally related to a morphine. It is a conjugate base of a codeine(1+).\n\nCodeine is a DEA Schedule II controlled substance. Substances in the DEA Schedule II have a high potential for abuse which may lead to severe psychological or physical dependence.\n\nContents\n\n1 Structures\n\n1.1 2D Structure\n\nChemical Structure Depiction\n\nCodeine.png\n\n1.2 3D Conformer\n\n1.3 Crystal Structures\n\n1 of 3\n\nView All\n\nCCDC Number\n\n643258\n\nAssociated Article\n\nDOI:10.1021/jp0709252\n\nCrystal Structure Data\n\nDOI:10.5517/ccplc8w\n\nCrystal Structure Depiction\n\nCrystal Structure Depiction\n\n2 Names and Identifiers\n\n\n                    Context: \n                    This segment provides chemical classification, regulatory status, and structure-related identifiers for codeine, highlighting its role as a morphinane alkaloid in opium poppy, with properties of a controlled substance (DEA Schedule II). It includes structural data references, such as CCDC number and DOI links, situating detailed chemical identifiers within the comprehensive PubChem framework.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_2", "document_index": 23, "latency_s": 1.9600725999916904, "prompt_toks": 51896, "completion_toks": 83}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    CCDC Number\n\n643258\n\nAssociated Article\n\nDOI:10.1021/jp0709252\n\nCrystal Structure Data\n\nDOI:10.5517/ccplc8w\n\nCrystal Structure Depiction\n\nCrystal Structure Depiction\n\n2 Names and Identifiers\n\n2.1 Computed Descriptors\n\n2.1.1 IUPAC Name\n\n(4R,4aR,7S,7aR,12bS)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-ol\n\nComputed by Lexichem TK 2.7.0 (PubChem release 2024.11.20)\n\n2.1.2 InChI\n\nInChI=1S/C18H21NO3/c1-19-8-7-18-11-4-5-13(20)17(18)22-16-14(21-2)6-3-10(15(16)18)9-12(11)19/h3-6,11-13,17,20H,7-9H2,1-2H3/t11-,12+,13-,17-,18-/m0/s1\n\nComputed by InChI 1.07.0 (PubChem release 2024.11.20)\n\n2.1.3 InChIKey\n\nOROGSEYTTFOCAN-DNJOTXNNSA-N\n\nComputed by InChI 1.07.0 (PubChem release 2024.11.20)\n\n2.1.4 SMILES\n\nCN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)OC)O[C@H]3[C@H](C=C4)O\n\nComputed by OEChem 2.3.0 (PubChem release 2024.12.12)\n\n2.2 Molecular Formula\n\nC18H21NO3\n\nComputed by PubChem 2.2 (PubChem release 2024.11.20)\n\n2.3 Other Identifiers\n\n2.3.1 CAS\n\n76-57-3\n\n\n                    Context: \n                    This excerpt provides detailed structural and identifier data for the compound with CCDC Number 643258, including computed descriptors such as IUPAC name, InChI, InChIKey, SMILES, molecular formula (C18H21NO3), CAS number 76-57-3, and associated article and crystal structure DOI references, offering critical information for chemical identification within the comprehensive PubChem data resource.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_3", "document_index": 23, "latency_s": 1.8825045999983558, "prompt_toks": 51849, "completion_toks": 114}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    Computed by OEChem 2.3.0 (PubChem release 2024.12.12)\n\n2.2 Molecular Formula\n\nC18H21NO3\n\nComputed by PubChem 2.2 (PubChem release 2024.11.20)\n\n2.3 Other Identifiers\n\n2.3.1 CAS\n\n76-57-3\n\n2.3.2 Related CAS\n\n41444-62-6 (PO4)\n\n2.3.3 European Community (EC) Number\n\n200-969-1\n\n2.3.4 UNII\n\nUX6OWY2V7J\n\n2.3.5 ChEBI ID\n\nCHEBI:16714\n\n2.3.6 ChEMBL ID\n\nCHEMBL485\n\n2.3.7 DEA Code Number\n\n9050 (DEA schedule II controlled substance)\n\n2.3.8 DrugBank ID\n\nDB00318\n\n2.3.9 DSSTox Substance ID\n\nDTXSID2020341\n\n2.3.10 HMDB ID\n\nHMDB0004995\n\n2.3.11 KEGG ID\n\nC06174\n\n2.3.12 Metabolomics Workbench ID\n\n42703\n\n2.3.13 NCI Thesaurus Code\n\nC383\n\nC77284\n\n2.3.14 Nikkaji Number\n\nJ4.178E\n\n2.3.15 PharmGKB ID\n\nPA449088\n\n2.3.16 Pharos Ligand ID\n\nMFTT55MXH58M\n\n2.3.17 RXCUI\n\n2670\n\n1545976\n\n2.3.18 Wikidata\n\nQ174723\n\n2.3.19 Wikipedia\n\nCodeine\n\n2.4 Synonyms\n\n2.4.1 MeSH Entry Terms\n\nArdinex\n\nCodeine\n\nCodeine Phosphate\n\nIsocodeine\n\nMorphinan-6-ol, 7,8-didehydro-4,5-epoxy-3-methoxy-17-methyl-, (5alpha,6alpha)-\n\nN Methylmorphine\n\n\n                    Context: \n                    This section compiles key computed chemical identifiers and database references for codeine, including molecular formula, various IDs (CAS, EC, UNII, ChEBI, ChEMBL, DrugBank, HMDB, KEGG, NCI Thesaurus), and synonyms such as MeSH terms and alternate names. It enhances searchability and cross-referencing within the comprehensive PubChem page on codeine, providing essential identifiers for chemical, pharmacological, and regulatory research. These details are crucial for effective retrieval of codeine's scientific data across multiple chemical databases.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_4", "document_index": 23, "latency_s": 1.7574501000053715, "prompt_toks": 51839, "completion_toks": 74}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    Codeine\n\n2.4 Synonyms\n\n2.4.1 MeSH Entry Terms\n\nArdinex\n\nCodeine\n\nCodeine Phosphate\n\nIsocodeine\n\nMorphinan-6-ol, 7,8-didehydro-4,5-epoxy-3-methoxy-17-methyl-, (5alpha,6alpha)-\n\nN Methylmorphine\n\nN-Methylmorphine\n\n2.4.2 Depositor-Supplied Synonyms\n\ncodeine\n\nMethylmorphine\n\nCodeine anhydrous\n\nCodicept\n\nCoducept\n\nl-Codeine\n\n76-57-3\n\nMorphine monomethyl ether\n\nO3-Methylmorphine\n\n(-)-Codeine\n\nMorphine 3-methyl ether\n\ncodeinum\n\nCODEINE BASE\n\nCodein\n\nMorphine-3-methyl ether\n\nNorcodine, N-methyl\n\nNorcodeine, N-methyl\n\nCodeine polistirex\n\ncodeina\n\nCCRIS 7555\n\nHSDB 3043\n\nO(3)-methylmorphine\n\nCHEBI:16714\n\nUNII-UX6OWY2V7J\n\nUX6OWY2V7J\n\nEINECS 200-969-1\n\nCodeine (CRM)\n\nCodeinum monohydricum\n\nMYTUSSIN\n\nDTXSID2020341\n\nKODELAK FITO\n\nMorphinan-6-ol, 7,8-didehydro-4,5-epoxy-3-methoxy-17-methyl-, (5alpha,6alpha)-\n\nIDS-NC-005(SECT.-2)\n\n7,8-Didehydro-4,5-epoxy-3-methoxy-17-methylmorphinan-6-ol\n\n7,8-didehydro-4,5alpha-epoxy-3-methoxy-17-methylmorphinan-6alpha-ol\n\nSS85U8K5ZN\n\nDTXCID40341\n\nCodeine Anhydrate\n\n\n                    Context: \n                    This excerpt details the synonyms and identifiers for codeine, including MeSH entry terms, depositor-supplied synonyms, chemical codes, and registry numbers such as CAS, CHEBI, UNII, and EINECS. It enhances chemical searchability and cross-referencing within the comprehensive PubChem data on codeine's chemical identifiers, alternative names, and related compounds.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_5", "document_index": 23, "latency_s": 1.5548879000125453, "prompt_toks": 51881, "completion_toks": 92}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    IDS-NC-005(SECT.-2)\n\n7,8-Didehydro-4,5-epoxy-3-methoxy-17-methylmorphinan-6-ol\n\n7,8-didehydro-4,5alpha-epoxy-3-methoxy-17-methylmorphinan-6alpha-ol\n\nSS85U8K5ZN\n\nDTXCID40341\n\nCodeine Anhydrate\n\nMorphinan-6alpha-ol, 7,8-didehydro-4,5alpha-epoxy-3-methoxy-17-methyl-\n\n(5alpha,6alpha)-7,8-Didehydro-4,5-epoxy-3-methoxy-17-methylmorphinan-6-ol\n\nDEA No. 9050\n\nLEAN\n\nMorphinan-6-alpha-ol, 7,8-didehydro-4,5-alpha-epoxy-3-methoxy-17-methyl-\n\nMorphinan-6-ol, 7,8-didehydro-4,5-epoxy-3-methoxy-17-methyl-, (5-alpha,6-alpha)-\n\nCODEINE (MART.)\n\nmetilmorfina\n\nCodeine (1.0 mg/mL in Methanol)\n\nMorphine-3-methyl ester\n\n3-methoxy-17-methyl-7,8-didehydro-4,5alpha-epoxymorphinan-6alpha-ol\n\nN Methylmorphine\n\nCHEMBL369475\n\nN-methylnorcodeine\n\nCODEINE (USP MONOGRAPH)\n\n(5alpha,6alpha)-17-methyl-3-(methyloxy)-7,8-didehydro-4,5-epoxymorphinan-6-ol\n\nUNII-Q830PW7520\n\nN-methyl norcodine\n\n(4R,4aR,7S,7aR,12bS)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-ol\n\nCodeine [INN:BAN]\n\n\n                    Context: \n                    This chunk provides multiple chemical identifiers and alternative names for a specific derivative of codeine, including its IUPAC name, structural variants, identifiers such as SS85U8K5ZN and DTXCID40341, and related compounds like N-methylnorcodeine. It is essential for precise chemical identification, classification, and database searching within the broader context of the full document on codeine's structure, properties, and related pharmacology resources.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_6", "document_index": 23, "latency_s": 1.5797186999989208, "prompt_toks": 51911, "completion_toks": 77}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    UNII-Q830PW7520\n\nN-methyl norcodine\n\n(4R,4aR,7S,7aR,12bS)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-ol\n\nCodeine [INN:BAN]\n\nCODEINE MONOHYDRATE (EP MONOGRAPH)\n\n3-o-methylmorphine monohydrate\n\nDIHYDROCODEINE HYDROGEN TARTRATE IMPURITY A (EP IMPURITY)\n\nDIHYDROCODEINE HYDROGEN TARTRATE IMPURITY A [EP IMPURITY]\n\nHYDROCODONE HYDROGEN TARTRATE 2.5-HYDRATE IMPURITY C (EP IMPURITY)\n\nHYDROCODONE HYDROGEN TARTRATE 2.5-HYDRATE IMPURITY C [EP IMPURITY]\n\n(Codeine)\n\nMorphinan-6-ol, 7,8-didehydro-4,5-epoxy-3-methoxy-17-methyl-, (5.alpha.,6.alpha.)-\n\n(1S,13R,14S,17R)-10-methoxy-4-methyl-12-oxa-4-azapentacyclo(9.6.1.0(1,13).0(5,17).0(7,18))octadeca-7(18),8,10,15-tetraen-14-ol\n\n(1S,13R,14S,17R)-10-methoxy-4-methyl-12-oxa-4-azapentacyclo[9.6.1.0(1,13).0(5,17).0(7,18)]octadeca-7(18),8,10,15-tetraen-14-ol\n\n10-methoxy-4-methyl-(1S,5R,13R,14S,17R)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraen-14-ol(Codeine)\n\n\n                    Context: \n                    This chunk provides detailed chemical identifiers, alternative names, and impurity descriptions for codeine-related compounds, including the UNII code Q830PW7520 and various chemical synonyms and impurities, situating it within the comprehensive chemical and pharmacological data presented in the full webpage. It is relevant for precise search retrieval of chemical structures, impurities, and regulatory identifiers related to codeine.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_7", "document_index": 23, "latency_s": 1.6337335999996867, "prompt_toks": 51864, "completion_toks": 72}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    10-methoxy-4-methyl-(1S,5R,13R,14S,17R)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraen-14-ol(Codeine)\n\n10-methoxy-4-methyl-(1S,5R,13R,14S,17R)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraen-14-ol[codeine]\n\nN-methyl-nordoceine\n\nNSC11427\n\n7,8-Didehydro-4,5-epoxy-3-methoxy-17-methyl-(5,6)-morphinan-6-ol\n\nNorcodeine, N-methyl-\n\nCODEINE [HSDB]\n\nCODEINE [MI]\n\nCODEINE [WHO-DD]\n\nCHEMBL485\n\nEpitope ID:120369\n\nCodeine polistirex [USAN]\n\nSCHEMBL3257\n\nGTPL1673\n\n831 - Opiates in poppy seeds\n\nCodeine 0.1 mg/ml in Methanol\n\nCodeine 1.0 mg/ml in Methanol\n\nCODEINE COMPONENT OF TUZISTRA\n\nTox21_200082\n\nTUZISTRA COMPONENT OF CODEINE\n\nBDBM50019351\n\nBDBM50105098\n\n7,8-didehydro-4,5-alpha-epoxy-3-methoxy-17-methylmorphinan-6-alpha-ol\n\nAKOS015955539\n\nDB00318\n\nCAS-76-57-3\n\nNCGC00248518-01\n\nNCGC00257636-01\n\nAC-11114\n\nDB-318946\n\nDB-318947\n\nNS00000391\n\nC-0010\n\nC06174\n\nMORPHINE SULFATE IMPURITY A [EP IMPURITY]\n\nQ174723\n\n\n                    Context: \n                    This excerpt lists alternative chemical names, identifiers, and related compounds of codeine, including its chemical structure, synonyms, and database IDs such as NSC11427 and CHEMBL485. It provides detailed chemical identifiers, impurity information, and references, situating within the full document’s comprehensive chemical, pharmacological, and database reference overview of codeine.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_8", "document_index": 23, "latency_s": 1.596250600006897, "prompt_toks": 51885, "completion_toks": 106}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    AKOS015955539\n\nDB00318\n\nCAS-76-57-3\n\nNCGC00248518-01\n\nNCGC00257636-01\n\nAC-11114\n\nDB-318946\n\nDB-318947\n\nNS00000391\n\nC-0010\n\nC06174\n\nMORPHINE SULFATE IMPURITY A [EP IMPURITY]\n\nQ174723\n\nMORPHINE HYDROCHLORIDE IMPURITY A [EP IMPURITY]\n\nCodeine, European Pharmacopoeia (EP) Reference Standard\n\nETHYLMORPHINE HYDROCHLORIDE IMPURITY C [EP IMPURITY]\n\n7,8-DIDEHYDRO-4,5-EPOXY-3-METHOXY-17-METHYL-(5 ALPHA, 6 ALPHA)-MORPHINAN 6-OL\n\nMORPHINAN-6-OL, 7,8-DIDEHYDRO-4,5-EPOXY-3-METHOXY-17-METHYL-(5 ALPHA, 6\n\nMorphinan-6-ol, 7,8-didehydro-4,5-epoxy-3-methoxy-17-methyl-, (5alpha,6alpha)- (9CI)\n\nMorphinan-6alpha-ol, 7,8-didehydro-4,5alpha-epoxy-3-methoxy-17-methyl- (8CI)\n\n(1S,5R,13R,14S,17R)-10-methoxy-4-methyl-12-oxa-4-azapentacyclo[9.6.1.0^{1,13}.0^{5,17}.0^{7,18}]octadeca-7(18),8,10,15-tetraen-14-ol\n\n(1S,5R,13R,14S,17R)-10-methoxy-4-methyl-12-oxa-4-azapentacyclo[9.6.1.0^{1,13}.0^{5,17}.0^{7,18}]octadeca-7,9,11(18),15-tetraen-14-ol\n\n\n                    Context: \n                    This section lists chemical identifiers, impurities, and related chemical names associated with codeine, including European Pharmacopoeia standards, specific impurity compounds such as morphine sulfate impurity A, ethylmorphine hydrochloride impurity C, and various morphinan derivatives. It provides detailed chemical nomenclature, registry numbers, and impurity descriptions relevant to pharmaceutical quality control and regulatory reference within the comprehensive chemical and pharmacological data on codeine. This data supports chemical verification, impurity profiling, and quality assurance documentation.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_9", "document_index": 23, "latency_s": 2.310002900005202, "prompt_toks": 51927, "completion_toks": 102}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    (1S,5R,13R,14S,17R)-10-methoxy-4-methyl-12-oxa-4-azapentacyclo[9.6.1.0^{1,13}.0^{5,17}.0^{7,18}]octadeca-7,9,11(18),15-tetraen-14-ol\n\n(5?,6?)-7,8-Didehydro-4,5-epoxy-3-methoxy-17-methylmorphinan-6-ol; (-)-Codeine; Codicept\n\n(codeine)10-methoxy-4-methyl-(1S,5R,13R,14S,17R)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraen-14-ol\n\n10-methoxy-4-methyl-(13R,14S)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10-trien-14-ol(Dihydrocodeine)\n\n10-methoxy-4-methyl-(1S,5R,13R,14S,17R)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraen-14-ol\n\n10-methoxy-4-methyl-(1S,5R,13R,14S,17R)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraen-14-ol phosphate(codeine)\n\n10-methoxy-4-methyl-(1S,5R,13R,14S,17R)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraen-14-ol(codeine (H3PO4))\n\n\n                    Context: \n                    This excerpt lists detailed chemical structure identifiers and systematic IUPAC names related to codeine and its derivatives, including stereochemistry, molecular modifications, and various chemical forms such as phosphates and H3PO4 salts, within the comprehensive chemical and pharmacological data provided in the PubChem record. It is crucial for chemical identification, structural analysis, and search optimization of codeine's stereochemistry and formulation variants in the overall database. The content aids in precise chemical search and classification of codeine and its analogs.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_10", "document_index": 23, "latency_s": 1.2038606999994954, "prompt_toks": 51773, "completion_toks": 92}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    10-methoxy-4-methyl-(1S,5R,13R,14S,17R)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraen-14-ol(codeine (H3PO4))\n\n10-methoxy-4-methyl-(1S,5R,13R,14S,17R)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraen-14-ol(codeine phosphate)\n\n200-969-1\n\n3 Chemical and Physical Properties\n\n3.1 Computed Properties\n\nProperty Name\n\nProperty Value\n\nReference\n\nProperty Name\n\nMolecular Weight\n\nProperty Value\n\n299.4 g/mol\n\nReference\n\nComputed by PubChem 2.2 (PubChem release 2024.11.20)\n\nProperty Name\n\nXLogP3\n\nProperty Value\n\n1.1\n\nReference\n\nComputed by XLogP3 3.0 (PubChem release 2024.11.20)\n\nProperty Name\n\nHydrogen Bond Donor Count\n\nProperty Value\n\nReference\n\nComputed by Cactvs 3.4.8.18 (PubChem release 2024.11.20)\n\nProperty Name\n\nHydrogen Bond Acceptor Count\n\nProperty Value\n\nReference\n\nComputed by Cactvs 3.4.8.18 (PubChem release 2024.11.20)\n\nProperty Name\n\nRotatable Bond Count\n\nProperty Value\n\nReference\n\n\n                    Context: \n                    This section provides detailed chemical identifiers and computed physical properties of codeine, including molecular weight, XLogP3, hydrogen bond donor and acceptor counts, and rotatable bonds, relevant for chemical and pharmacological characterization within the full PubChem compound profile. It situates the chemical's structure and properties in the context of its pharmacokinetics, safety, and regulatory information. Key identifiers include the chemical name, molecular formula, and the PubChem release version.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_11", "document_index": 23, "latency_s": 1.403928600004292, "prompt_toks": 51700, "completion_toks": 88}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    Property Name\n\nHydrogen Bond Acceptor Count\n\nProperty Value\n\nReference\n\nComputed by Cactvs 3.4.8.18 (PubChem release 2024.11.20)\n\nProperty Name\n\nRotatable Bond Count\n\nProperty Value\n\nReference\n\nComputed by Cactvs 3.4.8.18 (PubChem release 2024.11.20)\n\nProperty Name\n\nExact Mass\n\nProperty Value\n\n299.15214353 Da\n\nReference\n\nComputed by PubChem 2.2 (PubChem release 2024.11.20)\n\nProperty Name\n\nMonoisotopic Mass\n\nProperty Value\n\n299.15214353 Da\n\nReference\n\nComputed by PubChem 2.2 (PubChem release 2024.11.20)\n\nProperty Name\n\nTopological Polar Surface Area\n\nProperty Value\n\n41.9 Å²\n\nReference\n\nComputed by Cactvs 3.4.8.18 (PubChem release 2024.11.20)\n\nProperty Name\n\nHeavy Atom Count\n\nProperty Value\n\n22\n\nReference\n\nComputed by PubChem\n\nProperty Name\n\nFormal Charge\n\nProperty Value\n\nReference\n\nComputed by PubChem\n\nProperty Name\n\nComplexity\n\nProperty Value\n\n509\n\nReference\n\nComputed by Cactvs 3.4.8.18 (PubChem release 2024.11.20)\n\nProperty Name\n\nIsotope Atom Count\n\nProperty Value\n\nReference\n\n\n                    Context: \n                    This section provides key computed molecular properties of codeine, such as hydrogen bond acceptor count, rotatable bonds, exact and monoisotopic mass, topological polar surface area, heavy atom count, formal charge, complexity, and isotope atom count. These details are crucial for chemical identification and characterization, fitting into the overall PubChem compound profile which consolidates chemical, physical, and pharmacological data for search retrieval and research purposes.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_12", "document_index": 23, "latency_s": 1.4788666999957059, "prompt_toks": 51620, "completion_toks": 70}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    Computed by PubChem\n\nProperty Name\n\nComplexity\n\nProperty Value\n\n509\n\nReference\n\nComputed by Cactvs 3.4.8.18 (PubChem release 2024.11.20)\n\nProperty Name\n\nIsotope Atom Count\n\nProperty Value\n\nReference\n\nComputed by PubChem\n\nProperty Name\n\nDefined Atom Stereocenter Count\n\nProperty Value\n\nReference\n\nComputed by PubChem\n\nProperty Name\n\nUndefined Atom Stereocenter Count\n\nProperty Value\n\nReference\n\nComputed by PubChem\n\nProperty Name\n\nDefined Bond Stereocenter Count\n\nProperty Value\n\nReference\n\nComputed by PubChem\n\nProperty Name\n\nUndefined Bond Stereocenter Count\n\nProperty Value\n\nReference\n\nComputed by PubChem\n\nProperty Name\n\nCovalently-Bonded Unit Count\n\nProperty Value\n\nReference\n\nComputed by PubChem\n\nProperty Name\n\nCompound Is Canonicalized\n\nProperty Value\n\nYes\n\nReference\n\nComputed by PubChem (release 2021.10.14)\n\n3.2 Experimental Properties\n\n3.2.1 Physical Description\n\n\n                    Context: \n                    This section details the computed chemical properties of codeine, including complexity, stereocenter counts, bond centers, and unit count, along with experimental physical description data. It enhances the comprehensive chemical profile provided in the full PubChem webpage for research, identification, and analytical purposes. The information is relevant for chemical characterization and data validation within the overall document.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_13", "document_index": 23, "latency_s": 1.6867076000053203, "prompt_toks": 51675, "completion_toks": 83}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    Computed by PubChem\n\nProperty Name\n\nCompound Is Canonicalized\n\nProperty Value\n\nYes\n\nReference\n\nComputed by PubChem (release 2021.10.14)\n\n3.2 Experimental Properties\n\n3.2.1 Physical Description\n\nCodeine appears as colorless to white crystalline solid or white powder. Sublimes at 284 °F. Odorless. Bitter taste. pH (saturated aqueous solution) 9.8. (NTP, 1992)\n\nNational Toxicology Program, Institute of Environmental Health Sciences, National Institutes of Health (NTP). 1992. National Toxicology Program Chemical Repository Database. Research Triangle Park, North Carolina.\n\nSolid\n\n3.2.2 Color / Form\n\nOrthorhombic crystals from water, dilute alcohol, ether\n\nHaynes, W.M. (ed.). CRC Handbook of Chemistry and Physics. 95th Edition. CRC Press LLC, Boca Raton: FL 2014-2015, p. 3-126\n\nColorless or white crystals or powder\n\nLewis, R.J. Sr.; Hawley's Condensed Chemical Dictionary 15th Edition. John Wiley & Sons, Inc. New York, NY 2007., p. 318\n\n3.2.3 Boiling Point\n\n\n                    Context: \n                    This section provides the experimental physical properties of codeine, including its appearance as colorless to white crystalline solid or powder, sublimation point at 284°F, and pH of 9.8. It cites authoritative sources like NTP and chemistry handbooks, crucial for chemical identification and analysis within the comprehensive PubChem data resource. These details enhance search accuracy for physical characterization and safety information of codeine.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_14", "document_index": 23, "latency_s": 1.5666062000091188, "prompt_toks": 51686, "completion_toks": 98}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    Colorless or white crystals or powder\n\nLewis, R.J. Sr.; Hawley's Condensed Chemical Dictionary 15th Edition. John Wiley & Sons, Inc. New York, NY 2007., p. 318\n\n3.2.3 Boiling Point\n\n482 °F at 22 mmHg (sublimes) (NTP, 1992)\n\nNational Toxicology Program, Institute of Environmental Health Sciences, National Institutes of Health (NTP). 1992. National Toxicology Program Chemical Repository Database. Research Triangle Park, North Carolina.\n\n250\n\nhttp://www.chm.bris.ac.uk/webprojects2002/winder/information.htm\n\nBP: 250 °C at 22 mm Hg\n\nHaynes, W.M. (ed.). CRC Handbook of Chemistry and Physics. 95th Edition. CRC Press LLC, Boca Raton: FL 2014-2015, p. 3-126\n\n3.2.4 Melting Point\n\n309 to 313 °F (after drying at 176 °F) (NTP, 1992)\n\nNational Toxicology Program, Institute of Environmental Health Sciences, National Institutes of Health (NTP). 1992. National Toxicology Program Chemical Repository Database. Research Triangle Park, North Carolina.\n\n154-156\n\nMSDS\n\n157.5 °C\n\n\n                    Context: \n                    This chunk provides detailed physical and thermal properties of codeine, including its appearance as colorless or white crystals or powder, boiling point of 482°F at 22 mmHg, melting point of 309-313°F, and associated references from NTP and CRC Handbook. These data enhance the comprehensive chemical profile of codeine within the full document, supporting identification and analytical methods. Key details include boiling and melting points, temperature conversions, and authoritative sources crucial for laboratory and safety assessments.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_15", "document_index": 23, "latency_s": 1.3692271000036271, "prompt_toks": 51667, "completion_toks": 104}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    154-156\n\nMSDS\n\n157.5 °C\n\nHaynes, W.M. (ed.). CRC Handbook of Chemistry and Physics. 95th Edition. CRC Press LLC, Boca Raton: FL 2014-2015, p. 3-126\n\n3.2.5 Flash Point\n\n167 °F (NTP, 1992)\n\nNational Toxicology Program, Institute of Environmental Health Sciences, National Institutes of Health (NTP). 1992. National Toxicology Program Chemical Repository Database. Research Triangle Park, North Carolina.\n\n3.2.6 Solubility\n\nless than 1 mg/mL at 70 °F (NTP, 1992)\n\nNational Toxicology Program, Institute of Environmental Health Sciences, National Institutes of Health (NTP). 1992. National Toxicology Program Chemical Repository Database. Research Triangle Park, North Carolina.\n\nsoluble in water\n\nhttp://www.mhra.gov.uk/home/groups/par/documents/websiteresources/con126132.pdf\n\nHaynes, W.M. (ed.). CRC Handbook of Chemistry and Physics. 95th Edition. CRC Press LLC, Boca Raton: FL 2014-2015, p. 3-126\n\nSlightly soluble in water\n\n\n                    Context: \n                    This excerpt provides detailed physical and chemical property data for codeine, including flash point (167 °F), melting point range (154-156 °F), and solubility profile (less than 1 mg/mL at 70 °F, soluble in water, slightly soluble in water). It references authoritative sources such as the NTP database and CRC Handbook of Chemistry and Physics, supporting comprehensive chemical characterization within the full document. This information is critical for understanding codeine’s physical behavior, safety handling, and formulation considerations.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_16", "document_index": 23, "latency_s": 1.6672699000046123, "prompt_toks": 51707, "completion_toks": 84}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    Haynes, W.M. (ed.). CRC Handbook of Chemistry and Physics. 95th Edition. CRC Press LLC, Boca Raton: FL 2014-2015, p. 3-126\n\nSlightly soluble in water\n\nLewis, R.J. Sr.; Hawley's Condensed Chemical Dictionary 15th Edition. John Wiley & Sons, Inc. New York, NY 2007., p. 318\n\nSoluble in ethyl ether, benzene, chloroform, toluene; very soluble in ethanol; insoluble in petroleum ether\n\nHaynes, W.M. (ed.). CRC Handbook of Chemistry and Physics. 95th Edition. CRC Press LLC, Boca Raton: FL 2014-2015, p. 3-126\n\nSoluble in alcohol and chloroform\n\nLewis, R.J. Sr.; Hawley's Condensed Chemical Dictionary 15th Edition. John Wiley & Sons, Inc. New York, NY 2007., p. 318\n\n0.577 g/L\n\n3.2.7 Density\n\n1.32 at 68 °F (NTP, 1992) - Denser than water; will sink\n\nNational Toxicology Program, Institute of Environmental Health Sciences, National Institutes of Health (NTP). 1992. National Toxicology Program Chemical Repository Database. Research Triangle Park, North Carolina.\n\n3.2.8 LogP\n\n1.39\n\n\n                    Context: \n                    This excerpt provides detailed physical and chemical property data for codeine, including water solubility, solubility in organic solvents, density, and logP. It references established sources like the CRC Handbook of Chemistry and Physics and Hawley's Condensed Chemical Dictionary, making it essential for understanding codeine’s physicochemical characteristics within the comprehensive PubChem page on codeine’s structure, safety, and pharmacology.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_17", "document_index": 23, "latency_s": 1.1740231000003405, "prompt_toks": 51725, "completion_toks": 82}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    3.2.8 LogP\n\n1.39\n\nhttps://www.agilent.com/cs/library/applications/5990-9625EN.pdf\n\nlog Kow = 1.19\n\nAvdeef A et al; J Pharm Sci 39: 4377-81 (1996)\n\n1.19\n\nAVDEEF,A ET AL. (1996)\n\n3.2.9 LogS\n\n1.52\n\nADMET & DMPK 1(4) (2013) 48-62; doi: 10.5599/admet.1.4.24\n\n3.2.10 Stability / Shelf Life\n\nStable under recommended storage conditions. /Codeine monohydrate/\n\nSigma-Aldrich; Safety Data Sheet for Codeine monohydrate. Product Number: C5901, Version 5.3 (Revision Date 05/23/2015). Available from, as of January 29, 2016: https://www.sigmaaldrich.com/safety-center.html\n\nEffloresces slowly in dry air, affected by light.\n\nLewis, R.J. Sr.; Hawley's Condensed Chemical Dictionary 15th Edition. John Wiley & Sons, Inc. New York, NY 2007., p. 318\n\nStore codeine phosphate injection between 15 and 30 °C and protected from light. Freezing should be avoided. Do not use the injection if it is discolored or contains a precipitate. /Codeine phosphate/\n\n\n                    Context: \n                    This section provides key physical and chemical property data for codeine and its formulations, including LogP (1.39), LogS (1.52), and stability/shelf life information. It highlights the compound's lipophilicity, solubility, stability under storage conditions, and shelf life considerations, which are essential for understanding its pharmacokinetics, formulation, and handling in pharmaceutical and toxicological contexts.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_18", "document_index": 23, "latency_s": 1.8694369000004372, "prompt_toks": 51720, "completion_toks": 83}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    Trissel, L.A. Handbook on Injectable Drugs. 9th ed. Bethesda, MD. American Society of Health-System Pharmacists' Product Development. 1996., p. 293\n\n3.2.11 Optical Rotation\n\nOrthorhombic sphenoidal rods or tablets (octahedra) from water or dilute alcohol; MP, 154-156 °C (after drying at 80 °C); sublimes (when anhyd) at 140-145 °C under at 1.5 mm Hg. Melts to oily drops when heated in amount of water insufficient for complete solution, crystallizes on cooling. Specific gravity: 1.32 at 20 °C/4 °C. Specific optical rotation: -136 deg at 15 °C/D (c = 3 in alcohol); -112 deg at 15 °C/D (c = 2 in chloroform). pK at 15 °C, 6.05; pH of saturated aqueous solution 9.8. One gram dissolves in 120 mL water, 60 mL water at 80 °C, 2 mL alcohol, 1,2 mL hot alcohol, 13 mL benzene, 18 mL ether, 0.5 mL chloroform; freely soluble in amyl alcohol, methanol, dilute acids. Almost insoluble in petroleum ether or in solutions of alkali hydroxides. /Codeine monohydrate/\n\n\n                    Context: \n                    This section provides detailed physical and optical properties of codeine monohydrate, including melting point, solubility, specific gravity, and specific rotation, essential for identification and quality control. It complements the overall chemical and physical data on codeine, aiding in laboratory analysis and standardization of the compound. The specific optical rotation and solubility parameters are critical for precise characterization in pharmaceutical and forensic contexts.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_19", "document_index": 23, "latency_s": 1.2618244000041159, "prompt_toks": 51726, "completion_toks": 72}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    O'Neil, M.J. (ed.). The Merck Index - An Encyclopedia of Chemicals, Drugs, and Biologicals. Cambridge, UK: Royal Society of Chemistry, 2013., p. 439\n\nDihydrate, small needles. MP approximately 280 °C with some decomposition. Specific optical rotation: -108 deg at 22 °C/D. 1 g dissolves in 20 mL water, 1 mL boiling water, 180 mL alcohol. pH about 5. /Codeine hydrochloride/\n\nO'Neil, M.J. (ed.). The Merck Index - An Encyclopedia of Chemicals, Drugs, and Biologicals. Cambridge, UK: Royal Society of Chemistry, 2013., p. 439\n\n3.2.12 Decomposition\n\nWhen heated to decomposition it emits toxic fumes of /nitrogen oxides/.\n\nLewis, R.J. Sr. (ed) Sax's Dangerous Properties of Industrial Materials. 11th Edition. Wiley-Interscience, Wiley & Sons, Inc. Hoboken, NJ. 2004., p. 980\n\n3.2.13 Heat of Combustion\n\n2327.6 kg cal/g mole at 20 °C, 760 mm Hg (solid)\n\nWeast, R.C. (ed.) Handbook of Chemistry and Physics. 69th ed. Boca Raton, FL: CRC Press Inc., 1988-1989., p. D-275\n\n3.2.14 Dissociation Constants\n\n\n                    Context: \n                    This excerpt provides physicochemical and safety data for codeine hydrochloride, including melting point, optical rotation, solubility, decomposition, combustion heat, and dissociation constants. It is relevant for chemical identification, safety assessment, and regulatory reference within the comprehensive PubChem profile for codeine. The details support in-depth chemical property searches and toxicity evaluations.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_20", "document_index": 23, "latency_s": 1.2633997999946587, "prompt_toks": 51763, "completion_toks": 81}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    2327.6 kg cal/g mole at 20 °C, 760 mm Hg (solid)\n\nWeast, R.C. (ed.) Handbook of Chemistry and Physics. 69th ed. Boca Raton, FL: CRC Press Inc., 1988-1989., p. D-275\n\n3.2.14 Dissociation Constants\n\nBasic pKa\n\n8.2\n\nhttp://www.inchem.org/documents/pims/pharm/codeine.htm\n\npKa = 10.60 at 25 °C\n\nHaynes, W.M. (ed.). CRC Handbook of Chemistry and Physics. 95th Edition. CRC Press LLC, Boca Raton: FL 2014-2015, p. 5-103\n\n3.2.15 Collision Cross Section\n\n168.2 Å² [M+H]+ [CCS Type: TW; Method: Major Mix IMS/Tof Calibration Kit (Waters)]\n\nhttps://www.sciencedirect.com/science/article/pii/S0021967318301894\n\n169.3 Å² [M+H]+ [CCS Type: DT; Method: single field calibrated]\n\nhttps://pubs.rsc.org/en/content/articlelanding/2018/ay/c7ay02808c\n\n168.52 Å² [M+H]+\n\n173.43 Å² [M+Na]+\n\nS61 | UJICCSLIB | Collision Cross Section (CCS) Library from UJI | DOI:10.5281/zenodo.3549476\n\n3.2.16 Other Experimental Properties\n\nEffloresces slowly in dry air, affected by light. Levorotatory in acid and alcohol solutions.\n\n\n                    Context: \n                    This section provides detailed physical and chemical properties of codeine, including its combustion energy (2327.6 kcal/mol), dissociation constant (pKa about 8.2–10.6), collision cross section (~168-169 Å²), and other experimental data such as its slow efflorescence in dry air and optical activity, supporting its chemical characterization and analytical identification within the comprehensive database.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_21", "document_index": 23, "latency_s": 1.696968200005358, "prompt_toks": 51710, "completion_toks": 79}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    3.2.16 Other Experimental Properties\n\nEffloresces slowly in dry air, affected by light. Levorotatory in acid and alcohol solutions.\n\nLewis, R.J. Sr.; Hawley's Condensed Chemical Dictionary 15th Edition. John Wiley & Sons, Inc. New York, NY 2007., p. 318\n\nUV: 5-603 (Organic Electronic Spectral Data, Phillips et al, John Wiley & Sons, New York) /Codeine phosphate/\n\nLide, D.R., G.W.A. Milne (eds.). Handbook of Data on Organic Compounds. Volume I. 3rd ed. CRC Press, Inc. Boca Raton ,FL. 1994., p. V4: 3439\n\n3.3 SpringerMaterials Properties\n\nCrystal structure\n\nDensity\n\nFormula unit\n\nSpace group\n\nUnit cell\n\nUnit cell parameter\n\n3.4 Chemical Classes\n\nBiological Agents -> Plant Toxins\n\nPharmaceutical\n\n3.4.1 Drugs\n\nPharmaceuticals -> unsed in Switzerland 2014-2016\n\nS113 | SWISSPHARMA24 | 2024 Swiss Pharmaceutical List with Metabolites | DOI:10.5281/zenodo.10501043\n\nPharmaceuticals -> Listed in ZINC15\n\nS55 | ZINC15PHARMA | Pharmaceuticals from ZINC15 | DOI:10.5281/zenodo.3247749\n\n\n                    Context: \n                    This section provides additional experimental and chemical properties of codeine, including its physical behavior such as efflorescence and optical activity, spectral data, and structural information from SpringerMaterials, along with its classification as a plant toxin and pharmaceutical drug used in Switzerland and listed in ZINC15. It complements the comprehensive chemical, physical, and pharmacological data presented throughout the full PubChem compound record.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_22", "document_index": 23, "latency_s": 1.5983765999990283, "prompt_toks": 51715, "completion_toks": 77}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    Pharmaceuticals -> Listed in ZINC15\n\nS55 | ZINC15PHARMA | Pharmaceuticals from ZINC15 | DOI:10.5281/zenodo.3247749\n\nPharmaceuticals -> Illicit drugs\n\nS56 | UOATARGPHARMA | Target Pharmaceutical/Drug List from University of Athens | DOI:10.5281/zenodo.3248837\n\nPharmaceuticals -> Synthetic Cannabinoids or Psychoactive Compounds\n\nS58 | PSYCHOCANNAB | Synthetic Cannabinoids and Psychoactive Compounds | DOI:10.5281/zenodo.3247723\n\nPharmaceuticals -> Metabolite of Morphine\n\nS113 | SWISSPHARMA24 | 2024 Swiss Pharmaceutical List with Metabolites | DOI:10.5281/zenodo.10501043\n\n3.4.1.1 Human Drugs\n\nBreast Feeding; Lactation; Milk, Human; Analgesics, Opioid; Narcotics; Antitussive Agents\n\nHuman drug -> Active ingredient (CODEINE POLISTIREX)\n\nAntitussives\n\nMedicines for diarrhoea\n\nOpioid analgesics\n\n3.4.1.2 Animal Drugs\n\nPharmaceuticals -> Animal Drugs -> Approved in Taiwan\n\nS72 | NTUPHTW | Pharmaceutically Active Substances from National Taiwan University | DOI:10.5281/zenodo.3955664\n\n\n                    Context: \n                    This segment catalogs various pharmaceutical categories and related identifiers for codeine, including listings in ZINC15, illicit drugs, psychoactive compounds, and metabolites. It details human and animal drug classifications, with specific references to coded entries like CODEINE POLISTIREX and approvals in Taiwan. This information enhances the document's pharmaceutical taxonomy and facilitates targeted search and classification of codeine-related products.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_23", "document_index": 23, "latency_s": 2.0390691999928094, "prompt_toks": 51732, "completion_toks": 75}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    3.4.1.2 Animal Drugs\n\nPharmaceuticals -> Animal Drugs -> Approved in Taiwan\n\nS72 | NTUPHTW | Pharmaceutically Active Substances from National Taiwan University | DOI:10.5281/zenodo.3955664\n\n4 Spectral Information\n\n4.1 1D NMR Spectra\n\n4.1.1 13C NMR Spectra\n\n1 of 2\n\n13C NMR Spectra\n\n13C NMR: 479 (Johnson and Jankowski, Carbon-13 NMR Spectra, John Wiley & Sons, New York) /Codeine phosphate/\n\n2 of 2\n\nCopyright\n\nCopyright © 1980, 1981-2025 John Wiley & Sons, Inc. All Rights Reserved.\n\nThumbnail\n\nThumbnail\n\n4.2 Mass Spectrometry\n\n4.2.1 GC-MS\n\nSource of Spectrum\n\nMass Spectrometry Committee of the Toxicology Section of the American Academy of Forensic Sciences\n\nCopyright\n\nCopyright © 2012-2025 John Wiley & Sons, Inc. Portions provided by AAFS, Toxicology Section. All Rights Reserved.\n\nThumbnail\n\nThumbnail\n\n4.2.2 MS-MS\n\n1 of 6\n\nView All\n\nSpectra ID\n\n2226588\n\nIonization Mode\n\nPositive\n\nSPLASH\n\nsplash10-0159-0390000000-acdf6f4f8e9175ead0ee\n\nTop 5 Peaks\n\n215.1066 100\n\n243.1015 41.20\n\n\n                    Context: \n                    This excerpt provides spectral data for codeine phosphate, including 13C NMR and mass spectrometry information, as well as licensing and source citations. It is part of the broader spectral and analytical section of the document, supporting chemical identification and analytical methods for codeine-related compounds. These details are relevant for researchers conducting spectral analysis and compound verification within the comprehensive chemical database.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_24", "document_index": 23, "latency_s": 1.1546281000046292, "prompt_toks": 51811, "completion_toks": 97}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    Thumbnail\n\nThumbnail\n\n4.2.2 MS-MS\n\n1 of 6\n\nView All\n\nSpectra ID\n\n2226588\n\nIonization Mode\n\nPositive\n\nSPLASH\n\nsplash10-0159-0390000000-acdf6f4f8e9175ead0ee\n\nTop 5 Peaks\n\n215.1066 100\n\n243.1015 41.20\n\n225.0909 33.50\n\n282.1488 30.08\n\n183.0804 26.59\n\nThumbnail\n\nThumbnail\n\n2 of 6\n\nView All\n\nSpectra ID\n\n2228248\n\nIonization Mode\n\nPositive\n\nSPLASH\n\nsplash10-0udi-0359000000-aed4a6949e5a7870d902\n\nTop 5 Peaks\n\n300.1621 100\n\n301.1651 17.72\n\n215.1084 17.52\n\n243.1031 11.31\n\n199.0765 8.41\n\nThumbnail\n\nThumbnail\n\n4.2.3 LC-MS\n\n1 of 40\n\nView All\n\nAccession ID\n\nMSBNK-Athens_Univ-AU162301\n\nAuthors\n\nNikiforos Alygizakis, Reza Aalizadeh, Nikolaos Thomaidis, University of Athens\n\nInstrument\n\nBruker maXis Impact\n\nInstrument Type\n\nLC-ESI-QTOF\n\nMS Level\n\nMS2\n\nIonization Mode\n\nPOSITIVE\n\nIonization\n\nESI\n\nCollision Energy\n\n10 eV\n\nFragmentation Mode\n\nCID\n\nColumn Name\n\nAcclaim RSLC C18 2.2um, 2.1x100mm, Thermo\n\nRetention Time\n\n3.540 min\n\nPrecursor m/z\n\n300.1594\n\nPrecursor Adduct\n\n[M+H]+\n\nTop 5 Peaks\n\n300.1615 999\n\n\n                    Context: \n                    This section details mass spectrometry (MS-MS and LC-MS) spectral data for codeine, including two positive ionization spectra with SPLASH identifiers, top peaks, and associated metadata such as accession ID, authors, instrument type, ionization mode, collision energy, retention time, precursor m/z, and peak intensities. It provides critical analytical parameters and spectral fingerprints essential for chemical identification and database searches within the comprehensive document on codeine's chemical and pharmacological profile.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_25", "document_index": 23, "latency_s": 1.4110800000053132, "prompt_toks": 51781, "completion_toks": 105}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    10 eV\n\nFragmentation Mode\n\nCID\n\nColumn Name\n\nAcclaim RSLC C18 2.2um, 2.1x100mm, Thermo\n\nRetention Time\n\n3.540 min\n\nPrecursor m/z\n\n300.1594\n\nPrecursor Adduct\n\n[M+H]+\n\nTop 5 Peaks\n\n300.1615 999\n\n301.1647 192\n\n302.1669 18\n\nSPLASH\n\nsplash10-0udi-0009000000-d68b67071bf467a42afa\n\nThumbnail\n\nThumbnail\n\nLicense\n\nCC BY\n\n2 of 40\n\nView All\n\nAccession ID\n\nMSBNK-Athens_Univ-AU162302\n\nAuthors\n\nNikiforos Alygizakis, Reza Aalizadeh, Nikolaos Thomaidis, University of Athens\n\nInstrument\n\nBruker maXis Impact\n\nInstrument Type\n\nLC-ESI-QTOF\n\nMS Level\n\nMS2\n\nIonization Mode\n\nPOSITIVE\n\nIonization\n\nESI\n\nCollision Energy\n\n20 eV\n\nFragmentation Mode\n\nCID\n\nColumn Name\n\nAcclaim RSLC C18 2.2um, 2.1x100mm, Thermo\n\nRetention Time\n\n3.516 min\n\nPrecursor m/z\n\n300.1594\n\nPrecursor Adduct\n\n[M+H]+\n\nTop 5 Peaks\n\n300.1617 999\n\n301.165 187\n\n243.1026 19\n\n302.1677 15\n\n215.1076 13\n\nSPLASH\n\nsplash10-0udi-0009000000-a298cedb776a11677cf7\n\nThumbnail\n\nThumbnail\n\nLicense\n\nCC BY\n\n4.2.4 Other MS\n\nOther MS\n\n\n                    Context: \n                    This section presents detailed mass spectrometry data for a specific compound, including fragmentation mode, retention times around 3.5 minutes, precursor m/z of 300.1594, and top peaks with associated intensities. It references multiple LC-MS/MS experiments conducted with the same precursor ion, instrument, and ionization mode, providing essential analytical parameters for compound identification and comparison within the comprehensive chemical profile of codeine and related substances. This information enhances search accuracy in spectral databases and verifies compound presence in scientific studies.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_26", "document_index": 23, "latency_s": 1.1848389999940991, "prompt_toks": 51759, "completion_toks": 91}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    Top 5 Peaks\n\n300.1617 999\n\n301.165 187\n\n243.1026 19\n\n302.1677 15\n\n215.1076 13\n\nSPLASH\n\nsplash10-0udi-0009000000-a298cedb776a11677cf7\n\nThumbnail\n\nThumbnail\n\nLicense\n\nCC BY\n\n4.2.4 Other MS\n\nOther MS\n\nMASS: 4813 (National Bureau of Standards EPA-NIH Mass Spectra Data Base, NSRDS-NBS-63) /Codeine, hydrate/\n\nOther MS\n\nMASS: 14309 (NIST/EPA/MSDC Mass Spectral Database, 1990 version)\n\n4.3 UV Spectra\n\nMAX ABSORPTION (WATER): 212 NM (LOG E= 4.41); 284 NM (LOG E= 3.22) /CODEINE PHOSPHATE/\n\nWeast, R.C. (ed.). Handbook of Chemistry and Physics. 60th ed. Boca Raton, Florida: CRC Press Inc., 1979., p. C-253\n\nMAX ABSORPTION (ALCOHOL): 212 NM (LOG E= 4.4); 236 NM (LOG E= 3.7) SHOULDER; 286 NM (LOG E= 3.2)\n\nWeast, R.C. (ed.). Handbook of Chemistry and Physics. 60th ed. Boca Raton, Florida: CRC Press Inc., 1979., p. C-253\n\nUV: 5-603 (Organic Electronic Spectral Data, Phillips et al, John Wiley & Sons, New York)\n\n\n                    Context: \n                    This section provides spectroscopic data for codeine, including the top five mass spectral peaks with their intensities and SPLASH identifier, as well as UV absorption spectra in water and alcohol with corresponding wavelengths and extinction coefficients. It is relevant for analytical identification and confirmation of codeine in laboratory and forensic settings, supporting the overall comprehensive characterization of the compound. The details, such as spectral peak values and UV absorption maxima, enhance searchability for spectral analysis references.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_27", "document_index": 23, "latency_s": 1.6154237000009743, "prompt_toks": 51707, "completion_toks": 79}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    UV: 5-603 (Organic Electronic Spectral Data, Phillips et al, John Wiley & Sons, New York)\n\nLide, D.R., G.W.A. Milne (eds.). Handbook of Data on Organic Compounds. Volume I. 3rd ed. CRC Press, Inc. Boca Raton ,FL. 1994., p. V4: 3438\n\n4.4 IR Spectra\n\nIR Spectra\n\nIR: 5009 (Coblentz Society Spectral Collection) /Codeine, hydrochloride/\n\nIR Spectra\n\nIR: 5014 (Coblentz Society Spectral Collection) /Codeine, sulfate/\n\nIR Spectra\n\nIR: 1603 (Documentation of Molecular Spectroscopy Collection)\n\n4.5 Raman Spectra\n\nCopyright\n\nCopyright © 2024-2025 John Wiley & Sons, Inc. All Rights Reserved.\n\nThumbnail\n\nThumbnail\n\n4.6 Other Spectra\n\nIntense mass spectral peaks: 124 m/z, 162 m/z, 229 m/z, 299 m/z\n\nPfleger, K., H. Maurer and A. Weber. Mass Spectral and GC Data of Drugs, Poisons and their Metabolites. Parts I and II. Mass Spectra Indexes. Weinheim, Federal Republic of Germany. 1985., p. 522\n\n5 Related Records\n\n5.1 Related Compounds with Annotation\n\n\n                    Context: \n                    This section provides spectral data references for codeine, including UV absorption at 5-603 nm, IR spectra collections, Raman spectra, and significant mass spectral peaks, supporting detailed compound identification and analytical methods. It enhances the overall document's coverage of chemical characterization techniques relevant to codeine's structural and spectroscopic analysis. These data are vital for forensic, pharmacological, and analytical research applications.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_28", "document_index": 23, "latency_s": 1.624468900001375, "prompt_toks": 51662, "completion_toks": 79}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    5 Related Records\n\n5.1 Related Compounds with Annotation\n\nFollow these links to do a live 2D search or do a live 3D search for this compound, sorted by annotation score. This section is deprecated (see here for details), but these live search links provide equivalent functionality to the table that was previously shown here.\n\n5.2 Related Compounds\n\nSame Connectivity Count\n\n570\n\nSame Stereo Count\n\n11\n\nSame Isotope Count\n\n44\n\nSame Parent, Connectivity Count\n\n656\n\nSame Parent, Stereo Count\n\n56\n\nSame Parent, Isotope Count\n\n126\n\nSame Parent, Exact Count\n\n44\n\nMixtures, Components, and Neutralized Forms Count\n\n226\n\nSimilar Compounds (2D)\n\nView in PubChem Search\n\nSimilar Conformers (3D)\n\nView in PubChem Search\n\n5.3 Substances\n\n5.3.1 PubChem Reference Collection SID\n\n481107753\n\n5.3.2 Related Substances\n\nAll Count\n\n924\n\nSame Count\n\n107\n\nMixture Count\n\n817\n\n5.3.3 Substances by Category\n\n5.4 Entrez Crosslinks\n\nPubMed Count\n\n1920\n\nTaxonomy Count\n\nOMIM Count\n\n10\n\nGene Count\n\n11\n\n\n                    Context: \n                    This section details the related records and compound relationships for codeine, including counts of similar compounds, substructure matches, related substances, and crosslinks to PubMed, OMIM, and gene data. It enhances searchability and biological context by providing links to chemical matches, compound categories, and related genetic and publication resources, supporting comprehensive retrieval of codeine's chemical and biological data within the overall webpage.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_29", "document_index": 23, "latency_s": 1.9448666000098456, "prompt_toks": 51668, "completion_toks": 61}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    5.3.2 Related Substances\n\nAll Count\n\n924\n\nSame Count\n\n107\n\nMixture Count\n\n817\n\n5.3.3 Substances by Category\n\n5.4 Entrez Crosslinks\n\nPubMed Count\n\n1920\n\nTaxonomy Count\n\nOMIM Count\n\n10\n\nGene Count\n\n11\n\n5.5 Associated Chemicals\n\nCodeine acetate; 5913-71-3\n\nCodeine hydrochloride; 1422-07-7\n\nCodeine phosphate; 52-28-8\n\nCodeine sulfate; 1420-53-7\n\nFor more Associated Chemicals (Complete) data for CODEINE (15 total), please visit the HSDB record page.\n\n5.6 NCBI LinkOut\n\n6 Chemical Vendors\n\n7 Drug and Medication Information\n\n7.1 Drug Indication\n\nCodeine sulfate is a form of this drug that is commonly used. It is available in tablet form and indicated for the relief of mild to moderately severe pain, where the use of an opioid analgesic is appropriate. The solution form is used by itself or combined in a syrup with other drugs and is used as a cough suppressant in adults aged 18 and above,.\n\nFDA Label\n\n7.2 LiverTox Summary\n\n\n                    Context: \n                    This excerpt details related substances, crosslinks to NCBI and PubMed, associated chemicals, vendors, and drug indications for codeine, highlighting its uses in pain relief, formulations, and approvals. It is crucial for identifying chemical relationships, pharmacological categories, and clinical applications within the comprehensive PubChem data source.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_30", "document_index": 23, "latency_s": 1.4918044000078226, "prompt_toks": 51679, "completion_toks": 92}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    FDA Label\n\n7.2 LiverTox Summary\n\nCodeine is one of the natural plant alkaloids found in extracts of opium and is commonly used to treat mild-to-moderate pain and cough. Codeine, like other opioids, has not been linked to serum enzyme elevations during therapy or to clinically apparent liver injury.\n\n7.3 Drug Classes\n\nBreast Feeding; Lactation; Milk, Human; Analgesics, Opioid; Narcotics; Antitussive Agents\n\nOpioids\n\n7.4 Drug Transformations\n\nCodeine has known transformation products that include Morphine.\n\nS66 | EAWAGTPS | Parent-Transformation Product Pairs from Eawag | DOI:10.5281/zenodo.3754448\n\n7.5 WHO Essential Medicines\n\nDrug\n\nDrug Classes\n\nFormulation\n\nIndication\n\nDrug\n\nCodeine\n\nDrug Classes\n\nAntitussives\n\nFormulation\n\nOral - Solid: 10 mg tablet (codeine phosphate)\n\nIndication\n\nCough\n\nDrug\n\nCodeine\n\nDrug Classes\n\nMedicines for diarrhoea\n\nFormulation\n\nOral - Solid: 30 mg tablet (codeine phosphate)\n\nIndication\n\nDiarrhoea\n\nDrug\n\nCodeine\n\nDrug Classes\n\nOpioid analgesics\n\n\n                    Context: \n                    This excerpt summarizes key regulatory and pharmacological aspects of codeine, including its FDA label, safety profile, liver toxicity summary from LiverTox, and its categorization within WHO's essential medicines. It details codeine’s natural alkaloid origin, its transformation to morphine, formulation types, and clinical indications such as cough, diarrhea, and opioid analgesia, making it relevant for drug classification, safety evaluation, and therapeutic usage information within the full document.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_31", "document_index": 23, "latency_s": 1.7565451999980723, "prompt_toks": 51636, "completion_toks": 86}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    Cough\n\nDrug\n\nCodeine\n\nDrug Classes\n\nMedicines for diarrhoea\n\nFormulation\n\nOral - Solid: 30 mg tablet (codeine phosphate)\n\nIndication\n\nDiarrhoea\n\nDrug\n\nCodeine\n\nDrug Classes\n\nOpioid analgesics\n\nFormulation\n\nOral - Solid: 30 mg tablet (codeine phosphate)\n\nIndication\n\nPain\n\n7.6 FDA Approved Drugs\n\n7.7 FDA Orange Book\n\n7.8 Drug Labels\n\nHomeopathic product and label\n\n7.9 Clinical Trials\n\n7.9.1 ClinicalTrials.gov\n\n7.9.2 EU Clinical Trials Register\n\n7.10 DEA Drug and Chemical Information\n\n7.10.1 DEA Controlled Substances\n\nSubstance\n\nCodeine\n\nDEA Controlled Substances Code Number\n\n9050\n\nControlled Substances Act Schedule\n\nSchedule II - Substances in the DEA Schedule II have a high potential for abuse which may lead to severe psychological or physical dependence.\n\n7.11 Therapeutic Uses\n\nAnalgesics, Opioid; Antitussive Agents; Narcotics\n\n\n                    Context: \n                    This excerpt details the therapeutic applications, formulations, regulatory status, and drug scheduling information for codeine, highlighting its use for cough suppression and diarrhea treatment, its classification as a Schedule II opioid with high abuse potential, and its approval status in regulatory agencies like the FDA. It provides essential data for understanding codeine’s medical indications, regulatory classification, and controlled substance status within the comprehensive chemical and pharmacological profile presented in the full document.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_32", "document_index": 23, "latency_s": 1.5357890000013867, "prompt_toks": 51489, "completion_toks": 85}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    7.11 Therapeutic Uses\n\nAnalgesics, Opioid; Antitussive Agents; Narcotics\n\nNational Library of Medicine's Medical Subject Headings. Codeine. Online file (MeSH, 2016). Available from, as of August 12, 2016: https://www.nlm.nih.gov/mesh/2016/mesh_browser/MBrowser.html\n\n\n                    Context: \n                    This chunk details the therapeutic uses of codeine, listing its classifications as an opioid analgesic, antitussive agent, and narcotic, based on the MeSH database. Situated within the comprehensive full webpage, it highlights the specific medical indications and classification references that are crucial for drug information retrieval, research, and clinical application contexts. This information supports targeted searching for codeine’s medical uses and regulatory categorizations.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_33", "document_index": 23, "latency_s": 2.3400989000074333, "prompt_toks": 51584, "completion_toks": 80}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    /CLINICAL TRIALS/ ClinicalTrials.gov is a registry and results database of publicly and privately supported clinical studies of human participants conducted around the world. The Web site is maintained by the National Library of Medicine (NLM) and the National Institutes of Health (NIH). Each ClinicalTrials.gov record presents summary information about a study protocol and includes the following: Disease or condition; Intervention (for example, the medical product, behavior, or procedure being studied); Title, description, and design of the study; Requirements for participation (eligibility criteria); Locations where the study is being conducted; Contact information for the study locations; and Links to relevant information on other health Web sites, such as NLM's MedlinePlus for patient health information and PubMed for citations and abstracts for scholarly articles in the field of medicine. Codeine is included in the database.\n\n\n                    Context: \n                    This section provides an overview of ClinicalTrials.gov, a comprehensive registry of clinical studies, emphasizing its role in documenting research related to codeine. It details the database's content, such as study protocols, eligibility criteria, and research locations, highlighting its relevance for locating clinical trial data on codeine use and safety. This information is critical for researchers seeking current clinical evidence and trial outcomes involving codeine.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_34", "document_index": 23, "latency_s": 1.5354372000001604, "prompt_toks": 51528, "completion_toks": 78}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    NIH/NLM; ClinicalTrials.Gov. Available from, as of March 17, 2016: https://clinicaltrials.gov/ct2/results?term=codeine&Search=Search\n\n(VET): Codeine, or codeine with acetaminophen, is indicated for treatment of moderate pain. It also has been used as an antitussive.\n\nPapich, M.G. Saunders Handbook of Veterinary Drugs Small and Large Animal. 3rd ed. St. Louis, MO: Elsevier Saunders, 2011, p. 176\n\n\n                    Context: \n                    This chunk provides information on veterinary uses of codeine, noting its indication for moderate pain and use as an antitussive in animals. It references clinical trial data from NIH's ClinicalTrials.gov and a veterinary drug handbook, highlighting codeine's application in veterinary medicine. This content complements the overall document's comprehensive overview of codeine's pharmacology, safety, and regulatory status.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_35", "document_index": 23, "latency_s": 1.7059212000021944, "prompt_toks": 51593, "completion_toks": 84}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    CDC Guideline for Prescribing Opioids for Chronic Pain - United States, 2016; This guideline provides recommendations for primary care clinicians who are prescribing opioids for chronic pain outside of active cancer treatment, palliative care, and end-of-life care. The guideline addresses 1) when to initiate or continue opioids for chronic pain; 2) opioid selection, dosage, duration, follow-up, and discontinuation; and 3) assessing risk and addressing harms of opioid use. CDC developed the guideline using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) framework, and recommendations are made on the basis of a systematic review of the scientific evidence while considering benefits and harms, values and preferences, and resource allocation. CDC obtained input from experts, stakeholders, the public, peer reviewers, and a federally chartered advisory committee. It is important that patients receive appropriate pain treatment with careful consideration of the\n\n\n                    Context: \n                    This excerpt summarizes the CDC's 2016 guidelines for prescribing opioids for chronic pain, outlining recommendations on initiation, dosage, duration, risk assessment, and harms management for primary care clinicians. It is relevant to the overall document as it provides authoritative guidance on opioid use, complementing detailed pharmacological and safety information about codeine and related opioids. The guidelines emphasize evidence-based practices and risk mitigation strategies critical for safe opioid prescribing.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_36", "document_index": 23, "latency_s": 1.6117745999945328, "prompt_toks": 51501, "completion_toks": 67}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    experts, stakeholders, the public, peer reviewers, and a federally chartered advisory committee. It is important that patients receive appropriate pain treatment with careful consideration of the benefits and risks of treatment options. This guideline is intended to improve communication between clinicians and patients about the risks and benefits of opioid therapy for chronic pain, improve the safety and effectiveness of pain treatment, and reduce the risks associated with long-term opioid therapy, including opioid use disorder, overdose, and death.\n\n\n                    Context: \n                    This excerpt discusses the development of clinical guidelines for opioid use, emphasizing the importance of clear communication about risks and benefits to enhance safety and reduce dependency and overdose. It highlights the collaborative efforts of experts, stakeholders, and advisory committees in shaping recommendations for effective pain management within the overall document on codeine's properties, safety, and pharmacology.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_37", "document_index": 23, "latency_s": 1.5147827999899164, "prompt_toks": 51505, "completion_toks": 76}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    Dowell D et al; Morbidity and Mortality Weekly Report (MMWR) 65 (1):1-49 (2016); Available from, as of March 22, 2016: https://www.cdc.gov/mmwr/volumes/65/rr/rr6501e1.htm\n\nFor more Therapeutic Uses (Complete) data for CODEINE (11 total), please visit the HSDB record page.\n\n7.12 Drug Warnings\n\n\n                    Context: \n                    This snippet references a 2016 CDC report by Dowell et al. on opioid safety, specifically related to codeine, within the broader webpage containing comprehensive chemical, pharmacological, safety, and regulatory information about codeine. It highlights the authoritative source for drug warnings and provides a link for further details, emphasizing the importance of safety data and therapeutic information available elsewhere on the page.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_38", "document_index": 23, "latency_s": 1.3171463999897242, "prompt_toks": 51587, "completion_toks": 55}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    7.12 Drug Warnings\n\nThe U.S. Food and Drug Administration (FDA) is warning about several safety issues with the entire class of opioid pain medicines. These safety risks are potentially harmful interactions with numerous other medications, problems with the adrenal glands, and decreased sex hormone levels. We are requiring changes to the labels of all opioid drugs to warn about these risks. Opioids can interact with antidepressants and migraine medicines to cause a serious central nervous system reaction called serotonin syndrome, in which high levels of the chemical serotonin build up in the brain and cause toxicity. Taking opioids may lead to a rare, but serious condition in which the adrenal glands do not produce adequate amounts of the hormone cortisol. Cortisol helps the body respond to stress. Long-term use of opioids may be associated with decreased sex hormone levels and symptoms such as reduced interest in sex, impotence, or infertility.\n\n\n                    Context: \n                    This section outlines critical drug warnings issued by the FDA for opioids, including risks of harmful drug interactions, hormonal effects, and safety label changes. It is relevant for understanding safety considerations, adverse effects, and regulatory updates related to codeine and other opioid medications discussed throughout the document.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_39", "document_index": 23, "latency_s": 1.4309342999913497, "prompt_toks": 51609, "completion_toks": 77}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    FDA; FDA Drug Safety Communication: FDA Warns About Several Safety Issues with Opioid Pain Medicines; Requires Label Changes (March 22, 2016). Available from, as of March 22, 2016: https://www.fda.gov/Drugs/DrugSafety/ucm489676.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery\n\nIn a continuing effort to educate prescribers and patients about the potential risks related to opioid use, the U.S. Food and Drug Administration today announced required class-wide safety labeling changes for immediate-release (IR) opioid pain medications. Among the changes, the FDA is requiring a new boxed warning about the serious risks of misuse, abuse, addiction, overdose and death. Today's actions are among a number of steps the agency recently outlined in a plan to reassess its approach to opioid medications. The plan is focused on policies aimed at reversing the epidemic, while still providing patients in pain access to effective relief.\n\n\n                    Context: \n                    This excerpt details a 2016 FDA safety communication about new labeling requirements and boxed warnings for immediate-release opioid pain medicines, highlighting risks of misuse, abuse, addiction, overdose, and death. It provides critical regulatory context relevant to the comprehensive chemical and pharmacological data on codeine and other opioids within the full document. This information emphasizes ongoing safety measures and regulatory updates related to opioid medications.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_40", "document_index": 23, "latency_s": 1.6767103999882238, "prompt_toks": 51661, "completion_toks": 57}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    FDA; FDA News Release: FDA Announces Enhanced Warnings for Immediate-Release Opioid Pain Medications Related to Risks of Misuse, Abuse, Addiction, Overdose and Death (March 22, 2016). Available from, as of March 22, 2016 https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm491739.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery\n\nCodeine should be used with caution in nursing women who are known or suspected ultrarapid metabolizers of cytochrome P-450 (CYP) 2D6 substrates.\n\nAmerican Society of Health-System Pharmacists 2016; Drug Information 2016. Bethesda, MD. 2016, p. 2205\n\nChildren with obstructive sleep apnea receiving codeine for the management of postoperative pain following tonsillectomy and/or adenoidectomy, who also have evidence of ultrarapid metabolism of CYP2D6 substrates, are at increased risk of respiratory depression.\n\nAmerican Society of Health-System Pharmacists 2016; Drug Information 2016. Bethesda, MD. 2016, p. 2205\n\n\n                    Context: \n                    This excerpt summarizes key safety warnings and pharmacogenetic considerations for codeine, highlighting FDA alerts and risks in certain populations such as nursing women and children with sleep apnea, which are critical for understanding codeine's safety profile within the comprehensive chemical and pharmacological data provided in the document.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_41", "document_index": 23, "latency_s": 1.0256901999964612, "prompt_toks": 51703, "completion_toks": 61}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    American Society of Health-System Pharmacists 2016; Drug Information 2016. Bethesda, MD. 2016, p. 2205\n\nFor more Drug Warnings (Complete) data for CODEINE (12 total), please visit the HSDB record page.\n\n7.13 Reported Fatal Dose\n\nIn adults, ingestion of 7 to 14 mg/kg may cause death. Much higher doses may be tolerated by chronic users. Ingestion of more than 1 mg/kg of codeine in children is capable of producing symptoms, and doses more than 5 mg/kg have caused respiratory arrest.\n\nDart, R.C. (ed). Medical Toxicology. Third Edition, Lippincott Williams & Wilkins. Philadelphia, PA. 2004., p. 761\n\nThe lethal dose is between 500 mg and 1 g.\n\nGossel, T.A., J.D. Bricker. Principles of Clinical Toxicology. 3rd ed. New York, NY: Raven Press, Ltd., 1994., p. 298\n\nToxic codeine blood concentration: 20-50 ug/dL; Lethal codeine blood concentration: > 60 ug/dL /From table/\n\nGossel, T.A., J.D. Bricker. Principles of Clinical Toxicology. 3rd ed. New York, NY: Raven Press, Ltd., 1994., p. 298\n\n\n                    Context: \n                    This excerpt provides detailed information on the toxic and lethal doses of codeine, including adult and pediatric thresholds, fatal blood concentration ranges, and references from clinical toxicology sources. It is relevant for safety assessments, overdose management, and toxicity reference data within the comprehensive PubChem and HSDB documentation on codeine.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_42", "document_index": 23, "latency_s": 1.6710206999996444, "prompt_toks": 51478, "completion_toks": 102}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    Gossel, T.A., J.D. Bricker. Principles of Clinical Toxicology. 3rd ed. New York, NY: Raven Press, Ltd., 1994., p. 298\n\n8 Food Additives and Ingredients\n\n8.1 Associated Foods\n\n9 Pharmacology and Biochemistry\n\n9.1 Pharmacodynamics\n\n\n                    Context: \n                    This excerpt from Gossel and Bricker's Principles of Clinical Toxicology provides specific toxicological data on codeine, particularly its lethal dosage ranges, metabolic pathways, and toxic effects, complementing the broader pharmacology, safety, and toxicity information covered throughout the full PubChem document on codeine. It is relevant for understanding dose-response relationships and the mechanisms underlying codeine toxicity, essential for medical and forensic contexts. The section on food additives and associated foods indicates potential exposure sources involving food products containing codeine.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_43", "document_index": 23, "latency_s": 1.8691432000050554, "prompt_toks": 51609, "completion_toks": 99}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    **General effects** Codeine is a weak narcotic pain reliever and cough suppressant that is similar to morphine and hydrocodone. A small amount of ingested codeine is converted to morphine in the body. Codeine increases tolerance to pain, reducing existing discomfort. In addition to decreasing pain, codeine also causes sedation, drowsiness, and respiratory depression. **Antitussive activity** This drug has shown antitussive activity in clinical trials and has been effective in cough secondary to tuberculosis and insomnia due to coughing. Codeine suppresses the cough reflex through a direct effect on the cough center in the medulla. **Effects on intestinal motility** Codeine may reduce intestinal motility through both a local and possibly central mechanism of action. This may possibly lead to constipation. The chronic use of opioids, including codeine sulfate, may lead to obstructive bowel disease, particularly in patients with underlying disorders of intestinal motility. **Effects on\n\n\n                    Context: \n                    This excerpt summarizes the pharmacological effects and mechanisms of action of codeine, including its analgesic, antitussive, sedation, and gastrointestinal impact, aligned with detailed scientific data found in the full PubChem chemical profile. It highlights codeine’s conversion to morphine, its influence on the cough center, and effects on intestinal motility, providing essential information for pharmacological and toxicological reference within the comprehensive database. This information aids in drug safety, efficacy, and mechanism research.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_44", "document_index": 23, "latency_s": 2.603263099998003, "prompt_toks": 51605, "completion_toks": 83}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    to constipation. The chronic use of opioids, including codeine sulfate, may lead to obstructive bowel disease, particularly in patients with underlying disorders of intestinal motility. **Effects on the central nervous system** Codeine phosphate is an opioid analgesic with uses similar to those of morphine, but is much less potent as an analgesic. Its primary site of action is at the _mu_ opioid receptors distributed throughout the central nervous system. The sedative activities of codeine are less potent than those of morphine. Codeine may cause respiratory system depression by the activation of μ-opioid receptors at specific sites in the central nervous system. **Effects on blood pressure** This drug poses an increased risk of compromised ability to maintain blood pressure due to peripheral vasodilation and other mechanisms. **Effects on chronic cancer pain and other types of pain** Codeine is an opioid analgesic with similar indications to those of morphine, however, is much less\n\n\n                    Context: \n                    This excerpt provides detailed information on codeine's effects on the central nervous system, blood pressure, and types of pain management, complementing the broader pharmacological profile and safety data presented in the full PubChem webpage content. It highlights its mechanism as a mu-opioid receptor agonist, potency compared to morphine, and associated cardiovascular and respiratory risks, making it relevant for comprehensive drug safety and pharmacology references.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_45", "document_index": 23, "latency_s": 1.5546842999901855, "prompt_toks": 51515, "completion_toks": 78}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    vasodilation and other mechanisms. **Effects on chronic cancer pain and other types of pain** Codeine is an opioid analgesic with similar indications to those of morphine, however, is much less potent in its pain alleviating properties. Its primary action takes place at the mu opioid receptors, which are distributed throughout the central nervous system. The average duration of action is about 4 hours. Regular dosing of opioid analgesics such as codeine in patients with severe cancer pain has been well documented to improve symptoms,.\n\n\n                    Context: \n                    This excerpt discusses the pharmacological effects of codeine, highlighting its mechanisms of action at mu opioid receptors, duration of effect, and clinical use in managing chronic and cancer-related pain. It is relevant to the overall document’s detailed exploration of codeine’s pharmacodynamics, therapeutic indications, and its relative potency compared to morphine, providing key insights into its analgesic properties and clinical efficacy.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_46", "document_index": 23, "latency_s": 1.7878114999912214, "prompt_toks": 51666, "completion_toks": 109}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    9.2 MeSH Pharmacological Classification\n\nAntitussive Agents\n\nAgents that suppress cough. They act centrally on the medullary cough center. EXPECTORANTS, also used in the treatment of cough, act locally. (See all compounds classified as Antitussive Agents.)\n\nNarcotics\n\nAgents that induce NARCOSIS. Narcotics include agents that cause somnolence or induced sleep (STUPOR); natural or synthetic derivatives of OPIUM or MORPHINE or any substance that has such effects. They are potent inducers of ANALGESIA and OPIOID-RELATED DISORDERS. (See all compounds classified as Narcotics.)\n\nAnalgesics, Opioid\n\nCompounds with activity like OPIATE ALKALOIDS, acting at OPIOID RECEPTORS. Properties include induction of ANALGESIA or NARCOSIS. (See all compounds classified as Analgesics, Opioid.)\n\n9.3 FDA Pharmacological Classification\n\nFDA UNII\n\nUX6OWY2V7J\n\nActive Moiety\n\nCODEINE ANHYDROUS\n\nPharmacological Classes\n\nMechanisms of Action [MoA] - Full Opioid Agonists\n\nPharmacological Classes\n\n\n                    Context: \n                    This section provides the pharmacological classification of codeine, including its categorization as an antitussive agent that suppresses cough via central action, a narcotic inducing narcosis, and an opioid analgesic acting at opioid receptors. It also details the FDA UNII code (UX6OWY2V7J), the active moiety (codeine anhydrous), and its mechanism of action as a full opioid agonist. This information is essential for understanding codeine’s therapeutic and legal status within the overall chemical profile.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_47", "document_index": 23, "latency_s": 1.7686167000065325, "prompt_toks": 51703, "completion_toks": 93}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    9.3 FDA Pharmacological Classification\n\nFDA UNII\n\nUX6OWY2V7J\n\nActive Moiety\n\nCODEINE ANHYDROUS\n\nPharmacological Classes\n\nMechanisms of Action [MoA] - Full Opioid Agonists\n\nPharmacological Classes\n\nEstablished Pharmacologic Class [EPC] - Opioid Agonist\n\nFDA Pharmacology Summary\n\nCodeine anhydrous is an Opioid Agonist. The mechanism of action of codeine anhydrous is as a Full Opioid Agonist.\n\n9.4 ATC Code\n\nR05DA04\n\nS76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355\n\nR - Respiratory system\n\nR05 - Cough and cold preparations\n\nR05D - Cough suppressants, excl. combinations with expectorants\n\nR05DA - Opium alkaloids and derivatives\n\nR05DA04 - Codeine\n\n\n                    Context: \n                    This section details the FDA pharmacological classification and ATC code for codeine, highlighting its mechanism as a full opioid agonist and its classification within respiratory and cough suppressants, specifically under R05DA04. It situates codeine’s therapeutic and regulatory status within the comprehensive PubChem documentation, supporting drug identification, classification, and regulatory data retrieval. Key identifiers include the UNII UX6OWY2V7J and ATC code R05DA04.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_48", "document_index": 23, "latency_s": 1.322827399999369, "prompt_toks": 51610, "completion_toks": 79}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    R - Respiratory system\n\nR05 - Cough and cold preparations\n\nR05D - Cough suppressants, excl. combinations with expectorants\n\nR05DA - Opium alkaloids and derivatives\n\nR05DA04 - Codeine\n\n9.5 Absorption, Distribution and Excretion\n\nAbsorption\n\n**Absorption** Codeine is absorbed from the gastrointestinal tract. The maximum plasma concentration occurs 60 minutes after administration. **Food Effects** When 60 mg codeine sulfate was given 30 minutes post-ingestion of a high high-calorie meal, there was no significant change in the absorption of codeine. **Steady-state concentration** The administration of 15 mg codeine sulfate every 4 hours for 5 days lead to steady-state concentrations of codeine, morphine, morphine-3-glucuronide (M3G) and morphine-6-glucuronide (M6G) within 48 hours.\n\nRoute of Elimination\n\n\n                    Context: \n                    This excerpt summarizes the pharmacokinetics of codeine, including absorption from the gastrointestinal tract, peak plasma levels at 60 minutes, and the lack of significant food effects on absorption. It details steady-state concentrations achieved with dosing over 5 days and explains routes of elimination, making it essential for understanding codeine’s pharmacological profile within the comprehensive chemical and medical data provided in the full document.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_49", "document_index": 23, "latency_s": 2.3689287999877706, "prompt_toks": 51583, "completion_toks": 106}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    Route of Elimination\n\nAbout 90% of the total dose of codeine is excreted by the kidneys. Approximately 10% of the drug excreted by the kidneys is unchanged codeine. The majority of the excretion products can be found in the urine within 6 hours of ingestion, and 40-60 % of the codeine is excreted free or conjugated, approximately 5 to 15 percent as free and conjugated morphine, and approximately 10-20% free and conjugated norcodeine.\n\nVolume of Distribution\n\nApparent volume of distribution: about 3-6 L/kg, showing an extensive distribution of the drug into tissues.\n\nClearance\n\nRenal clearance of codeine was 183 +/- 59 ml min-1 in a clinical study. Renal impairment may decrease codeine clearance [LABEL].\n\n\n                    Context: \n                    This section details key pharmacokinetic parameters of codeine, including its elimination pathway, volume of distribution, and clearance rates, which are critical for understanding its duration of action and dose adjustments. It emphasizes that about 90% of the dose is kidney-excreted, primarily as metabolites, with extensive tissue distribution indicated by a volume of 3-6 L/kg. Renal clearance estimates and the potential impact of kidney impairment are also highlighted, relevant for dose management and toxicity assessment within the broader pharmacology and safety overview.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_50", "document_index": 23, "latency_s": 1.7370270999963395, "prompt_toks": 51593, "completion_toks": 92}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    Clearance\n\nRenal clearance of codeine was 183 +/- 59 ml min-1 in a clinical study. Renal impairment may decrease codeine clearance [LABEL].\n\nOral absorption of codeine is good, but there is a significant first-pass effect. The Vd is 2.6 L/kg, and there is a minimal protein binding. The onset os analgesic effect is 30 to 60 minutes, and antitussive effect is 1 to 2 hours. Peak effect is reached in 2 to 4 hours. ... Between 3% and 16% is excreted unchanged in the urine, and 90% of the absorbed dose if excreted via the kidney.\n\nDart, R.C. (ed). Medical Toxicology. Third Edition, Lippincott Williams & Wilkins. Philadelphia, PA. 2004., p. 761\n\n\n                    Context: \n                    This excerpt details the pharmacokinetics and renal clearance of codeine, highlighting key parameters such as renal clearance rate, volume of distribution, absorption, protein binding, onset and peak effects, and excretion percentages. It is relevant for understanding drug disposition, metabolism, and safety considerations, forming part of the comprehensive pharmacology and physical properties section in the overall document. These details support data retrieval related to codeine's absorption, excretion, and dosing characteristics.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_51", "document_index": 23, "latency_s": 1.6022576000104891, "prompt_toks": 51636, "completion_toks": 80}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    Postmortem samples from 14 cases of suspected heroin overdose were subjected to a preliminary systematic toxicological analysis in order to highlight the presence of unknown exogenous compounds (e.g., drugs of abuse, alcohol) that may have played a role in the mechanism of death. This analysis unveiled histories of poly-drug use in seven of the cases under investigation. Moreover, the concentrations of morphine and codeine in the brain were also investigated, and the results were compared with the data obtained from the blood specimens. The concentration of morphine in blood ranged from 33 to 688 ng/mL, while the concentration of codeine ranged from 0 to 193 ng/mL. However, in the brain, the concentration of morphine was found to be between 85 and 396 ng/g, while the levels of codeine ranged from 11 to 160 ng/g. The codeine/morphine ratio in the blood ranged from 0.043 to 0.619; however, in the brain, the same ratio was found to be between 0.129 and 0.552. In most cases, a\n\n\n                    Context: \n                    This excerpt discusses forensic toxicology findings from postmortem cases of suspected heroin overdose, highlighting the levels and ratios of morphine and codeine in blood and brain tissues. It provides specific concentration ranges and ratio comparisons critical for understanding drug accumulation and toxicity. This information is relevant for contextualizing the pharmacokinetic and toxicological data of opioids within the comprehensive chemical and safety profile detailed in the full document.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_52", "document_index": 23, "latency_s": 1.7768680000008317, "prompt_toks": 51507, "completion_toks": 84}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    codeine ranged from 11 to 160 ng/g. The codeine/morphine ratio in the blood ranged from 0.043 to 0.619; however, in the brain, the same ratio was found to be between 0.129 and 0.552. In most cases, a significantly higher codeine/morphine ratio was found in the brain, suggesting the accumulation of codeine in brain tissue due its high lipophilicity as compared with morphine.\n\n\n                    Context: \n                    This excerpt details toxicological findings related to codeine and morphine concentrations and ratios in postmortem tissue samples, highlighting the higher accumulation of codeine in brain tissue due to lipophilicity. It is relevant within the document’s comprehensive overview of codeine’s pharmacokinetics, metabolism, and toxicology, providing specific postmortem data that informs understanding of drug distribution and accumulation in tissues during overdose or death investigations.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_53", "document_index": 23, "latency_s": 1.1119312000082573, "prompt_toks": 51439, "completion_toks": 68}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    PMID:24727081\n\nGambaro V et al; J Anal Toxicol 38 (5): 289-94 (2014)\n\n\n                    Context: \n                    This section provides details of a 2014 toxicological study by Gambaro et al. analyzing postmortem codeine and morphine concentrations in blood and brain tissue, highlighting the significance of codeine/morphine ratios and tissue accumulation patterns relevant to forensic toxicology and overdose interpretation within the comprehensive chemical and safety profile of codeine.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_54", "document_index": 23, "latency_s": 1.431186899993918, "prompt_toks": 51637, "completion_toks": 85}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    Opiates are an important component for drug testing due to their high abuse potential. Proper urine opiate interpretation includes ruling out poppy seed ingestion; however, detailed elimination studies after controlled poppy seed administration with known morphine and codeine doses are not available. Therefore, we investigated urine opiate pharmacokinetics after controlled oral administration of uncooked poppy seeds with known morphine and codeine content. Participants were administered two 45 g oral poppy seed doses 8 hr apart, each containing 15.7 mg morphine and 3 mg codeine. Urine was collected ad libitum up to 32 hr after the first dose. Specimens were analyzed with the Roche Opiates II immunoassay at 2000 and 300 ug/L cutoffs, and the ThermoFisher CEDIA heroin metabolite (6-acetylmorphine, 6-AM) and Lin-Zhi 6-AM immunoassays with 10 ug/L cutoffs to determine if poppy seed ingestion could produce positive results in these heroin marker assays. In addition, all specimens were\n\n\n                    Context: \n                    This excerpt details a study on urine opiate pharmacokinetics after controlled oral ingestion of poppy seeds containing known morphine and codeine levels, highlighting the potential for false-positive drug tests. It describes the dosing protocol, urine collection timeframe, and analytical methods used to detect opiates and heroin metabolites, emphasizing the importance of interpreting drug test results accurately in forensic and clinical settings within the broader context of opioid pharmacology.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_55", "document_index": 23, "latency_s": 1.704050999993342, "prompt_toks": 51685, "completion_toks": 101}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    6-AM) and Lin-Zhi 6-AM immunoassays with 10 ug/L cutoffs to determine if poppy seed ingestion could produce positive results in these heroin marker assays. In addition, all specimens were quantified for morphine and codeine by GC/MS. Participants (N=22) provided 391 urine specimens over 32 hr following dosing; 26.6% and 83.4% were positive for morphine at 2000 and 300 ug/L GC/MS cutoffs, respectively. For the 19 subjects who completed the study, morphine concentrations ranged from <300 to 7522 ug/L with a median peak concentration of 5239 ug/L. The median first morphine-positive urine sample at 2000 ug/L cutoff concentration occurred at 6.6 hr (1.2-12.1), with the last positive from 2.6 to 18 hr after the second dose. No specimens were positive for codeine at a cutoff concentration of 2000 ug/L, but 20.2% exceeded 300 ug/L, with peak concentrations of 658 ug/L (284-1540). The Roche Opiates II immunoassay had efficiencies greater than 96% for the 2000 and 300 ug/L cutoffs. The CEDIA\n\n\n                    Context: \n                    This excerpt details analytical methods and results from urine drug testing studies assessing morphine and codeine detection following poppy seed ingestion, including GC/MS quantification, immunoassay cutoff thresholds, and detection timeframes. It highlights the sensitivity and specificity of different immunoassays (e.g., Roche Opiates II, CEDIA), including peak concentrations, detection windows, and false-positive considerations, which are relevant for interpreting opioid test results in forensic toxicology within the comprehensive drug information resource.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_56", "document_index": 23, "latency_s": 1.0796818999951938, "prompt_toks": 51511, "completion_toks": 81}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    ug/L, but 20.2% exceeded 300 ug/L, with peak concentrations of 658 ug/L (284-1540). The Roche Opiates II immunoassay had efficiencies greater than 96% for the 2000 and 300 ug/L cutoffs. The CEDIA 6-AM immunoassay had a specificity of 91%, while the Lin-Zhi assay had no false positive results. These data provide valuable information for interpreting urine opiate results.\n\n\n                    Context: \n                    This excerpt summarizes analytical data and assay performance metrics related to urine drug testing for opiates, specifically codeine and its metabolites, as included in the comprehensive webpage on codeine. It highlights detection rates, peak concentrations, and assay specificity, providing crucial information for interpreting toxicological and forensic results within the broader discussion of codeine's pharmacokinetics, metabolism, and analytical methods detailed in the full document.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_57", "document_index": 23, "latency_s": 1.716566100003547, "prompt_toks": 51454, "completion_toks": 87}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    PMID:24887324\n\nFull text: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4127332\n\nSmith ML et al; Forensic Sci Int 241: 87-90 (2014)\n\n\n                    Context: \n                    This chunk provides detailed information on urine opiate pharmacokinetics and interpretation post-poppy seed ingestion, including detection windows for morphine and codeine. It is relevant to understanding drug testing, metabolism, and forensic analysis aspects discussed in the full webpage, especially in sections related to spectral data, analytical methods, toxicology, and legal standards for codeine detection. The PMID and link direct users to the full article for comprehensive research data.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_58", "document_index": 23, "latency_s": 1.8910986999981105, "prompt_toks": 51641, "completion_toks": 92}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    Opiates are an important drug class in drug testing programs. Ingestion of poppy seeds containing morphine and codeine can yield positive opiate tests and mislead result interpretation in forensic and clinical settings. Multiple publications evaluated urine opiate concentrations following poppy seed ingestion, but only two addressed oral fluid (OF) results; neither provided the ingested morphine and codeine dosage. We administered two 45 g raw poppy seed doses, each containing 15.7 mg morphine and 3.1 mg codeine, 8 hr apart to 17 healthy adults. All OF specimens were screened by on-site OF immunoassay Draeger DrugTest 5000, and confirmed with OF collected with Oral-Eze device and quantified by liquid chromatography-tandem mass spectrometry (1 ug/L morphine and codeine limits of quantification). Specimens (n=459) were collected before and up to 32 hr after the first dose. All specimens screened positive 0.5 hr after dosing and remained positive for 0.5-13 hr at Draeger 20 ug/L morphine\n\n\n                    Context: \n                    This section details recent research on urinary and oral fluid detection of morphine and codeine following controlled poppy seed ingestion, highlighting pharmacokinetics, detection windows, and testing methods. It provides specific data on doses, sample collection times, and immunoassay screening results, which are relevant for understanding drug testing and interpreting opiate levels in forensic and clinical toxicology within the broader context of opioid safety, toxicity, and analytical methods discussed in the full document.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_59", "document_index": 23, "latency_s": 1.3407590999995591, "prompt_toks": 51648, "completion_toks": 85}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    Specimens (n=459) were collected before and up to 32 hr after the first dose. All specimens screened positive 0.5 hr after dosing and remained positive for 0.5-13 hr at Draeger 20 ug/L morphine cut-off. Maximum OF morphine and codeine concentrations (Cmax) were 177 and 32.6 ug/L, with times to Cmax (Tmax) of 0.5-1 hr and 0.5-2.5 hr post-dose, respectively. Windows of detection after the second dose extended at least 24 hr for morphine and to 18 hr for codeine. After both doses, the last morphine positive OF result was 1 hr with 40 ug/L 2004 proposed US Substance Abuse and Mental Health Services Administration cut-off, and 0.5 hr with 95 ug/L cut-off, recently recommended by the Driving under the Influence of Drugs and Medicines project. Positive OF morphine results are possible 0.5-1 hr after ingestion of 15.7 mg of morphine in raw poppy seeds, depending on the cut-off employed.\n\n\n                    Context: \n                    This excerpt details the pharmacokinetics and detection window of morphine and codeine in oral fluid after controlled poppy seed ingestion. It reports specimen collection timing, positive screening results, maximum concentrations, times to peak levels, and detection duration, highlighting how recent poppy seed intake can produce measurable opioid levels within specific timeframes. This information is vital for interpreting forensic and clinical toxicology results related to opioid exposure from dietary sources.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_60", "document_index": 23, "latency_s": 1.1854344999883324, "prompt_toks": 51496, "completion_toks": 74}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    PMID:25345619\n\nFull text: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4409445\n\nConcheiro M et al; Drug Test Anal 7 (7): 586-91 (2015)\n\nFor more Absorption, Distribution and Excretion (Complete) data for CODEINE (7 total), please visit the HSDB record page.\n\n9.6 Metabolism / Metabolites\n\n\n                    Context: \n                    This excerpt provides detailed information on codeine's metabolism and metabolites as documented in a 2015 research article, complementing the comprehensive pharmacokinetic, safety, and chemical data presented throughout the full PubChem webpage. It highlights the metabolic pathways and the HSDB record for further data, making it relevant for researchers seeking detailed biochemical and excretion profiles of codeine.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_61", "document_index": 23, "latency_s": 2.0801319000020158, "prompt_toks": 51694, "completion_toks": 130}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    Approximately 70 to 80% of the ingested dose of codeine is metabolized in the liver by conjugation with glucuronic acid to _codeine-6­ glucuronide_ (C6G) and by O-demethylation to _morphine_ (about 5-10%) and N-demethylation to _norcodeine_ (about 10%) respectively. UDP-glucuronosyltransferase (UGT) 2B7 and 2B4 are the major metabolic enzymes mediating the glucurodination of codeine to the metabolite, _codeine 6 glucuronide_. Cytochrome P450 2D6 is the major enzyme responsible for the transformation of codeine to morphine and P450 3A4 is the main enzyme mediating the conversion of codeine to _norcodeine_. Morphine and norcodeine are then further metabolized by conjugation with glucuronic acid. The glucuronide metabolites of morphine are _morphine-3-glucuronide_ (M3G) and_ morphine-6-glucuronide _(M6G). Morphine and M6G have been proven to have analgesic activity in humans. The analgesic activity of C6G in humans is not known at this time. Norcodeine and M3G are generally not\n\n\n                    Context: \n                    This excerpt details the metabolic pathways of codeine, highlighting that 70-80% is conjugated with glucuronic acid to form codeine-6-glucuronide, while 5-10% is transformed into morphine, and around 10% into norcodeine. It identifies key enzymes such as UGT2B7, UGT2B4, CYP2D6, and CYP3A4 involved in these processes and notes the analgesic activity of morphine and its glucuronides, emphasizing the complex biotransformation relevant to codeine’s pharmacology and safety profile discussed throughout the document.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_62", "document_index": 23, "latency_s": 1.4680949000030523, "prompt_toks": 51468, "completion_toks": 119}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    _(M6G). Morphine and M6G have been proven to have analgesic activity in humans. The analgesic activity of C6G in humans is not known at this time. Norcodeine and M3G are generally not considered to have analgesic properties.\n\n\n                    Context: \n                    This excerpt details the metabolic pathways and pharmacological activities of codeine, including its key metabolites morphine (M) and morphine-6-glucuronide (M6G), highlighting that both have proven analgesic effects in humans, while the activity of codeine-6-glucuronide (C6G) remains uncertain; it also notes that norcodeine and morphine-3-glucuronide (M3G) are not considered analgesic, providing important context for chemical and pharmacodynamic data relevant to drug identification and efficacy assessment within the full document.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_63", "document_index": 23, "latency_s": 1.6776200999884168, "prompt_toks": 51660, "completion_toks": 114}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    Codeine is metabolized in the liver by glucuronidation to codeine-6-glucuronide, by O-demethylation to morphine via CYP2D6, and by N-demethylation to norcodeine via CYP3A, all active metabolites. There is genetic polymorphism od CYP2D6. .. Poor /CYP2D6/ metabolizers have decreased analgesic effectiveness by inhibiting conversion of codeine to morphine. Concomitant administration with CYP2D6 inducers may result in increased metabolism and clearance of drug and also produce decreased clinical efficacy. Examples of CYP2D6 inducers include dexamethasone and rifampin.\n\nDart, R.C. (ed). Medical Toxicology. Third Edition, Lippincott Williams & Wilkins. Philadelphia, PA. 2004., p. 761\n\n... Results confirm biotransformation of codeine to ... normorphine in rodents.\n\nThe Chemical Society. Foreign Compound Metabolism in Mammals. Volume 2: A Review of the Literature Published Between 1970 and 1971. London: The Chemical Society, 1972., p. 190\n\n\n                    Context: \n                    This excerpt details the metabolic pathways of codeine in the liver, highlighting the formation of active metabolites such as codeine-6-glucuronide, morphine, and norcodeine, with emphasis on the role of CYP2D6 polymorphism. It discusses genetic variability affecting analgesic efficacy and interactions with CYP2D6 inducers like dexamethasone and rifampin. Additionally, rodent studies confirming biotransformation to normorphine are referenced, providing pharmacokinetic context within the broader chemical and toxicological profile.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_64", "document_index": 23, "latency_s": 2.021737999995821, "prompt_toks": 51653, "completion_toks": 89}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    Cytochrome P450 2D6 (CYP2D6) is a member of the cytochrome P450 (CYP) superfamily involved in the biotransformation of drugs and substances of abuse encountered in clinical toxicology. Among the CYP superfamily, the CYP2D6 gene is considered as the most polymorphic as more than 105 different alleles have been identified so far. CYP2D6 genetic polymorphisms have the potential to affect the toxicity of their substrates. This review will focus specifically on CYP2D6 genetic polymorphisms and their relevance for poisoning due to amphetamines, opioid analgesics and antidepressants in humans. PubMed (up to August 2013) was searched with the following selection criteria: 'CYP2D6 AND (toxicology OR poisoning OR intoxication OR overdose)'. Of the 454 citations retrieved, only 46 papers dealt with the impact of CYP2D6 polymorphisms on poisoning due to amphetamines, opioid analgesics and antidepressants. ... Opioid analgesics. CYP2D6 ultra-rapid metabolizers are more likely to experience the\n\n\n                    Context: \n                    This excerpt discusses the role of CYP2D6 genetic polymorphisms in drug metabolism, particularly their impact on toxicity and poisoning from opioids, amphetamines, and antidepressants. It is part of a comprehensive section on pharmacology and biotransformation mechanisms within the full webpage on codeine, highlighting genetic variability's influence on drug safety and overdose risk. This information is relevant for understanding individual differences in codeine efficacy and adverse effects.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_65", "document_index": 23, "latency_s": 1.9159406999970088, "prompt_toks": 51585, "completion_toks": 109}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    the impact of CYP2D6 polymorphisms on poisoning due to amphetamines, opioid analgesics and antidepressants. ... Opioid analgesics. CYP2D6 ultra-rapid metabolizers are more likely to experience the adverse effects of codeine and tramadol. Opioid analgesics that do not rely on CYP2D6 for therapeutic activity, such as morphine and hydromorphone, may therefore be a better alternative to codeine and tramadol, with the limitation that these drugs have their own set of adverse reactions. ... Either poor or extensive/ultra-rapid CYP2D6 metabolizers may be exposed to toxic effects of amphetamines, opioid analgesics and antidepressants. In these three categories, the level of evidence is substance dependent, with differences within the same pharmacological class.\n\n\n                    Context: \n                    This excerpt discusses the influence of CYP2D6 genetic polymorphisms on drug toxicity and individual responses, highlighting that ultra-rapid metabolizers risk adverse effects from drugs like codeine and tramadol, while other opioids less dependent on CYP2D6 may be safer alternatives. It situates within the broader pharmacology section of the full document, which covers drug metabolism, mechanisms of action, and safety considerations for substances like codeine. The content emphasizes genetic variability's impact on opioid and stimulant toxicity, informing clinical and forensic interpretations.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_66", "document_index": 23, "latency_s": 1.6572556000028271, "prompt_toks": 51445, "completion_toks": 96}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    PMID:25998998\n\nHaufroid V, Hantson P; Clin Toxicol (Phila) 53 (6): 501-10 (2015)\n\n\n                    Context: \n                    This chunk references a 2015 review by Haufroid and Hantson on opioid metabolism, toxicity, and drug interactions, highlighting its relevance to the document's comprehensive coverage of codeine pharmacology, safety, and toxicology data. It provides authoritative context on opioid biotransformation mechanisms and risks, supporting search retrieval for metabolic pathways and safety assessments related to codeine. This citation is crucial for research on opioid pharmacokinetics and toxicology within the overall webpage content.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_67", "document_index": 23, "latency_s": 1.819030600003316, "prompt_toks": 51635, "completion_toks": 104}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    Opioid analgesics are commonly prescribed for acute and chronic pain, but are subject to abuse. Consequently, toxicology testing programs are frequently implemented for both forensic and clinical applications. Understanding opioid metabolism and disposition is essential for assessing risk of toxicity and, in some cases, providing additional information regarding risk of therapeutic failure. Opioids significantly metabolized by the cytochromeP450 (CYP450) enzyme system maybe subject to drug-drug interactions, including codeine, hydrocodone, oxycodone, fentanyl, meperidine, methadone, buprenorphine, and tramadol. CYP2D6 metabolism is polymorphic, and pharmacogenetic testing has been investigated for codeine, tramadol, oxycodone, and hydrocodone. CYP2B6 pharmacogenetic testing of methadone may reduce the risk of cardiac toxicity associated with the S-enantiomer. Opioids metabolized primarily by uridine 5'-diphospho-glucuronsyltransferase (UGT) enzymes include morphine, hydromorphone,\n\n\n                    Context: \n                    This section provides an overview of the metabolic pathways and drug-drug interactions relevant to opioid analgesics, including key enzymes like CYP450 and UGT involved in drugs such as codeine, hydrocodone, oxycodone, fentanyl, and methadone. It highlights genetic polymorphisms affecting CYP2D6 metabolism and the importance of pharmacogenetic testing for assessing toxicity and therapeutic failure risks, situating these details within the comprehensive discussion of opioid pharmacology and safety in the full document.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_68", "document_index": 23, "latency_s": 1.6512452000024496, "prompt_toks": 51574, "completion_toks": 79}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    may reduce the risk of cardiac toxicity associated with the S-enantiomer. Opioids metabolized primarily by uridine 5'-diphospho-glucuronsyltransferase (UGT) enzymes include morphine, hydromorphone, dihydrocodeine, oxymorphone, levorphanol, and tapentadol. Parent and metabolite disposition is described for blood, oral fluid, and urine. Parent drug is most commonly detected in blood and oral fluid, whereas metabolites typically predominate in urine. Oral fluid/blood ratios exceed 1 for most opioids, making this an excellent alternative matrix for testing of this drug class. Metabolites of codeine, hydrocodone, and oxycodone are commercially available, and knowledge of metabolism is necessary for correct interpretation.\n\n\n                    Context: \n                    This excerpt details the metabolism, detection, and analytical considerations of opioids, including codeine, in biological samples. It emphasizes the role of UGT enzymes in metabolizing opioids, discusses parent/metabolite detection in blood, oral fluid, and urine, and notes the availability of metabolite standards. This information is crucial for accurate interpretation in toxicology, drug testing, and pharmacokinetic studies.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_69", "document_index": 23, "latency_s": 1.783139699997264, "prompt_toks": 51623, "completion_toks": 68}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    PMID:26227254\n\nDePriest AZ et al; Forensic Sci Rev 27 (2): 115-45 (2015)\n\nFor more Metabolism/Metabolites (Complete) data for CODEINE (7 total), please visit the HSDB record page.\n\nCodeine has known human metabolites that include (2S,3S,4S,5R)-6-[[(4R,4Ar,7S,7aR,12bS)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-yl]oxy]-3,4,5-trihydroxyoxane-2-carboxylic acid, morphine, and norcodeine.\n\nS73 | METXBIODB | Metabolite Reaction Database from BioTransformer | DOI:10.5281/zenodo.4056560\n\n\n                    Context: \n                    This excerpt details the metabolic pathways and human metabolites of codeine, referencing a 2015 forensic toxicology review and database entries. It highlights the known biotransformation products, such as morphine and norcodeine, and provides database identifiers relevant for chemical and metabolite data retrieval within the comprehensive PubChem and HSDB records.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_70", "document_index": 23, "latency_s": 1.8525147000036668, "prompt_toks": 51698, "completion_toks": 129}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    Hepatic. Codeine is a prodrug, itself inactive, but demethylated to the active morphine by the liver enzyme CYP2D6 to morphine. 70-80% of the dose undergoes glucuronidation to form codeine-6-glucuronide. This process is mediated by UDP-glucuronosyltransferase UGT2B7 and UGT2B4. 5-10% of the dose undergoes O-demethylation to morphine and 10% undergoes N-demethylation to form norcodeine. CYP2D6 mediates the biotransformation to morphine. CYP3A4 is the enzymes that mediates the conversion to norcodiene. Morphine and norcodeine are further metabolized and undergo glucuronidation. The glucuronide metabolites of morphine are morphine-3-glucuronide (M3G) and morphine-6-glucuronide (M6G). Both morphine and morphine-6-glucuronide are active and have analgesic activity. Norcodiene and M3G do not have any analgesic properties. Route of Elimination: 90% of the total dose of codeine is excreted through the kidneys, of which 10% is unchanged codeine. Half Life: Plasma half-lives of codeine and its\n\n\n                    Context: \n                    This excerpt details the hepatic metabolism and biotransformation pathways of codeine, highlighting its conversion to active metabolites like morphine and norcodeine, and their respective roles in analgesic activity. It discusses the roles of enzymes CYP2D6, CYP3A4, and UDP-glucuronosyltransferases UGT2B7 and UGT2B4 in these processes, as well as routes of excretion and elimination half-life. This information is crucial for understanding codeine’s pharmacokinetics and metabolic variability, situating it within the broader discussion of chemical properties, safety, and pharmacology.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_71", "document_index": 23, "latency_s": 1.423626099989633, "prompt_toks": 51472, "completion_toks": 93}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    any analgesic properties. Route of Elimination: 90% of the total dose of codeine is excreted through the kidneys, of which 10% is unchanged codeine. Half Life: Plasma half-lives of codeine and its metabolites have been reported to be approximately 3 hours.\n\n\n                    Context: \n                    This excerpt summarizes key pharmacokinetic details about codeine's route of elimination and half-life, which are crucial for understanding its metabolism and duration of action. It highlights that 90% of the drug is excreted via the kidneys, with 10% unchanged, and reports a plasma half-life of approximately 3 hours. These details support the overall document's focus on chemical, physical, and biological properties relevant to codeine's clinical and toxicological profile.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_72", "document_index": 23, "latency_s": 1.2565858000016306, "prompt_toks": 51439, "completion_toks": 77}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    9.7 Biological Half-Life\n\nPlasma half-lives of codeine and its metabolites have been reported to be approximately 3 hours.\n\n\n                    Context: \n                    This excerpt from section 9.7 provides the reported biological half-life of codeine and its metabolites, approximately 3 hours, and is situated within the pharmacokinetic details of the comprehensive webpage. It is relevant for understanding drug elimination and duration of action, aiding in pharmacology, toxicity, and therapeutic considerations related to the detailed chemical and clinical data presented in the full document.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_73", "document_index": 23, "latency_s": 1.57487029999902, "prompt_toks": 51614, "completion_toks": 80}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    Radioimmunoassay (RIA) was used to determine several pharmacokinetic parameters of codeine in man, including the relative bioavailability after oral and intramuscular administration. The study followed a crossover design in 6 healthy, young (18 to 21 yr), male volunteers. Three subjects received 65 mg codeine phosphate orally in an analgesic mixture which also contained aspirin, phenacetin, and caffeine. At the same time a similar group received an equivalent dose of codeine phosphate in a single intramuscular injection. Two weeks later the study was repeated so that each group received the alternate treatment. Plasma samples were collected at various times after drug administration, and codeine concentrations were determined by a specific RIA procedure. The procedure can detect less than 50 pg of codeine. Following intramuscular administration, peak plasma concentrations (194 to 340 ng/ml) were observed between 0.25 to 1 hr; after oral dosing, peak codeine plasma concentrations (102\n\n\n                    Context: \n                    This excerpt details a pharmacokinetic study using radioimmunoassay (RIA) to measure codeine concentrations in humans following oral and intramuscular administration in a crossover design with young male volunteers. It provides key data on peak plasma levels, timing, and the assay’s detection sensitivity. This information is relevant for understanding codeine absorption, bioavailability, and analytical measurement methods discussed throughout the document.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_74", "document_index": 23, "latency_s": 1.231273900004453, "prompt_toks": 51547, "completion_toks": 88}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    50 pg of codeine. Following intramuscular administration, peak plasma concentrations (194 to 340 ng/ml) were observed between 0.25 to 1 hr; after oral dosing, peak codeine plasma concentrations (102 to 140 ng/ml) appeared within 0.75 to 1 hr. The mean plasma t1/2 and volume of distribution of codeine following intramuscular injection were 3.32 hr and 5.1 L/kg, respectively. Oral, relative to intramuscular, bioavailability of codeine, based on areas under the codeine plasma curves, was 42% to 71% (mean, 53%).\n\n\n                    Context: \n                    This excerpt summarizes key pharmacokinetic parameters of codeine administration, including peak plasma concentrations, times to peak, plasma half-life, volume of distribution, and bioavailability comparisons between intramuscular and oral routes. It is part of the larger detailed section on absorption, distribution, and excretion properties of codeine, essential for understanding its behavior and metabolism in humans. These data are critical for pharmacological reference and clinical application of the compound.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_75", "document_index": 23, "latency_s": 1.3205907000083243, "prompt_toks": 51699, "completion_toks": 97}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    PMID:902456\n\nFindlay JW et al; Clin Pharmacol Ther 22 (10): 439-46 (1977)\n\nAssuming a rate of hair growth of 1 cm/month, the mean hair elimination half-life of /codeine was 0.61 months (95% CI, 0.54-0.69)/ ... .\n\nPMID:23165127\n\nShen M et al; Forensic Sci Int 227 (1-3): 64-8 (2013)\n\nThe elimination half-life of codeine is 2.5 to 3.5 hours with a clinical duration of 4 to 8 hours because of active metabolites.\n\nDart, R.C. (ed). Medical Toxicology. Third Edition, Lippincott Williams & Wilkins. Philadelphia, PA. 2004., p. 761\n\nCodeine is metabolized rapidly by the tissues of humans, dogs, & rats. Metabolic alteration followed by rapid urinary excretion begins a few minutes after im injection & after a slight delay following oral admin. About one-half an ordinary dose is eliminated within 6 hr & all within 24 hr.\n\nBooth, N.H., L.E. McDonald (eds.). Veterinary Pharmacology and Therapeutics. 5th ed. Ames, Iowa: Iowa State University Press, 1982., p. 284\n\n9.8 Mechanism of Action\n\n\n                    Context: \n                    This chunk provides detailed information on codeine's pharmacokinetics, including its elimination half-life (ranging from 2.5 to 3.5 hours in humans and other animals) and metabolism, emphasizing rapid tissue processing and urinary excretion within 24 hours. It is essential for understanding codeine's duration of action, detection window, and how its metabolism influences its pharmacological effects, situating these specifics within the comprehensive chemical and toxicological profile provided in the larger document.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_76", "document_index": 23, "latency_s": 1.3970773000037298, "prompt_toks": 51643, "completion_toks": 121}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    Although the exact mechanism of action of codeine is still unknown, it is generally thought to be mediated through the agonism of opioid receptors, particularly the mu-opioid receptors. Morphine was previously postulated to contribute to the analgesic effect of codeine due to the O-demethylation of codeine to morphine by CYP2D6. Particularly, CYP2D6 poor metabolizer did not experience the analgesic effect of codeine. However, this is unlikely to be the main mechanism of action of codeine as only 5% of codeine is metabolized to morphine. Other hypotheses also postulate that codeine-6-glucuronide, the main metabolite of codeine, mediates the analgesic effect of codeine as it not only has an affinity to the mu receptors as codeine but also can be metabolized to morphine-6-glucuronide, which was observed to be more potent than morphine. Binding to the mu receptors by codeine activates the G-proteins Gαi, causing a decrease in intracellular cAMP and Ca2+ level. This causes\n\n\n                    Context: \n                    This excerpt details the proposed mechanisms of opioid receptor activation by codeine, including its metabolism to morphine and the role of main metabolites like codeine-6-glucuronide and morphine-6-glucuronide, highlighting their affinity for mu-opioid receptors and their contribution to analgesic effects. It situates within the broader pharmacology section, emphasizing the uncertainty of the main action pathway while discussing biotransformation and receptor activation processes. Key details include the low percentage of codeine metabolized to morphine and the significance of metabolite potency in its analgesic mechanism.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_77", "document_index": 23, "latency_s": 1.5519247000047471, "prompt_toks": 51473, "completion_toks": 88}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    which was observed to be more potent than morphine. Binding to the mu receptors by codeine activates the G-proteins Gαi, causing a decrease in intracellular cAMP and Ca2+ level. This causes hyperpolarization of nociceptive neurons, thus imparing the transmission of pain signals.\n\n\n                    Context: \n                    This excerpt discusses the pharmacodynamics of codeine as an opioid analgesic, highlighting its mechanism of action involving mu receptor activation and G-protein signaling leading to decreased neuronal excitability. It emphasizes that codeine's analgesic potency is partly due to its conversion to morphine and details how receptor binding causes hyperpolarization of pain-transmitting neurons, which is essential for understanding its pain-relieving effects and related search queries.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_78", "document_index": 23, "latency_s": 1.7843225999968126, "prompt_toks": 51647, "completion_toks": 98}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    Codeine causes suppression of the cough reflex by a direct effect on the cough center in the medulla of the brain and appears to exert a drying effect on respiratory tract mucosa and to increase viscosity of bronchial secretions.\n\nAmerican Society of Health-System Pharmacists 2016; Drug Information 2016. Bethesda, MD. 2016, p. 2869\n\n9.9 Human Metabolite Information\n\n9.9.1 Tissue Locations\n\nEpidermis\n\nHair\n\n9.9.2 Cellular Locations\n\nMembrane\n\n9.9.3 Metabolite Pathways\n\nCodeine Action Pathway\n\nCodeine Metabolism Pathway\n\n9.10 Biochemical Reactions\n\n9.11 Transformations\n\n10 Use and Manufacturing\n\n10.1 Uses\n\nEPA CPDat Chemical and Product Categories\n\nThe Chemical and Products Database, a resource for exposure-relevant data on chemicals in consumer products, Scientific Data, volume 5, Article number: 180125 (2018), DOI:10.1038/sdata.2018.125\n\nAnalgesics, Opioid; Antitussive Agents; Narcotics\n\n\n                    Context: \n                    This excerpt details the pharmacological action of codeine as a cough suppressant through a direct effect on the medullary cough center, along with information on its human metabolites, tissue and cellular locations, and metabolic pathways. It also references its primary uses in opioid analgesics, antitussives, and narcotics, and links to exposure data from the EPA's chemical database. These details are relevant for understanding codeine's mechanisms, metabolism, and applications within the comprehensive chemical profile.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_79", "document_index": 23, "latency_s": 1.255118399989442, "prompt_toks": 51616, "completion_toks": 102}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    Analgesics, Opioid; Antitussive Agents; Narcotics\n\nNational Library of Medicine's Medical Subject Headings. Codeine. Online file (MeSH, 2016). Available from, as of August 12, 2016: https://www.nlm.nih.gov/mesh/2016/mesh_browser/MBrowser.html\n\nCodeine (DEA Code Number: 9050) is a Schedule II controlled substance.\n\n21 CFR 1308.12 (USFDA); U.S. National Archives and Records Administration's Electronic Code of Federal Regulations. Available from, as of February 18, 2016: https://www.ecfr.gov\n\nSchedule II Controlled Substance: (A) The drug or other substance has a high potential for abuse; (B) The drug or other substance has a currently accepted medical use in treatment in the United States or a currently accepted medical use with severe restrictions; and (C) Abuse of the drug or other substances may lead to severe psychological or physical dependence.\n\n\n                    Context: \n                    This excerpt provides regulatory classification information for codeine, including its listing as an opioid analgesic, antitussive, and narcotic in the MeSH database, along with its DEA Schedule II status, highlighting its high abuse potential and legal restrictions. It is relevant to the comprehensive data on chemical properties, safety, and legal controls within the full document, emphasizing its classification under US federal regulations. Key details include DEA code number 9050 and its classification as a Schedule II controlled substance with severe restrictions.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_80", "document_index": 23, "latency_s": 1.6364729000051739, "prompt_toks": 51690, "completion_toks": 87}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    US Department of Justice/Office of Diversion Control; Schedule of Controlled Substances. Available from, as of February 18, 2016: https://www.deadiversion.usdoj.gov/21cfr/21usc/812.htm\n\nCodeine is an opiate, a component of opium, and an opioid agonist used as an analgesic, antitussive, and antidiarrheal agent. In Europe, codeine has been used in an illicit synthetic opioid mixture including hydrocodone and dihydrocodeine, called Brown.\n\nDart, R.C. (ed). Medical Toxicology. Third Edition, Lippincott Williams & Wilkins. Philadelphia, PA. 2004., p. 761\n\nFor more Uses (Complete) data for CODEINE (6 total), please visit the HSDB record page.\n\nUse (kg; approx.) in Germany (2009): >2500\n\nUse (kg) in USA (2002): 10800\n\nConsumption (g per capita; approx.) in Germany (2009): 0.0305\n\nConsumption (g per capita) in the USA (2002): 0.0383\n\nExcretion rate: 0.382\n\nCalculated removal (%): 8.9\n\nDOI:10.1021/acs.est.5b03332\n\n\n                    Context: \n                    This excerpt provides regulatory classification, usage data, and demographic consumption statistics for codeine, including references to the Schedule of Controlled Substances and specifics on global usage (Germany and the USA). It contextualizes codeine's legal status, pharmaceutical use, and environmental removal rates, supporting comprehensive chemical and pharmacological information within the full PubChem profile. These details are essential for researchers seeking legal, regulatory, and environmental exposure data on codeine.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_81", "document_index": 23, "latency_s": 1.6818500000081258, "prompt_toks": 51684, "completion_toks": 81}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    Consumption (g per capita; approx.) in Germany (2009): 0.0305\n\nConsumption (g per capita) in the USA (2002): 0.0383\n\nExcretion rate: 0.382\n\nCalculated removal (%): 8.9\n\nDOI:10.1021/acs.est.5b03332\n\nFor treatment and management of pain (systemic). It is also used as an antidiarrheal and as a cough suppressant.\n\n10.1.1 Use Classification\n\nHuman Drugs -> FDA Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book) -> Active Ingredients\n\nPharmaceuticals -> Anaesthetics -> Antitussives\n\nS66 | EAWAGTPS | Parent-Transformation Product Pairs from Eawag | DOI:10.5281/zenodo.3754448\n\nPharmaceuticals -> Animal Drugs -> Approved in Taiwan\n\nS72 | NTUPHTW | Pharmaceutically Active Substances from National Taiwan University | DOI:10.5281/zenodo.3955664\n\n10.2 Methods of Manufacturing\n\nCodeine is extracted from opium (concentration in opium 0.7 to 2.5%, depending on the source), but mostly prepared by methylation of morphine in a phase transfer reaction.\n\n\n                    Context: \n                    This section provides key data on codeine usage and environmental removal metrics, including national consumption estimates for Germany and the USA, and an excretion rate of 0.382. It highlights codeine’s approved therapeutic uses, classification categories, and manufacturing process, specifically methylation of morphine from opium, which is relevant for understanding environmental impact, regulatory context, and production methods detailed elsewhere in the document.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_82", "document_index": 23, "latency_s": 1.3784164000098826, "prompt_toks": 51510, "completion_toks": 89}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    Codeine is extracted from opium (concentration in opium 0.7 to 2.5%, depending on the source), but mostly prepared by methylation of morphine in a phase transfer reaction.\n\nFriderichs E et al; Analgesics, Centrally Acting. Ullmann's Encyclopedia of Industrial Chemistry 7th ed. (1999-2016). NY, NY: John Wiley & Sons. Online Posting Date: October 15, 2011\n\n\n                    Context: \n                    This excerpt details the chemical synthesis and extraction methods of codeine, highlighting its natural source in opium and its synthetic production via methylation of morphine. It is relevant to the overall document's comprehensive overview of codeine's chemical origins, manufacturing processes, and regulatory considerations, aiding in searchability related to chemical synthesis, sources, and industrial production methods. Key details include the concentration range in opium and the phase transfer reaction used for synthesis.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_83", "document_index": 23, "latency_s": 1.190831400002935, "prompt_toks": 51593, "completion_toks": 76}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    Although some codeine is obtained from opium directly, the quantity is not sufficient to meet the extensive use of this alkaloid as a valuable medicinal agent. Much more codeine is used than morphine. This need is met by making it by partial synthesis from morphine. The process involves methylating the phenolic OH of the latter with phenyltrimethylammonium hydroxide. Dry morphine is dissolved in a solution of potassium hydroxide in absolute alcohol, the methylating agent added, and the solution heated. After cooling, water is added, the solution is acidified with sulfuric acid, the dimethylaniline product separated, and the alcohol removed by distillation. Treatment with caustic soda solution precipitates the codeine, while any unreacted morphine is held in solution by the sodium hydroxide. The crude codeine is purified by crystallization as the sulfate.\n\n\n                    Context: \n                    This excerpt details the chemical synthesis process of codeine from morphine, including methylation steps and purification methods. It provides essential information on manufacturing techniques relevant to the compound's production, supporting the document's comprehensive overview of codeine’s sources, chemistry, and safety considerations. This information enhances understanding of codeine’s origin, aiding in search related to pharmaceutical synthesis and chemical manufacturing routes.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_84", "document_index": 23, "latency_s": 1.7581187000032514, "prompt_toks": 51688, "completion_toks": 100}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    Troy, D.B. (Ed); Remmington The Science and Practice of Pharmacy. 21 st Edition. Lippincott Williams & Williams, Philadelphia, PA 2005, p. 1527\n\n10.3 Formulations / Preparations\n\nGrade: Technical, NF\n\nLewis, R.J. Sr.; Hawley's Condensed Chemical Dictionary 15th Edition. John Wiley & Sons, Inc. New York, NY 2007., p. 318\n\nCodeine Phosphate, USP, and Codeine Sulfate, USP, are available primarily in combination with antihistamine (chlorpheniramine), expectorant (guaifenesin), decongestant (phenylephrine), and other combinations of drugs ...\n\nBooth, N.H., L.E. McDonald (eds.). Veterinary Pharmacology and Therapeutics. 5th ed. Ames, Iowa: Iowa State University Press, 1982., p. 676\n\nTerpin Hydrate, USP, Codeine Elixir, NF, contains 10 mg codeine in each 5 ml (limit for nonprescription use).\n\nBooth, N.H., L.E. McDonald (eds.). Veterinary Pharmacology and Therapeutics. 5th ed. Ames, Iowa: Iowa State University Press, 1982., p. 676\n\n\n                    Context: \n                    This excerpt details the formulations and preparations of codeine, including available pharmaceutical grades such as Codeine Phosphate and Codeine Sulfate, often in combination with other drugs like antihistamines, expectorants, and decongestants. It also specifies nonprescription formulations like Terpin Hydrate in Codeine Elixir containing 10 mg per 5 mL. This information supports the comprehensive overview of codeine's pharmaceutical formulations, indications, and standard preparations detailed throughout the document.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_85", "document_index": 23, "latency_s": 1.4747830999986036, "prompt_toks": 51565, "completion_toks": 97}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    Booth, N.H., L.E. McDonald (eds.). Veterinary Pharmacology and Therapeutics. 5th ed. Ames, Iowa: Iowa State University Press, 1982., p. 676\n\nAvailable commercially as the free base monohydrate or as the hydrobromide or hydrochloride salts.\n\nAshford, R.D. Ashford's Dictionary of Industrial Chemicals. London, England: Wavelength Publications Ltd., 1994., p. 234\n\nDerivatives: dihydrocodeine; hydrocodone; oxycodone\n\nAshford, R.D. Ashford's Dictionary of Industrial Chemicals. London, England: Wavelength Publications Ltd., 1994., p. 234\n\n10.4 Sampling Procedures\n\n\n                    Context: \n                    This excerpt discusses the chemical formulations, derivatives, and commercial availability of opioid compounds such as codeine salts, including monohydrate, hydrobromide, and hydrochloride, as detailed in authoritative sources like veterinary pharmacology and industrial chemical references. It also covers sampling procedures relevant to drug analysis, highlighting methods for specimen collection and handling in toxicological contexts. This information is essential for chemical identification, formulation standards, and toxicology testing within the broader scope of the document.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_86", "document_index": 23, "latency_s": 1.5702065999939805, "prompt_toks": 51633, "completion_toks": 91}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    Stability of drugs during storage is important in forensic toxicology. For the analytes detected after intake of heroin (6-acetylmorphine (6-AM), morphine and codeine), long-time stability in real life whole blood samples are studied in only a small number of cases. Whole blood post mortem (n=37) and whole blood samples from living persons (n=22) containing morphine and codeine as well as 6-AM in blood or urine were selected. All cases represented intake of heroin. All samples contained fluoride and were initially analyzed and stored in normal conditions (-20 °C) for 4-9 years. All samples were then reanalyzed using the same analytical methods and the results were compared. For samples from living persons, the median change in concentration was -3.7% for morphine and -5.3% for codeine. For post mortem samples, the median change in concentration was -12% for morphine and -11% for codeine. Both for samples from living persons and post mortem samples, the decrease in the concentrations\n\n\n                    Context: \n                    This excerpt discusses the stability and storage considerations of opioids such as codeine and morphine in forensic samples, detailing long-term stability data from post-mortem and living blood specimens stored for 4-9 years at -20°C. It highlights the minimal concentration changes observed, emphasizing the importance of consistent analysis methods for accurate toxicological interpretation. This information is relevant within the comprehensive review of codeine's physical, chemical, and toxicological properties on the webpage.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_87", "document_index": 23, "latency_s": 2.1205611000041245, "prompt_toks": 51598, "completion_toks": 84}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    post mortem samples, the median change in concentration was -12% for morphine and -11% for codeine. Both for samples from living persons and post mortem samples, the decrease in the concentrations from the original analysis to reanalysis were statistically significant for morphine and codeine. Regarding 6-AM, all living samples were negative at reanalysis. For post mortem samples, four cases still tested positive for 6-AM at reanalysis with a median change in the concentrations of -81%. There was no significant change in the morphine to codeine concentration ratios neither for living nor post mortem samples. This study showed that in real life whole blood samples, the concentrations of morphine and codeine are relatively stable during long-term storage at -20 °C. 6-AM on the other hand, shows a considerable decrease in concentrations that is important to consider when interpreting results from reanalysis of forensic cases.\n\n\n                    Context: \n                    This excerpt summarizes research findings on the stability of opioids in stored blood samples, highlighting that morphine and codeine concentrations remain relatively stable over long-term storage at -20°C in forensic analysis, while 6-AM levels significantly decrease. It is relevant to the document's comprehensive overview of analytical methods, stability, and interpretation of opioid-related toxicology results, emphasizing the importance of considering degradation when reanalyzing case samples.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_88", "document_index": 23, "latency_s": 1.9233456999936607, "prompt_toks": 51437, "completion_toks": 104}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    PMID:24709028\n\nHoiseth G et al; Forensic Sci Int 239: 6-10 (2014)\n\n\n                    Context: \n                    This excerpt summarizes a forensic toxicology study (PMID:24709028) on the long-term stability of morphine and codeine in postmortem and living blood samples stored at -20°C, highlighting that these drugs remain relatively stable over time. It provides critical information relevant to drug identification and toxicology testing accuracy, situating it within the broader discussion of analytical methods, physical and chemical properties, and safety data for codeine. Its focus on stability underpins proper interpretation of toxicological results in forensic contexts.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_89", "document_index": 23, "latency_s": 1.6872071999969194, "prompt_toks": 51641, "completion_toks": 106}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    The stability of drugs in biological specimens is a major concern during the evaluation of the toxicological results. The stability of morphine, codeine, and 6-acetyl-morphine in blood was studied after different sampling conditions: (i) in glass, polypropylene or polystyrene tubes, (ii) with addition of dipotassium ethylene diamine tetraacetic acid (K2EDTA) or sodium oxalate (Na2C2O4), and (iii) with or without the addition of sodium fluoride (NaF). Spiked blood samples were stored at two different temperatures (4 and -20 °C), analyzed after different storage times and after three freeze-thaw cycles. Opiate concentrations were decreased in all conditions, but the most unstable was 6-acetyl-morphine. The addition of NaF as preservative improved the stability of opiates at all conditions studied, whereas the type of anticoagulant did not affect the stability of opiates. It was concluded that blood samples should be stored at -20 °C in glass tubes containing oxalate and NaF for maximum\n\n\n                    Context: \n                    This excerpt details research on the stability of morphine, codeine, and 6-acetyl-morphine in blood samples under various storage conditions, highlighting factors such as container type, preservatives, temperature, and freeze-thaw cycles. It is relevant to sections on drug stability, analytical methods, and sample handling, emphasizing that blood samples are best stored at -20°C in glass tubes with oxalate and NaF for accurate toxicological evaluation. The findings inform best practices for preserving opioid concentrations during forensic and clinical analysis.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_90", "document_index": 23, "latency_s": 1.086667800002033, "prompt_toks": 51454, "completion_toks": 76}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    whereas the type of anticoagulant did not affect the stability of opiates. It was concluded that blood samples should be stored at -20 °C in glass tubes containing oxalate and NaF for maximum stability.\n\n\n                    Context: \n                    This excerpt summarizes a key finding from a section on the stability and storage of opiates in biological specimens. It highlights that the type of anticoagulant does not influence opiate stability, emphasizing that blood samples should be stored at -20°C in glass tubes with oxalate and NaF to ensure maximum stability, which is crucial for accurate toxicological analysis and forensic interpretation.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_91", "document_index": 23, "latency_s": 1.6893175000004703, "prompt_toks": 51665, "completion_toks": 88}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    PMID:24745085\n\nPapoutsis I et al; J Forensic Sci 59 (2): 550-4 (2014)\n\n11 Identification\n\n11.1 Analytic Laboratory Methods\n\nMethod: EPA-OW/OST 1694; Procedure: high performance liquid chromatography combined with tandem mass spectrometry; Analyte: codeine; Matrix: water, soil, sediment, and biosolids; Detection Limit: 1.5 ng/L.\n\nNational Environmental Methods Index; Analytical, Test and Sampling Methods. Codeine (76-57-3). Available from, as of February 19, 2016: https://www.nemi.gov\n\nMethod: USGS-NWQL O-2080-08; Procedure: high performance liquid chromatography/mass spectrometry; Analyte: codeine; Matrix: broad range of filtered water types; Detection Limit: 0.0111 ug/L.\n\nNational Environmental Methods Index; Analytical, Test and Sampling Methods. Codeine (76-57-3). Available from, as of February 19, 2016: https://www.nemi.gov\n\nAOAC Method 916.04. Acetanilid, caffeine, and codeine in drugs.\n\n\n                    Context: \n                    This section details analytical laboratory methods for detecting and quantifying codeine (CAS 76-57-3) in environmental samples such as water, soil, sediment, and biosolids. It provides specific procedures, detection limits, and sources like the EPA-OW/OST 1694 and USGS-NWQL O-2080-08 methods, highlighting key techniques used in forensic toxicology and environmental analysis within the full document.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_92", "document_index": 23, "latency_s": 1.3658079000015277, "prompt_toks": 51670, "completion_toks": 72}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    AOAC Method 916.04. Acetanilid, caffeine, and codeine in drugs.\n\nAssociation of Official Analytical Chemists. Official Methods of Analysis. 15th ed. and Supplements. Washington, DC: Association of Analytical Chemists, 1990, p. 555\n\nAOAC Method 961.19. Codeine in presence of antihistamines in drugs. Chromatogrpahic method.\n\nAssociation of Official Analytical Chemists. Official Methods of Analysis. 15th ed. and Supplements. Washington, DC: Association of Analytical Chemists, 1990, p. 579\n\nFor more Analytic Laboratory Methods (Complete) data for CODEINE (9 total), please visit the HSDB record page.\n\n11.2 Clinical Laboratory Methods\n\nCodeine ... with /its/ corresponding O-glucuronide conjugates can be quantified by HPLC. The detection limits for codeine, codeine-6-glucuronide, and norcodeine are 5 ng/mL in plasma and 25 ng/mL in urine.\n\nDart, R.C. (ed). Medical Toxicology. Third Edition, Lippincott Williams & Wilkins. Philadelphia, PA. 2004., p. 761\n\n\n                    Context: \n                    This section details analytical laboratory methods for detecting and quantifying codeine in drugs and biological samples, including specific AOAC chromatography procedures and detection limits for HPLC analysis of codeine and its glucuronide conjugates, as well as references to comprehensive methods available on the HSDB record page, highlighting key detection thresholds used in forensic and clinical toxicology.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_93", "document_index": 23, "latency_s": 1.0479392999986885, "prompt_toks": 51526, "completion_toks": 79}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    Dart, R.C. (ed). Medical Toxicology. Third Edition, Lippincott Williams & Wilkins. Philadelphia, PA. 2004., p. 761\n\nModified davidow thin-layer chromatography procedure. Extract drug from urine; separate by using silica gel G. For further analysis elute spots from silica gel & characterize by UV spectrophotometry, gas liquid chromatography or immunoassay.\n\nSunshine, Irving (ed.) Methodology for Analytical Toxicology. Cleveland: CRC Press, Inc., 1975., p. 443\n\n\n                    Context: \n                    This section details analytical laboratory methods for detecting and characterizing codeine in biological samples, specifically urine. It references specific chromatography procedures, including modified davidow thin-layer chromatography, and analysis techniques such as UV spectrophotometry, gas chromatography, and immunoassay, highlighting their relevance for forensic toxicology and drug identification within the comprehensive chemical and safety data provided in the document.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_94", "document_index": 23, "latency_s": 1.7425202000013087, "prompt_toks": 51622, "completion_toks": 109}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    Xylazine, a veterinary sedative, has been found as an adulterant of heroin in street drugs in Puerto Rico. It was found in combination with free morphine and 6-acetylmorphine, codeine, cocaine and benzoylecgonine in postmortem cases at the Puerto Rico Institute of Forensic Sciences (PRIFS). Xylazine is not approved for human use because it has been proven harmful. Currently, three separate analyses are required to determine all the aforementioned drugs at the PRIFS's toxicology laboratory. To reduce analysis time consumption, sample volume, run time, sample preparation and cost, a high-throughput ultra-high-pressure liquid chromatography-tandem mass spectrometry method was developed and validated for the simultaneous quantification of xylazine, free morphine, 6-acetylmorphine, codeine, cocaine and benzoylecgonine in 0.25 mL postmortem blood by protein precipitation, fulfilling confirmation criteria with three transitions for each compound with acceptable relative ion intensities.\n\n\n                    Context: \n                    This excerpt details the detection of xylazine as an adulterant in heroin in Puerto Rico, highlighting its co-occurrence with other opioids and cocaine in postmortem toxicology cases. It emphasizes the development of a high-throughput UHPLC-MS/MS method for simultaneous quantification of xylazine, morphine, acetylmorphine, codeine, and related compounds in blood samples. This information enhances the document's coverage of emerging drugs and analytical techniques relevant to opioid adulteration and forensic drug testing.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_95", "document_index": 23, "latency_s": 1.7120406000030925, "prompt_toks": 51573, "completion_toks": 73}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    cocaine and benzoylecgonine in 0.25 mL postmortem blood by protein precipitation, fulfilling confirmation criteria with three transitions for each compound with acceptable relative ion intensities. Linearity was established between 10-1,000 ng/mL. Total run time was 2.5 min. Limit of detection was 1 ng/mL for cocaine and xylazine, 2 ng/mL for 6-acetylmorphine and 10 ng/mL for free morphine, codeine and benzoylecgonine. The intra-day and inter-day precision and accuracy was less than 15.6%. Process efficiencies ranged from 35.9 to 123.4% and recoveries from 59.9 to 110.1%. The developed method was successfully applied to casework.\n\n\n                    Context: \n                    This excerpt details advanced analytical methods for detecting opioids and related compounds, including cocaine, benzoylecgonine, and xylazine, in postmortem blood samples. It emphasizes sensitivity, linearity, and precision parameters critical for forensic toxicology confirmation. Its relevance lies in illustrating specific laboratory procedures and validation criteria within the comprehensive chemical and toxicological reference document.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_96", "document_index": 23, "latency_s": 1.968526099997689, "prompt_toks": 51440, "completion_toks": 111}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    PMID:22582266\n\nRuiz-Colon K et al; J Anal Toxicol 36 (5): 319-26 (2012)\n\n\n                    Context: \n                    This excerpt summarizes a study by Ruiz-Colon et al. (PMID:22582266) on the stability of opioid compounds, specifically morphine, codeine, and 6-acetyl-morphine, in postmortem blood samples following heroin intake. It provides vital analytical data relevant to forensic toxicology and complements the comprehensive information on codeine’s physical, chemical, and toxicological properties presented in the overall webpage. The findings are essential for interpreting trace levels of these opioids in forensic analyses and ensuring accurate postmortem drug quantification.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_97", "document_index": 23, "latency_s": 1.526781699998537, "prompt_toks": 51618, "completion_toks": 83}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    Opiates continue to be used at high rates in East and Southeast Asia. Hair analysis for drugs of abuse has been developed into a powerful and widely used tool in forensic and clinical toxicology. Specifically, testing the proximal segment of scalp hair to confirm morphine (MOR) positive urine samples could solve the poppy seed problem. Human scalp hair grows approximately 1cm per month and can therefore reflect a retrospective timeline of drug exposure. This study is the first to investigate the disappearance of 6-acetylmorphine (6-AM), MOR and codeine (COD) from human scalp hair after the discontinuation of drug use. Thirty-two healthy women (ages 21-51 years) with a known history of heroin abuse, who went to a rehabilitation center and ceased consuming heroin (for 4-5 months), were recruited into the study. A pharmacokinetic analysis in seven individual hair segments was performed using a first-order kinetic. Assuming a rate of hair growth of 1 cm/month, the mean hair elimination\n\n\n                    Context: \n                    This excerpt discusses forensic hair analysis techniques for detecting opioid exposure, specifically examining the disappearance rates of 6-acetylmorphine, morphine, and codeine from human scalp hair after cessation of drug use. It provides pharmacokinetic data on hair segment analysis and drug elimination timelines, relevant for understanding detection windows and drug monitoring within the broader context of chemical identification, safety, and toxicology in the full document.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_98", "document_index": 23, "latency_s": 1.4484307000093395, "prompt_toks": 51600, "completion_toks": 82}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    into the study. A pharmacokinetic analysis in seven individual hair segments was performed using a first-order kinetic. Assuming a rate of hair growth of 1 cm/month, the mean hair elimination half-lives of 6-AM, MOR and COD were 0.88 months (95% CI, 0.74-1.03), 0.73 months (95% CI, 0.64-0.81), and 0.61 months (95% CI, 0.54-0.69), respectively. Our results suggest that to evaluate the discontinuation of opiate abuse after a 6-month period of abstinence, the results from a 3-cm proximal hair segment should be free of 6-AM at the proposed 0.2 ng/mg cutoff level. This finding should become the basis for the interpretation of results from segmental hair analyses in the evaluation of drug abstinence.\n\n\n                    Context: \n                    This excerpt details a pharmacokinetic analysis of opiate metabolite elimination from human hair segments, providing critical data on the half-lives of 6-AM, MOR, and COD. It is relevant within the document's section on drug metabolism, detection, and interpretation in forensic toxicology, informing the assessment of drug abstinence duration via segmental hair analysis and establishing cutoff levels for detecting opioid use cessation.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_99", "document_index": 23, "latency_s": 1.4887942999921506, "prompt_toks": 51667, "completion_toks": 56}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    PMID:23165127\n\nShen M et al; Forensic Sci Int 227 (1-3): 64-8 (2013)\n\nFor more Clinical Laboratory Methods (Complete) data for CODEINE (19 total), please visit the HSDB record page.\n\n12 Safety and Hazards\n\n12.1 Hazards Identification\n\n12.1.1 GHS Classification\n\n1 of 3\n\nView All\n\nPictogram(s)\n\nCorrosive\n\nIrritant\n\nHealth Hazard\n\nSignal\n\nDanger\n\nGHS Hazard Statements\n\nH302 (93.4%): Harmful if swallowed [Warning Acute toxicity, oral]\n\nH317 (19.7%): May cause an allergic skin reaction [Warning Sensitization, Skin]\n\nH318 (14.8%): Causes serious eye damage [Danger Serious eye damage/eye irritation]\n\nH336 (16.4%): May cause drowsiness or dizziness [Warning Specific target organ toxicity, single exposure; Narcotic effects]\n\nH361d (13.1%): Suspected of damaging the unborn child [Warning Reproductive toxicity]\n\nH362 (18%): May cause harm to breast-fed children [Reproductive toxicity, effects on or via lactation]\n\nPrecautionary Statement Codes\n\n\n                    Context: \n                    This excerpt provides detailed information on the hazards, hazard classification, and safety hazards associated with codeine, including GHS hazard statements, pictograms, and precautionary codes. It is relevant for understanding codeine's safety profile and hazard management within the comprehensive PubChem chemical data resource.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_100", "document_index": 23, "latency_s": 1.6800662000023294, "prompt_toks": 51660, "completion_toks": 87}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    H362 (18%): May cause harm to breast-fed children [Reproductive toxicity, effects on or via lactation]\n\nPrecautionary Statement Codes\n\nP203, P260, P261, P263, P264, P264+P265, P270, P271, P272, P280, P301+P317, P302+P352, P304+P340, P305+P354+P338, P317, P318, P319, P321, P330, P333+P317, P362+P364, P403+P233, P405, and P501\n\n(The corresponding statement to each P-code can be found at the GHS Classification page.)\n\nECHA C&L Notifications Summary\n\nAggregated GHS information provided per 61 reports by companies from 9 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.\n\nInformation may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. For more detailed information, please visit ECHA C&L website.\n\n\n                    Context: \n                    This excerpt provides detailed hazard classification information for codeine, highlighting its reproductive toxicity (H362: harm to breast-fed children) with an 18% notification rate. It includes applicable precautionary statement codes, their corresponding hazard statements, and summaries of ECHA C&L notifications, emphasizing variations based on impurity and additive factors. This data is relevant for understanding codeine’s safety profile and regulatory classifications within the comprehensive chemical hazard overview.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_101", "document_index": 23, "latency_s": 1.5259367999969982, "prompt_toks": 51685, "completion_toks": 74}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    12.1.2 Hazard Classes and Categories\n\nAcute Tox. 4 (93.4%)\n\nSkin Sens. 1 (19.7%)\n\nEye Dam. 1 (14.8%)\n\nSTOT SE 3 (16.4%)\n\nRepr. 2 (13.1%)\n\nLact. (18%)\n\nAcute Tox. 4 (90.5%)\n\nSkin Sens. 1 (90.5%)\n\nAcute Tox. 4 (81%)\n\nResp. Sens. 1 (90.5%)\n\nRepr. 2 (14.3%)\n\n12.1.3 Health Hazards\n\nSYMPTOMS: Symptoms of exposure to this compound may include gastrointestinal distress, nausea, vomiting, constipation; dizziness; palpitations; drowsiness; pruritis; restlessness, excitement; vertigo; and mydrasis. Larger doses result in muscle weakness; tremors; miosis (pinpoint pupils); delirium; coma; and convulsions with possible development of central nervous system and respiratory depression which may result in death. Body temperature and blood pressure may fall. Sensitivity reactions and pulmonary edema (fitting the description of \"heroin lung\") have been reported. Chronic symptoms may include miosis and rapid mood changes. Excessive use may lead to physical dependence and tolerance.\n\n\n                    Context: \n                    This section details the hazard classification and health hazard symptoms associated with codeine, including specific GHS categories like Acute Toxicity and Skin Sensitization, as well as detailed exposure symptoms such as gastrointestinal distress, central nervous system depression, and signs of overdose. Its comprehensive hazard profile is crucial for safety assessments and emergency response planning within the full chemical safety and toxicity documentation.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_102", "document_index": 23, "latency_s": 1.601582100003725, "prompt_toks": 51655, "completion_toks": 74}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    ACUTE/CHRONIC HAZARDS: When heated to decomposition this compound emits toxic fumes of NOx. (NTP, 1992)\n\nNational Toxicology Program, Institute of Environmental Health Sciences, National Institutes of Health (NTP). 1992. National Toxicology Program Chemical Repository Database. Research Triangle Park, North Carolina.\n\n12.1.4 Fire Hazards\n\nThis chemical is combustible. (NTP, 1992)\n\nNational Toxicology Program, Institute of Environmental Health Sciences, National Institutes of Health (NTP). 1992. National Toxicology Program Chemical Repository Database. Research Triangle Park, North Carolina.\n\n12.1.5 Hazards Summary\n\nAllergic contact dermatitis reported in pharmaceutical workers; [Kanerva, p. 1139] Asthma reported in pharmaceutical workers processing opiate compounds; [Malo]\n\nKanerva - Rustemeyer L, Elsner P, John SM, Maibach HI (eds). Kanerva's Occupational Dermatology, 2nd Ed. Berlin: Springer-Verlag, 2012., p. 1139\n\n12.1.6 Fire Potential\n\nFlammable when exposed to heat or flame.\n\n\n                    Context: \n                    This section summarizes the safety hazards associated with heating, decomposition, and fire risks of codeine, highlighting that it emits toxic NOx fumes when heated to decomposition, is combustible, and may cause allergic dermatitis and asthma in pharmaceutical workers. These hazard details are crucial for safety protocols and risk assessment within the comprehensive chemical safety and hazard overview provided in the full document.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_103", "document_index": 23, "latency_s": 1.2607568000094034, "prompt_toks": 51584, "completion_toks": 52}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    12.1.6 Fire Potential\n\nFlammable when exposed to heat or flame.\n\nLewis, R.J. Sr. (ed) Sax's Dangerous Properties of Industrial Materials. 11th Edition. Wiley-Interscience, Wiley & Sons, Inc. Hoboken, NJ. 2004., p. 980\n\n12.2 First Aid Measures\n\n12.2.1 First Aid\n\nEYES: First check the victim for contact lenses and remove if present. Flush victim's eyes with water or normal saline solution for 20 to 30 minutes while simultaneously calling a hospital or poison control center. Do not put any ointments, oils, or medication in the victim's eyes without specific instructions from a physician. IMMEDIATELY transport the victim after flushing eyes to a hospital even if no symptoms (such as redness or irritation) develop.\n\n\n                    Context: \n                    This segment provides critical safety information about codeine's fire potential and first aid measures, including specific eye exposure protocols. It is essential for quick emergency reference within the comprehensive hazard and safety section of the full document, supporting effective search retrieval for handling and response procedures.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_104", "document_index": 23, "latency_s": 1.5728871000028448, "prompt_toks": 51586, "completion_toks": 81}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    SKIN: IMMEDIATELY flood affected skin with water while removing and isolating all contaminated clothing. Gently wash all affected skin areas thoroughly with soap and water. If symptoms such as redness or irritation develop, IMMEDIATELY call a physician and be prepared to transport the victim to a hospital for treatment.\n\nINHALATION: IMMEDIATELY leave the contaminated area; take deep breaths of fresh air. If symptoms (such as wheezing, coughing, shortness of breath, or burning in the mouth, throat, or chest) develop, call a physician and be prepared to transport the victim to a hospital. Provide proper respiratory protection to rescuers entering an unknown atmosphere. Whenever possible, Self-Contained Breathing Apparatus (SCBA) should be used; if not available, use a level of protection greater than or equal to that advised under Protective Clothing.\n\n\n                    Context: \n                    This excerpt summarizes emergency first aid procedures for skin and inhalation exposures to the chemical, highlighting immediate actions such as skin flooding with water, washing with soap, and prompt medical evaluation. It is part of the broader safety and hazard section of the full document, providing critical response guidelines for acute exposure incidents involving this substance. These procedures are essential for effective hazard management and risk mitigation in toxicology and safety contexts.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_105", "document_index": 23, "latency_s": 1.4243504999903962, "prompt_toks": 51624, "completion_toks": 55}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    INGESTION: DO NOT INDUCE VOMITING. If the victim is conscious and not convulsing, give 1 or 2 glasses of water to dilute the chemical and IMMEDIATELY call a hospital or poison control center. Be prepared to transport the victim to a hospital if advised by a physician. If the victim is convulsing or unconscious, do not give anything by mouth, ensure that the victim's airway is open and lay the victim on his/her side with the head lower than the body. DO NOT INDUCE VOMITING. IMMEDIATELY transport the victim to a hospital.\n\nOTHER: This chemical is legally restricted. (NTP, 1992)\n\nNational Toxicology Program, Institute of Environmental Health Sciences, National Institutes of Health (NTP). 1992. National Toxicology Program Chemical Repository Database. Research Triangle Park, North Carolina.\n\n12.3 Fire Fighting\n\nFires involving this material can be controlled with a dry chemical, carbon dioxide or Halon extinguisher. (NTP, 1992)\n\n\n                    Context: \n                    This excerpt provides critical emergency response information, including instructions for ingestion, first aid, and fire safety related to the chemical described in the full document. It details poisoning management protocols and fire handling guidelines, essential for safety, toxicology, and regulatory contexts within the comprehensive chemical profile.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_106", "document_index": 23, "latency_s": 1.4120392999902833, "prompt_toks": 51611, "completion_toks": 63}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    12.3 Fire Fighting\n\nFires involving this material can be controlled with a dry chemical, carbon dioxide or Halon extinguisher. (NTP, 1992)\n\nNational Toxicology Program, Institute of Environmental Health Sciences, National Institutes of Health (NTP). 1992. National Toxicology Program Chemical Repository Database. Research Triangle Park, North Carolina.\n\n12.3.1 Fire Fighting Procedures\n\nSuitable extinguishing media: Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide. /Codeine monohydrate/\n\nSigma-Aldrich; Safety Data Sheet for Codeine monohydrate. Product Number: C5901, Version 5.3 (Revision Date 05/23/2015). Available from, as of January 29, 2016: https://www.sigmaaldrich.com/safety-center.html\n\nAdvice for firefighters: Wear self-contained breathing apparatus for firefighting if necessary. /Codeine monohydrate/\n\n\n                    Context: \n                    This chunk provides detailed fire fighting instructions and hazard control procedures for handling codeine monohydrate, including recommended extinguishing media and safety advice for responders. It is part of the comprehensive safety and hazard information section of the full document, which covers chemical hazards, safety measures, and response protocols for codeine.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_107", "document_index": 23, "latency_s": 1.2020129000011366, "prompt_toks": 51573, "completion_toks": 46}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    Advice for firefighters: Wear self-contained breathing apparatus for firefighting if necessary. /Codeine monohydrate/\n\nSigma-Aldrich; Safety Data Sheet for Codeine monohydrate. Product Number: C5901, Version 5.3 (Revision Date 05/23/2015). Available from, as of January 29, 2016: https://www.sigmaaldrich.com/safety-center.html\n\nTo fight fire, use alcohol foam.\n\nLewis, R.J. Sr. (ed) Sax's Dangerous Properties of Industrial Materials. 11th Edition. Wiley-Interscience, Wiley & Sons, Inc. Hoboken, NJ. 2004., p. 980\n\n12.4 Accidental Release Measures\n\n12.4.1 Cleanup Methods\n\n\n                    Context: \n                    This excerpt provides emergency response procedures for handling fires and accidental releases of codeine monohydrate, including recommended firefighting equipment, methods, and cleanup protocols, relevant to safety hazard management sections within the comprehensive chemical safety documentation.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_108", "document_index": 23, "latency_s": 1.5118233000102919, "prompt_toks": 51595, "completion_toks": 43}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    12.4 Accidental Release Measures\n\n12.4.1 Cleanup Methods\n\nACCIDENTAL RELEASE MEASURES: Personal precautions, protective equipment and emergency procedures: Use personal protective equipment. Avoid dust formation. Avoid breathing vapors, mist or gas. Ensure adequate ventilation. Avoid breathing dust; Environmental precautions: Do not let product enter drains; Methods and materials for containment and cleaning up: Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed containers for disposal. /Codeine monohydrate/\n\nSigma-Aldrich; Safety Data Sheet for Codeine monohydrate. Product Number: C5901, Version 5.3 (Revision Date 05/23/2015). Available from, as of January 29, 2016: https://www.sigmaaldrich.com/safety-center.html\n\n12.4.2 Disposal Methods\n\n\n                    Context: \n                    This section provides safety guidelines for handling accidental releases of codeine, including cleanup procedures and environmental precautions, referencing specific safety data sheets. It is part of the comprehensive hazard and safety information in the full drug safety document.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_109", "document_index": 23, "latency_s": 1.5113493999961065, "prompt_toks": 51622, "completion_toks": 64}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    12.4.2 Disposal Methods\n\nSRP: Expired or waste pharmaceuticals shall carefully take into consideration applicable DEA, EPA, and FDA regulations. It is not appropriate to dispose by flushing the pharmaceutical down the toilet or discarding to trash. If possible return the pharmaceutical to the manufacturer for proper disposal being careful to properly label and securely package the material. Alternatively, the waste pharmaceutical shall be labeled, securely packaged and transported by a state licensed medical waste contractor to dispose by burial in a licensed hazardous or toxic waste landfill or incinerator.\n\nProduct: Offer surplus and non-recyclable solutions to a licensed disposal company; Contaminated packaging: Dispose of as unused product. /Codeine monohydrate/\n\nSigma-Aldrich; Safety Data Sheet for Codeine monohydrate. Product Number: C5901, Version 5.3 (Revision Date 05/23/2015). Available from, as of January 29, 2016: https://www.sigmaaldrich.com/safety-center.html\n\n\n                    Context: \n                    This section provides detailed disposal methods and regulatory considerations for handling expired or waste codeine monohydrate, emphasizing proper packaging, transport, and compliance with DEA, EPA, and FDA regulations, referencing Sigma-Aldrich safety data. It is relevant for ensuring safe pharmacological waste management within the comprehensive chemical safety overview.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_110", "document_index": 23, "latency_s": 1.106169000006048, "prompt_toks": 51613, "completion_toks": 66}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    SRP: At the time of review, criteria for land treatment or burial (sanitary landfill) disposal practices are subject to significant revision. Prior to implementing land disposal of waste residue (including waste sludge), consult with environmental regulatory agencies for guidance on acceptable disposal practices.\n\n12.4.3 Preventive Measures\n\nPrecautions for safe handling: Avoid contact with skin and eyes. Avoid formation of dust and aerosols. Further processing of solid materials may result in the formation of combustible dusts. The potential for combustible dust formation should be taken into consideration before additional processing occurs. Provide appropriate exhaust ventilation at places where dust is formed. /Codeine monohydrate/\n\nSigma-Aldrich; Safety Data Sheet for Codeine monohydrate. Product Number: C5901, Version 5.3 (Revision Date 05/23/2015). Available from, as of January 29, 2016: https://www.sigmaaldrich.com/safety-center.html\n\n\n                    Context: \n                    This excerpt covers disposal and handling precautions for codeine monohydrate, including environmental disposal criteria and safety measures to prevent dust formation during processing. It is relevant for safety protocols and regulatory compliance sections in the comprehensive chemical safety document. Key details include advice to consult environmental agencies and specific handling precautions from Sigma-Aldrich SDS.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_111", "document_index": 23, "latency_s": 1.1816569000075106, "prompt_toks": 51639, "completion_toks": 65}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    Appropriate engineering controls: Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and at the end of workday. /Codeine monohydrate/\n\nSigma-Aldrich; Safety Data Sheet for Codeine monohydrate. Product Number: C5901, Version 5.3 (Revision Date 05/23/2015). Available from, as of January 29, 2016: https://www.sigmaaldrich.com/safety-center.html\n\nGloves must be inspected prior to use. Use proper glove removal technique (without touching glove's outer surface) to avoid skin contact with this product. Dispose of contaminated gloves after use in accordance with applicable laws and good laboratory practices. Wash and dry hands. /Codeine monohydrate/\n\nSigma-Aldrich; Safety Data Sheet for Codeine monohydrate. Product Number: C5901, Version 5.3 (Revision Date 05/23/2015). Available from, as of January 29, 2016: https://www.sigmaaldrich.com/safety-center.html\n\n\n                    Context: \n                    This section provides specific safety measures and handling instructions for codeine monohydrate, emphasizing engineering controls, personal protective equipment, glove inspection, proper disposal, and hand hygiene. As part of the full safety and hazard information in the document, it supports comprehensive risk management protocols essential for laboratory and industrial contexts involving this compound.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_112", "document_index": 23, "latency_s": 1.1796611000027042, "prompt_toks": 51499, "completion_toks": 66}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    SRP: Local exhaust ventilation should be applied wherever there is an incidence of point source emissions or dispersion of regulated contaminants in the work area. Ventilation control of the contaminant as close to its point of generation is both the most economical and safest method to minimize personnel exposure to airborne contaminants. Ensure that the local ventilation moves the contaminant away from the worker.\n\n12.5 Handling and Storage\n\n12.5.1 Nonfire Spill Response\n\n\n                    Context: \n                    This excerpt from the full document covers safety protocols related to handling and controlling airborne contaminants of codeine in industrial settings. It details ventilation strategies for minimizing personnel exposure, specifically emphasizing local exhaust ventilation at point sources and proper contaminant removal methods. This information is critical for ensuring safe handling during manufacturing, spill response, and workplace safety procedures.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_113", "document_index": 23, "latency_s": 1.5743088999879546, "prompt_toks": 51582, "completion_toks": 78}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    12.5 Handling and Storage\n\n12.5.1 Nonfire Spill Response\n\nSMALL SPILLS AND LEAKAGE: Should a spill occur while you are handling this chemical, FIRST REMOVE ALL SOURCES OF IGNITION, then you should dampen the solid spill material with 60-70% ethanol and transfer the dampened material to a suitable container. Use absorbent paper dampened with 60-70% ethanol to pick up any remaining material. Seal the absorbent paper, and any of your clothes, which may be contaminated, in a vapor-tight plastic bag for eventual disposal. Solvent wash all contaminated surfaces with 60-70% ethanol followed by washing with a soap and water solution. Do not reenter the contaminated area until the Safety Officer (or other responsible person) has verified that the area has been properly cleaned.\n\n\n                    Context: \n                    This section provides detailed handling and storage procedures for accidental nonfire spills of codeine, emphasizing safety measures such as ignition source removal, ethanol dampening, containment, and surface decontamination. It is part of the comprehensive safety and hazards information in the full document, essential for toxicology management and emergency response. Key details include spill cleanup steps, protective measures, and verification before reentry.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_114", "document_index": 23, "latency_s": 1.7415235999942524, "prompt_toks": 51642, "completion_toks": 73}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    STORAGE PRECAUTIONS: You should protect this chemical from exposure to light. Keep the container tightly closed under an inert atmosphere, and store under refrigerated temperatures. STORE AWAY FROM SOURCES OF IGNITION. This compound is a Schedule II DEA Controlled Substance and is to be stored according to State and Federal Regulations. Refer to Code of Federal Regulations Title 21 Part 1300 to End. (NTP, 1992)\n\nNational Toxicology Program, Institute of Environmental Health Sciences, National Institutes of Health (NTP). 1992. National Toxicology Program Chemical Repository Database. Research Triangle Park, North Carolina.\n\n12.5.2 Storage Conditions\n\nKeep container tightly closed in a dry and well-ventilated place. Recommended storage temperature 2 - 8 °C /Codeine monohydrate/\n\nSigma-Aldrich; Safety Data Sheet for Codeine monohydrate. Product Number: C5901, Version 5.3 (Revision Date 05/23/2015). Available from, as of January 29, 2016: https://www.sigmaaldrich.com/safety-center.html\n\n\n                    Context: \n                    This section provides specific storage precautions and conditions for codeine, highlighting the importance of protecting the substance from light, storing under inert atmosphere and refrigerated temperatures, and keeping it away from ignition sources. It emphasizes regulatory requirements for Schedule II DEA controlled substances and references authoritative safety data and storage guidelines, making it essential for safe handling and compliance within the comprehensive chemical safety overview.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_115", "document_index": 23, "latency_s": 1.6959836000023643, "prompt_toks": 51602, "completion_toks": 70}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    Codeine sulfate tablets should be stored in well-closed, light-resistant containers at a temperature less than 40 °C, preferably between 15-30 °C.\n\nAmerican Society of Health-System Pharmacists 2016; Drug Information 2016. Bethesda, MD. 2016, p. 2205\n\n12.6 Exposure Control and Personal Protection\n\n12.6.1 Personal Protective Equipment (PPE)\n\nRECOMMENDED RESPIRATOR: Where the neat test chemical is weighed and diluted, wear a NIOSH-approved half face respirator equipped with an organic vapor/acid gas cartridge (specific for organic vapors, HCl, acid gas and SO2) with a dust/mist filter. (NTP, 1992)\n\nNational Toxicology Program, Institute of Environmental Health Sciences, National Institutes of Health (NTP). 1992. National Toxicology Program Chemical Repository Database. Research Triangle Park, North Carolina.\n\n\n                    Context: \n                    This excerpt provides detailed storage guidelines and personal protective equipment recommendations for handling codeine sulfate tablets, situating it within the broader context of the full document's comprehensive safety and hazard information on codeine, including storage conditions, safety measures, and protective protocols. It emphasizes best practices for storage temperature and PPE usage, relevant for safety considerations in pharmaceutical handling.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_116", "document_index": 23, "latency_s": 1.0487649999995483, "prompt_toks": 51651, "completion_toks": 77}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    Eye/face protection: Safety glasses with side-shields conforming to EN166. Use equipment for eye protection tested and approved under appropriate government standards such as NIOSH (US) or EN 166(EU). /Codeine monohydrate/\n\nSigma-Aldrich; Safety Data Sheet for Codeine monohydrate. Product Number: C5901, Version 5.3 (Revision Date 05/23/2015). Available from, as of January 29, 2016: https://www.sigmaaldrich.com/safety-center.html\n\nSkin protection: Handle with gloves. /Codeine monohydrate/\n\nSigma-Aldrich; Safety Data Sheet for Codeine monohydrate. Product Number: C5901, Version 5.3 (Revision Date 05/23/2015). Available from, as of January 29, 2016: https://www.sigmaaldrich.com/safety-center.html\n\nBody Protection: Complete suit protecting against chemicals. The type of protective equipment must be selected according to the concentration and amount of the dangerous substance at the specific workplace. /Codeine monohydrate/\n\n\n                    Context: \n                    This chunk details recommended personal protective equipment for handling codeine monohydrate, including eye/face protection, gloves, and full-body suits, based on safety data sheets. It is relevant for safety, handling, and regulatory sections within this comprehensive chemical safety and hazard management document. Key details include standards like EN166 and NIOSH, with specific product references and source links.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_117", "document_index": 23, "latency_s": 1.5754350000061095, "prompt_toks": 51689, "completion_toks": 71}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    Sigma-Aldrich; Safety Data Sheet for Codeine monohydrate. Product Number: C5901, Version 5.3 (Revision Date 05/23/2015). Available from, as of January 29, 2016: https://www.sigmaaldrich.com/safety-center.html\n\nRespiratory protection: For nuisance exposures use type P95 (US) or type P1 (EU EN 143) particle respirator. For higher level protection use type OV/AG/P99 (US) or type ABEK-P2 (EU EN 143) respirator cartridges. Use respirators and components tested and approved under appropriate government standards such as NIOSH (US) or CEN (EU). /Codeine monohydrate/\n\nSigma-Aldrich; Safety Data Sheet for Codeine monohydrate. Product Number: C5901, Version 5.3 (Revision Date 05/23/2015). Available from, as of January 29, 2016: https://www.sigmaaldrich.com/safety-center.html\n\n12.7 Stability and Reactivity\n\n12.7.1 Air and Water Reactions\n\nThis compound is light sensitive and sensitive to prolonged exposure to air. Insoluble in water.\n\n12.7.2 Reactive Group\n\nAlcohols and Polyols\n\n\n                    Context: \n                    This excerpt from Sigma-Aldrich's safety data sheet for codeine monohydrate details stability, reactivity, air and water reactions, and respiratory protection measures. It is essential for understanding storage, handling, and safety protocols of codeine in pharmaceutical and laboratory settings, complementing the overall chemical safety and reactivity information within the full document.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_118", "document_index": 23, "latency_s": 1.855423899993184, "prompt_toks": 51633, "completion_toks": 127}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    12.7.1 Air and Water Reactions\n\nThis compound is light sensitive and sensitive to prolonged exposure to air. Insoluble in water.\n\n12.7.2 Reactive Group\n\nAlcohols and Polyols\n\nAmines, Phosphines, and Pyridines\n\nEthers\n\n12.7.3 Reactivity Profile\n\nCODEINE is incompatible with bromides, iodides and salts of heavy metals. (NTP, 1992). It is an amine. Amines are chemical bases. They neutralize acids to form salts plus water. These acid-base reactions are exothermic. The amount of heat that is evolved per mole of amine in a neutralization is largely independent of the strength of the amine as a base. Amines may be incompatible with isocyanates, halogenated organics, peroxides, phenols (acidic), epoxides, anhydrides, and acid halides. Flammable gaseous hydrogen is generated by amines in combination with strong reducing agents, such as hydrides.\n\n\n                    Context: \n                    This section details chemical reactivity and incompatibility profiles for codeine, highlighting its sensitivity to light and air, insolubility in water, and reactive groups such as alcohols, polyols, amines, phosphines, pyridines, and ethers. It notes that codeine is incompatible with salts of heavy metals, halogenated organics, oxidizers, phenols, epoxides, anhydrides, and acid halides, and warns that amines can generate flammable hydrogen gas with strong reducing agents. This information is critical for understanding chemical stability and safe handling within the broader document.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_119", "document_index": 23, "latency_s": 1.758122799990815, "prompt_toks": 51588, "completion_toks": 102}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    National Toxicology Program, Institute of Environmental Health Sciences, National Institutes of Health (NTP). 1992. National Toxicology Program Chemical Repository Database. Research Triangle Park, North Carolina.\n\n12.7.4 Hazardous Reactivities and Incompatibilities\n\nPrecipitates from its aqueous solution by most alkaloidal precipitants but not by sodium, potassium or ammonium carbonate, or sodium bicarbonate. Aqueous solutions are sufficiently alkaline to precipitate other less soluble alkaloids from solutions of their salts. Ammonia may be liberated from ammonium salts.\n\nTroy, D.B. (Ed); Remmington The Science and Practice of Pharmacy. 21 st Edition. Lippincott Williams & Williams, Philadelphia, PA 2005, p. 1527\n\nIncompatible materials: Strong oxidizing agents. /Codeine monohydrate/\n\n\n                    Context: \n                    This excerpt provides detailed information on the hazardous reactivities and chemical incompatibilities of codeine, referencing authoritative sources including the 1992 NTP database and the 21st edition of Remmington's Pharmacy. It highlights codeine's tendency to precipitate with alkaloidal precipitants and its incompatibility with strong oxidizing agents, relevant for safety and handling guidelines within the comprehensive chemical profile. This information is essential for understanding codeine’s reactivity, hazards, and appropriate storage or disposal measures.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_120", "document_index": 23, "latency_s": 1.5383460000011837, "prompt_toks": 51614, "completion_toks": 76}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    Incompatible materials: Strong oxidizing agents. /Codeine monohydrate/\n\nSigma-Aldrich; Safety Data Sheet for Codeine monohydrate. Product Number: C5901, Version 5.3 (Revision Date 05/23/2015). Available from, as of January 29, 2016: https://www.sigmaaldrich.com/safety-center.html\n\n12.8 Regulatory Information\n\nDEA Controlled Substances\n\nDEA schedule II controlled substance\n\n21 CFR Sections 1308.11-1308.15 https://www.ecfr.gov/current/title-21/chapter-II/part-1308\n\nREACH Registered Substance\n\nStatus: Active Update: 29-06-2022 https://echa.europa.eu/registration-dossier/-/registered-dossier/19207\n\nNew Zealand EPA Inventory of Chemical Status\n\nCodeine: Does not have an individual approval but may be used under an appropriate group standard\n\n12.8.1 FDA Requirements\n\n\n                    Context: \n                    This excerpt details the regulatory classification, authorized uses, and safety considerations for codeine monohydrate, including its status as a DEA schedule II controlled substance, recent regulatory updates, and compliance information from the US FDA, REACH, and New Zealand EPA. It provides essential regulatory context relevant to understanding legal restrictions and safety protocols related to this compound within the full chemical profile.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_121", "document_index": 23, "latency_s": 1.2246510999975726, "prompt_toks": 51644, "completion_toks": 70}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    New Zealand EPA Inventory of Chemical Status\n\nCodeine: Does not have an individual approval but may be used under an appropriate group standard\n\n12.8.1 FDA Requirements\n\nSchedule I shall consist of the drugs and other substances, by whatever official name, common or usual name, chemical name, or brand name designated, listed in this section. Each drug or substance has been assigned the DEA Controlled Substances Code Number set forth opposite it. Unless specifically excepted or unless listed in another schedule, any of the following opium derivatives, its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation. /Acetyldihydrocodeine, Codeine methylbromide, Codeine-N-Oxide, Nicocodeine/\n\nOpium Derivative\n\nDEA Code\n\nOpium Derivative\n\nAcetyldihydrocodeine\n\nDEA Code\n\n9051\n\nOpium Derivative\n\nCodeine methylbromide\n\nDEA Code\n\n9070\n\nOpium Derivative\n\nCodeine-N-Oxide\n\nDEA Code\n\n9053\n\n\n                    Context: \n                    This section details the regulatory status and classification of codeine, specifically its approval status in New Zealand and its listing under FDA Schedule I. It includes FDA scheduling information, alternative chemical names, DEA codes for related opium derivatives, and key regulatory references, which are essential for legal, safety, and compliance searches related to codeine's controlled substance status.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_122", "document_index": 23, "latency_s": 1.6950212999945506, "prompt_toks": 51540, "completion_toks": 62}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    Opium Derivative\n\nDEA Code\n\nOpium Derivative\n\nAcetyldihydrocodeine\n\nDEA Code\n\n9051\n\nOpium Derivative\n\nCodeine methylbromide\n\nDEA Code\n\n9070\n\nOpium Derivative\n\nCodeine-N-Oxide\n\nDEA Code\n\n9053\n\nOpium Derivative\n\nNicocodeine\n\nDEA Code\n\n9309\n\n21 CFR 1308.11(c) (USFDA); U.S. National Archives and Records Administration's Electronic Code of Federal Regulations. Available from, as of May 13, 2016: https://www.ecfr.gov\n\n\n                    Context: \n                    This section lists specific opium derivatives and their associated DEA drug codes, along with relevant regulatory reference to the USFDA’s electronic code. It is part of the detailed classification and regulatory framework context within the comprehensive chemical and pharmacological profile of codeine and related compounds, aiding in precise identification and legal categorization.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_123", "document_index": 23, "latency_s": 1.7784209999954328, "prompt_toks": 51617, "completion_toks": 85}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    Schedule II shall consist of the drugs and other substances, by whatever official name, common or usual name, chemical name, or brand name designated, listed in this section. Each drug or substance has been assigned the DEA Controlled Substances Code Number set forth opposite it. Substances, vegetable origin or chemical synthesis. Unless specifically excepted or unless listed in another schedule, any of the following substances whether produced directly or indirectly by extraction from substances of vegetable origin, or independently by means of chemical synthesis, or by a combination of extraction and chemical synthesis: (1) Opium and opiate, and any salt, compound, derivative, or preparation of opium or opiate excluding apomorphine, thebaine-derived butorphanol, dextrorphan, nalbuphine, nalmefene, naloxegol, naloxone, and naltrexone, and their respective salts, but including the following. Codeine (DEA Code Number: 9050) is included on this list.\n\n\n                    Context: \n                    This excerpt details the classification of Schedule II controlled substances under the DEA, listing drugs like opium, its derivatives, and specifically mentions codeine with DEA Code Number 9050. It is relevant for understanding legal drug scheduling and regulatory status, providing context for the comprehensive chemical and pharmacological data on codeine presented in the full document. This section emphasizes codeine’s legal classification as a Schedule II drug of high abuse potential.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_124", "document_index": 23, "latency_s": 1.693941100005759, "prompt_toks": 51616, "completion_toks": 81}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    21 CFR 1308.12 (USFDA); U.S. National Archives and Records Administration's Electronic Code of Federal Regulations. Available from, as of February 18, 2016: https://www.ecfr.gov\n\nSchedule II shall consist of the drugs and other substances, by whatever official name, common or usual name, chemical name, or brand name designated, listed in this section. Each drug or substance has been assigned the DEA Controlled Substances Code Number set forth opposite it. ... Opiates. Unless specifically excepted or unless in another schedule any of the following opiates, including its isomers, esters, ethers, salts and salts of isomers, esters and ethers whenever the existence of such isomers, esters, ethers, and salts is possible within the specific chemical designation, dextrorphan and levopropoxyphene excepted: Dihydrocodeine (DEA Code Number: 9120) is included on this list. /Dihydrocodeine/\n\n\n                    Context: \n                    This excerpt from the US FDA regulations details the classification and scheduling of controlled substances under 21 CFR 1308.12, specifically listing opiates including dihydrocodeine (DEA Code: 9120) as a Schedule II substance. It provides relevant legal context for drug scheduling, regulatory control, and substance code identification within the full document on chemical safety and legal classifications of opioids like codeine.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_125", "document_index": 23, "latency_s": 1.6854983999946853, "prompt_toks": 51627, "completion_toks": 90}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    21 CFR 1308.12 (USFDA); U.S. National Archives and Records Administration's Electronic Code of Federal Regulations. Available from, as of February 18, 2016: https://www.ecfr.gov\n\nSchedule III shall consist of the drugs and other substances, by whatever official name, common or usual name, chemical name, or brand name designated, listed in this section. Each drug or substance has been assigned the DEA Controlled Substances Code Number set forth opposite it. ... Narcotic drugs. Unless specifically excepted or unless listed in another schedule: (1) Any material, compound, mixture, or preparation containing any of the following narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid, in limited quantities as set forth below: (i) Not more than 1.8 grams of codeine per 100 milliliters or not more than 90 milligrams per dosage unit, with an equal or greater quantity of an isoquinoline alkaloid of opium. DEA Code Number: 9803.\n\n\n                    Context: \n                    This excerpt provides the USFDA regulation details from 21 CFR 1308.12 regarding Schedule III narcotic drugs, specifically citing limits on codeine content—no more than 1.8 grams per 100 mL or 90 mg per dosage unit—and includes the DEA drug code number 9803. It is relevant for understanding regulatory classifications and legal dosage restrictions of codeine within the broader context of controlled substance laws discussed in the full document.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_126", "document_index": 23, "latency_s": 1.6852144000004046, "prompt_toks": 51706, "completion_toks": 71}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    21 CFR 1308.13 (USFDA); U.S. National Archives and Records Administration's Electronic Code of Federal Regulations. Available from, as of February 18, 2016: https://www.ecfr.gov\n\nFor more FDA Requirements (Complete) data for CODEINE (8 total), please visit the HSDB record page.\n\n12.9 Other Safety Information\n\nChemical Assessment\n\nIMAP assessments - Morphinan-6-ol, 7,8-didehydro-4,5-epoxy-3-methoxy-17-methyl-, (5.alpha.,6.alpha.)-: Environment tier I assessment\n\nIMAP assessments - Morphinan-6-ol, 7,8-didehydro-4,5-epoxy-3-methoxy-17-methyl-, (5.alpha.,6.alpha.)-: Human health tier I assessment\n\n12.9.1 Toxic Combustion Products\n\nSpecial hazards arising from the substance or mixture: Carbon oxides, Nitrogen oxides (NOx) /Codeine monohydrate/\n\nSigma-Aldrich; Safety Data Sheet for Codeine monohydrate. Product Number: C5901, Version 5.3 (Revision Date 05/23/2015). Available from, as of January 29, 2016: https://www.sigmaaldrich.com/safety-center.html\n\n12.9.2 Special Reports\n\n\n                    Context: \n                    This section provides US FDA regulatory references, including the CFR citation for codeine, and details on safety assessments such as tiered environmental and human health evaluations, as well as hazards from combustion by-products like carbon oxides and NOx, with specific safety data sources. It complements the document's comprehensive safety, regulatory, and hazard information on codeine.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_127", "document_index": 23, "latency_s": 0.0025973000010708347, "prompt_toks": 51593, "completion_toks": 84}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    CDC Guideline for Prescribing Opioids for Chronic Pain - United States, 2016; This guideline provides recommendations for primary care clinicians who are prescribing opioids for chronic pain outside of active cancer treatment, palliative care, and end-of-life care. The guideline addresses 1) when to initiate or continue opioids for chronic pain; 2) opioid selection, dosage, duration, follow-up, and discontinuation; and 3) assessing risk and addressing harms of opioid use. CDC developed the guideline using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) framework, and recommendations are made on the basis of a systematic review of the scientific evidence while considering benefits and harms, values and preferences, and resource allocation. CDC obtained input from experts, stakeholders, the public, peer reviewers, and a federally chartered advisory committee. It is important that patients receive appropriate pain treatment with careful consideration of the\n\n\n                    Context: \n                    This excerpt summarizes the CDC's 2016 guidelines for prescribing opioids for chronic pain, outlining recommendations on initiation, dosage, duration, risk assessment, and harms management for primary care clinicians. It is relevant to the overall document as it provides authoritative guidance on opioid use, complementing detailed pharmacological and safety information about codeine and related opioids. The guidelines emphasize evidence-based practices and risk mitigation strategies critical for safe opioid prescribing.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_128", "document_index": 23, "latency_s": 1.6023763999983203, "prompt_toks": 51566, "completion_toks": 68}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    experts, stakeholders, the public, peer reviewers, and a federally chartered advisory committee. It is important that patients receive appropriate pain treatment with careful consideration of the benefits and risks of treatment options. This guideline is intended to improve communication between clinicians and patients about the risks and benefits of opioid therapy for chronic pain, improve the safety and effectiveness of pain treatment, and reduce the risks associated with long-term opioid therapy, including opioid use disorder, overdose, and death.[Dowell D et al; Morbidity and Mortality Weekly Report (MMWR) 65 (1):1-49 (2016); Available from, as of March 22, 2016: http://www.cdc.gov/mmwr/volumes/65/rr/rr6501e1.htm]\n\n\n                    Context: \n                    This excerpt summarizes the development of clinical guidelines aimed at improving communication, safety, and risk management in long-term opioid therapy for chronic pain. It highlights the collaborative process involving experts, stakeholders, and advisory committee input, referencing a 2016 CDC report, making it relevant for understanding the overall framework of safe opioid prescribing practices discussed in the document.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_129", "document_index": 23, "latency_s": 1.5901082000054885, "prompt_toks": 51568, "completion_toks": 90}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    DHHS/NIDA; Research Monograph Series 52: Testing Drugs for Physical Dependence Potential and Abuse Liability (1984) DHHS Pub No. (ADM)87-1332\n\nDHHS/NIDA; Research Monograph Series 54: Mechanisms of Tolerance and Dependence (1984) DHHS Pub No. (ADM)88-1330\n\nDHHS/NIDA; Research Monograph Series 56: Etiology of Drug Abuse: Implications for Prevention (1987) DHHS Pub No. (ADM)87-1335\n\nFor more Special Reports (Complete) data for CODEINE (12 total), please visit the HSDB record page.\n\n13 Toxicity\n\n13.1 Toxicological Information\n\n13.1.1 Toxicity Summary\n\n\n                    Context: \n                    This segment provides references to U.S. DHHS/NIDA research monographs on drug dependence, tolerance, and abuse mechanisms, published between 1984 and 1987. It supports the toxicity and safety discussion of codeine within the comprehensive webpage, linking to detailed reports on drug liability, dependence, and abuse, and directs to the HSDB record for complete special report data. This enhances references for toxicity-related research and regulatory information on codeine.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_130", "document_index": 23, "latency_s": 1.5965180000057444, "prompt_toks": 51651, "completion_toks": 81}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    IDENTIFICATION AND USE: Codeine occurs as colorless or white crystals or powder. Codeine is an opiate, a component of opium, and an opioid agonist used as an analgesic, antitussive, and antidiarrheal agent. It commonly is given in combination with aspirin, acetaminophen, or other agents. It may also be used in veterinary care as an analgesic and antitussive. HUMAN EXPOSURE AND TOXICITY: Toxic doses of codeine may produce exhilaration, excitement, seizures, delirium, hypotension, miosis, slow pulse, tachycardia, narcosis, flushed facies, tinnitus, lassitude, muscular weakness, and circulatory collapse or respiratory paralysis. Cardiovascular side effects, ataxia, and headache have been observed in cases of accidental exposure. Respiratory arrest, coma, and death have occurred in young children receiving oral codeine doses of 5-12 mg/kg. Codeine should not be prescribed to children due to its poor analgesic effect and risk of opioid toxicity and oversedation. All opioid analgesics are\n\n\n                    Context: \n                    This excerpt provides a detailed description of codeine's physical form, uses as an opioid analgesic, antitussive, and antidiarrheal agent, and highlights its human toxicity, including high-dose effects, risks in children, and adverse cardiovascular and respiratory outcomes. It is relevant for understanding codeine’s identification, medical applications, and safety concerns within the comprehensive PubChem drug profile.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_131", "document_index": 23, "latency_s": 2.269489699989208, "prompt_toks": 51622, "completion_toks": 81}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    receiving oral codeine doses of 5-12 mg/kg. Codeine should not be prescribed to children due to its poor analgesic effect and risk of opioid toxicity and oversedation. All opioid analgesics are metabolized by the liver and should be used with caution in patients with hepatic disease because increased bioavailability after oral administration of cumulative effects may occur. In patients with asthma or pulmonary emphysema, the indiscriminate use of antitussives may precipitate respiratory insufficiency. One case of opiate toxicity resulting in neonatal death has been reported in the nursing infant of a mother receiving codeine; genetic testing of the mother indicated that she was an ultrarapid metabolizer of codeine. First trimester use in 563 cases was associated with: respiratory malformations, genitourinary tract defects other than hypospadias, Down's syndrome, tumors, umbilical hernia, and inguinal hernia. After 2522 exposures to codeine anytime in pregnancy, the following were\n\n\n                    Context: \n                    This excerpt summarizes key safety considerations and adverse effects of oral codeine use, including risks in children, patients with liver, respiratory, or genetic factors, as well as pregnancy-related outcomes. It situates within the broader document's detailed pharmacological, toxicological, and regulatory discussion on codeine's safety profile and authorized medical use. Relevant for understanding contraindications, overdose risks, and special populations.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_132", "document_index": 23, "latency_s": 2.0891749000002164, "prompt_toks": 51647, "completion_toks": 107}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    genitourinary tract defects other than hypospadias, Down's syndrome, tumors, umbilical hernia, and inguinal hernia. After 2522 exposures to codeine anytime in pregnancy, the following were noted: hydrocephaly, pyloric stenosis, umbilical hernia, inguinal hernia. Chronic codeine-containing syrup abuse may be associated with disruptions in brain white matter (WM) integrity. These WM microstructural deficits may be linked to higher impulsivity in chronic codeine-containing syrup users. Codeine is metabolized in the liver by glucuronidation to codeine-6-glucuronide, by O-demethylation to morphine via CYP2D6, and by N-demethylation to norcodeine via CYP3A, all active metabolites. There is genetic polymorphism od CYP2D6. Poor CYP2D6 metabolizers have decreased analgesic effectiveness by inhibiting conversion of codeine to morphine. Concomitant administration with CYP2D6 inducers may result in increased metabolism and clearance of drug and also produce decreased clinical efficacy. Examples\n\n\n                    Context: \n                    This excerpt details the developmental and metabolic effects of codeine exposure during pregnancy, highlighting associated congenital defects such as hydrocephaly and hernias, as well as potential impacts on brain white matter and impulsivity. It emphasizes codeine’s metabolic pathways in the liver involving glucuronidation and cytochrome P450 enzymes, particularly CYP2D6 polymorphisms that affect analgesic efficacy. This information situates within the broader discussion of codeine’s safety, pharmacology, and risks during pregnancy in the full document.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_133", "document_index": 23, "latency_s": 1.6834291999984998, "prompt_toks": 51632, "completion_toks": 72}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    conversion of codeine to morphine. Concomitant administration with CYP2D6 inducers may result in increased metabolism and clearance of drug and also produce decreased clinical efficacy. Examples of CYP2D6 inducers include dexamethasone and rifampin. ANIMAL STUDIES: Codeine given intravenously to rabbits has in most instances reduced ocular pressure but occasionally has produced small rise. Hamsters and mice were gavaged with up to 300 or 150 mg/kg twice daily respectively. Decreased fetal weight was found at maternally toxic doses but no teratogenicity. Pregnant hamsters injected on day 8 subcutaneously with 73 to 360 mg/kg produced 6 to 8 percent cranioschisis in the offspring. In mice, codeine exposure during gestation failed to increase the incidence of major fetal malformations even at the highest dose (300 mg/kg, bid) which produced a significant increase in the percentage of resorptions per litter. The 300 mg/kg dose was also associated with a significant decrease in average\n\n\n                    Context: \n                    This excerpt summarizes animal studies on the reproductive toxicity and teratogenic effects of codeine exposure during pregnancy, highlighting doses used in rabbits, hamsters, and mice, and their developmental outcomes. It is relevant for understanding codeine’s potential risks during pregnancy and its safety profile, complementing the overall pharmacology, toxicity, and safety sections of the full document.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_134", "document_index": 23, "latency_s": 1.5274313999980222, "prompt_toks": 51595, "completion_toks": 77}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    at the highest dose (300 mg/kg, bid) which produced a significant increase in the percentage of resorptions per litter. The 300 mg/kg dose was also associated with a significant decrease in average fetal body weight per litter, and 19% mortality among pregnant females. Embryo/fetal development of the hamster was sensitive to codeine administered at a maternally nontoxic dose of 50 mg/kg, twice daily. At that dose, fetal body weight was significantly reduced while all parameters of maternal toxicity indicated no effect.There was no evidence of carcinogenic activity of codeine in male or female rats exposed to 400, 800, or 1,600 ppm of codeine for 2 years. There was no evidence of carcinogenic activity of codeine in male or female mice exposed to 750, 1,500, or 3,000 ppm of codeine for 2 years.\n\n\n                    Context: \n                    This excerpt summarizes key findings from toxicity and carcinogenicity studies of codeine in animal models, highlighting its effects on fetal development and tumor risk. It notes that high doses caused fetal weight reduction and maternal mortality in hamsters, while long-term studies in rats and mice showed no evidence of carcinogenic activity at various exposure levels, providing vital context for understanding codeine's toxicological profile.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_135", "document_index": 23, "latency_s": 1.9436630999989575, "prompt_toks": 51510, "completion_toks": 101}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    Deaths related to opioid toxicity have increased in the past decades, and a significant proportion of the increase derives from accidental overdoses. Opioid overdose is characteristically associated with a triad of abnormally slow respiration (apnea), decreased consciousness (coma), and pinpoint pupils (miosis). Codeine has a narrow therapeutic index, with a dose of 500 to 1000 mg usually proving fatal, though codeine-dependent individuals have been reported to use as much as 1536 mg daily.\n\n\n                    Context: \n                    This excerpt provides critical information on the toxicity and overdose risks of codeine, highlighting the increasing prevalence of opioid-related deaths and the narrow margin between therapeutic and fatal doses. It emphasizes the clinical triad of opioid overdose symptoms—respiratory depression, decreased consciousness, and pinpoint pupils—and notes that doses as high as 1536 mg can be lethal for dependent individuals. This content is essential for understanding the safety profile and toxicological concerns of codeine within the broader scope of its pharmacology and safety hazards.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_136", "document_index": 23, "latency_s": 1.525864499999443, "prompt_toks": 51539, "completion_toks": 77}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    This patient population is presumed to have a history of issues related to substance misuse/abuse, injection drug use, and chronic pain. These patterns indicate that, in accidental deaths, any number of strategies are being used by patients who engage in codeine misuse, including supplementing codeine with prescribed pain medication, persistently escalating dosages without clinician approval, and selling/buying the drug outside of regulatory control. Therefore, a clear need exists for specialist intervention for pain management in a complex patient population.\n\nMaximum Tolerated Dose\n\nImmediate-release preparation: 360 mg per day\n\nControlled-release preparation: 600 mg per day\n\n\n                    Context: \n                    This excerpt discusses the behavior and risks associated with codeine misuse in vulnerable populations, emphasizing patterns like escalating doses and drug trading that contribute to accidental deaths. It provides specific maximum tolerated doses for immediate-release (360 mg/day) and controlled-release (600 mg/day) formulations, highlighting critical safety thresholds within the broader context of codeine safety, toxicity, and regulatory considerations detailed throughout the document.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_137", "document_index": 23, "latency_s": 1.7252532000129577, "prompt_toks": 51538, "completion_toks": 74}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    Maximum Tolerated Dose\n\nImmediate-release preparation: 360 mg per day\n\nControlled-release preparation: 600 mg per day\n\nTreatment of toxicity depends on both the symptoms and degree of intoxication. Toxicity involves symptomatic treatment (ie, enema for constipation) and definitive reversal with the opioid antagonist naloxone for life-threatening adverse effects like respiratory depression. If the patient is physically dependent on opioids, the administration of opioid antagonists may precipitate acute withdrawal syndrome. Consequently, clinicians should prescribe opioid antagonists cautiously in patients with physical opioid dependence, and decreased dosages of antagonists should be considered for known dependent patients.\n\n\n                    Context: \n                    This section details the maximum tolerated doses of codeine for both immediate-release (360 mg/day) and controlled-release (600 mg/day) formulations, and outlines the management of codeine toxicity. It is relevant for understanding safe dosage limits and emergency treatment protocols, including the use of naloxone for reversing life-threatening effects like respiratory depression, especially in patients with opioid dependence.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_138", "document_index": 23, "latency_s": 1.860204699987662, "prompt_toks": 51629, "completion_toks": 93}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    Opiate receptors are coupled with G-protein receptors and function as both positive and negative regulators of synaptic transmission via G-proteins that activate effector proteins. Binding of the opiate stimulates the exchange of GTP for GDP on the G-protein complex. As the effector system is adenylate cyclase and cAMP located at the inner surface of the plasma membrane, opioids decrease intracellular cAMP by inhibiting adenylate cyclase. Subsequently, the release of nociceptive neurotransmitters such as substance P, GABA, dopamine, acetylcholine and noradrenaline is inhibited. Opioids also inhibit the release of vasopressin, somatostatin, insulin and glucagon. Codeine's analgesic activity is, most likely, due to its conversion to morphine. Opioids close N-type voltage-operated calcium channels (OP2-receptor agonist) and open calcium-dependent inwardly rectifying potassium channels (OP3 and OP1 receptor agonist). This results in hyperpolarization and reduced neuronal excitability.\n\n\n                    Context: \n                    This excerpt details the molecular mechanism and receptor interactions underlying opioid analgesic effects, specifically describing how opiate receptors modulate G-proteins and intracellular signaling pathways. It emphasizes the conversion of codeine to morphine and the subsequent inhibition of neurotransmitter release, as well as ion channel modulation leading to neuronal hyperpolarization. This technical description enhances understanding of the pharmacodynamics and receptor activity profiles discussed throughout the comprehensive chemical and pharmacological profile of codeine.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_139", "document_index": 23, "latency_s": 1.299354200004018, "prompt_toks": 51621, "completion_toks": 98}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    13.1.2 USGS Health-Based Screening Levels for Evaluating Water-Quality\n\nChemical\n\nCodeine\n\nChemical Classes\n\nPharmaceutical\n\nReference\n\nSmith, C.D. and Nowell, L.H., 2024. Health-Based Screening Levels for evaluating water-quality data (3rd ed.). DOI:10.5066/F71C1TWP\n\n13.1.3 Hepatotoxicity\n\nDespite wide use for many years, codeine has not been linked to serum enzyme elevations during therapy and there have been no convincing cases of idiosyncratic acute, clinically apparent liver injury attributed to its use.\n\nLiklihood score: E (unlikely cause of clinically apparent liver injury).\n\nReferences on the safety and potential hepatotoxicity of codeine are given in the Overview section of the Opioids.\n\nDrug Class: Opioids\n\n13.1.4 Drug Induced Liver Injury\n\nCompound\n\ncodeine\n\nDILI Annotation\n\nNo-DILI-Concern\n\nLabel Section\n\nNo match\n\nReferences\n\n\n                    Context: \n                    This segment provides detailed information on codeine's water safety screening levels, hepatotoxicity, and drug-induced liver injury assessment, which supports the comprehensive chemical safety profile presented in the fuller webpage. It highlights that despite widespread use, codeine has no significant evidence linking it to liver injury, with an \"unlikely cause\" rating, making it crucial for toxicity and safety evaluations within the overall chemical and pharmacological data. This data aids both research and regulatory reference regarding codeine's hepatotoxic risk.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_140", "document_index": 23, "latency_s": 1.6679603999946266, "prompt_toks": 51725, "completion_toks": 73}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    Drug Class: Opioids\n\n13.1.4 Drug Induced Liver Injury\n\nCompound\n\ncodeine\n\nDILI Annotation\n\nNo-DILI-Concern\n\nLabel Section\n\nNo match\n\nReferences\n\nM Chen, V Vijay, Q Shi, Z Liu, H Fang, W Tong. FDA-Approved Drug Labeling for the Study of Drug-Induced Liver Injury, Drug Discovery Today, 16(15-16):697-703, 2011. PMID:21624500 DOI:10.1016/j.drudis.2011.05.007\n\nM Chen, A Suzuki, S Thakkar, K Yu, C Hu, W Tong. DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug Discov Today 2016, 21(4): 648-653. PMID:26948801 DOI:10.1016/j.drudis.2016.02.015\n\n13.1.5 Carcinogen Classification\n\n1 of 2\n\nSubstance\n\nCodeine\n\nNTP Technical Report\n\nTR-455: Toxicology and Carcinogenesis Studies of Codeine (CASRN 76-57-3) in F344/N Rats and B6C3F1 Mice (Feed Studies) (1996 )\n\nPeer Review Date\n\n06/20/95\n\nConclusion for Male Rat\n\nNo Evidence\n\nNo Evidence\n\nConclusion for Female Rat\n\nNo Evidence\n\nNo Evidence\n\nConclusion for Male Mice\n\nNo Evidence\n\n\n                    Context: \n                    This section provides detailed information on drug-induced liver injury (DILI) and carcinogenicity assessments for codeine, including references to FDA labeling studies, the DILIrank reference list, and results from NTP toxicity studies showing no evidence of carcinogenicity in rodent models, essential for understanding codeine's safety profile within the broader chemical and pharmacological data.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_141", "document_index": 23, "latency_s": 1.2094760999898426, "prompt_toks": 51657, "completion_toks": 83}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    Peer Review Date\n\n06/20/95\n\nConclusion for Male Rat\n\nNo Evidence\n\nNo Evidence\n\nConclusion for Female Rat\n\nNo Evidence\n\nNo Evidence\n\nConclusion for Male Mice\n\nNo Evidence\n\nNo Evidence\n\nConclusion for Female Mice\n\nNo Evidence\n\nNo Evidence\n\nSummary\n\nUnder the conditions of these 2-year feed studies, there was no evidence of carcinogenic activity of codeine in male or female F344/N rats exposed to 400, 800, or 1,600 ppm. There was no evidence of carcinogenic activity of codeine in male or female B6C3F1 mice exposed to 750, 1,500, or 3,000 ppm.\n\nThyroid gland follicular cell hyperplasia was increased in exposed male and female mice.\n\nDecreased incidences of benign pheochromocytomas of the adrenal medulla in male rats and mammary gland fibroadenomas and fibroadenomas or adenocarcinomas (combined) in female rats were related to codeine exposure.\n\n2 of 2\n\nCarcinogen Classification\n\nNo indication of carcinogenicity to humans (not listed by IARC).\n\n13.1.6 Health Effects\n\n\n                    Context: \n                    This excerpt summarizes the carcinogenicity and health effects findings from a 2-year feeding study of codeine in rats and mice, indicating no evidence of carcinogenic activity and noting specific tissue changes such as thyroid hyperplasia. It also highlights that codeine is not classified as carcinogenic to humans by IARC. This information is relevant for understanding codeine’s long-term safety profile within the comprehensive chemical data document.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_142", "document_index": 23, "latency_s": 1.1481211000063922, "prompt_toks": 51583, "completion_toks": 74}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    2 of 2\n\nCarcinogen Classification\n\nNo indication of carcinogenicity to humans (not listed by IARC).\n\n13.1.6 Health Effects\n\nMedical problems can include congested lungs, liver disease, tetanus, infection of the heart valves, skin abscesses, anemia and pneumonia. Death can occur from overdose.\n\n13.1.7 Effects During Pregnancy and Lactation\n\n◉ Summary of Use during Lactation\n\nMaternal use of oral opioids during breastfeeding can cause infant drowsiness, which may progress to rare but severe central nervous system depression.[1,2] Newborn infants seem to be particularly sensitive to the effects of even small dosages of narcotic analgesics. If codeine is required by the mother of a newborn, it is not a reason to discontinue breastfeeding; however, once\n\n\n                    Context: \n                    This excerpt summarizes the carcinogenicity classification and health effects of codeine, emphasizing that it is not listed as a carcinogen by IARC and highlighting potential health issues such as lung and liver problems, overdose risks, and the effects of maternal use during breastfeeding. It provides critical information relevant for toxicology, safety assessments, and clinical guidance within the comprehensive PubChem resource.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_143", "document_index": 23, "latency_s": 1.586348700002418, "prompt_toks": 51604, "completion_toks": 79}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    the mother's milk comes in, it is best to provide pain control with a nonnarcotic analgesic and limit maternal intake of oral codeine to 2 to 3 days at a low dosage with close infant monitoring, especially in the outpatient setting.[2-4] If the baby shows signs of increased sleepiness (more than usual), difficulty breastfeeding, breathing difficulties, or limpness, a physician should be contacted immediately.[5] Excessive sedation in the mother often correlates with excess sedation in the breastfed infant. Following these precautions can lower the risk of neonatal sedation.[6] Numerous professional organizations and regulatory agencies recommend that other agents are preferred over codeine or to avoid codeine completely during breastfeeding;[7-11] however, a large population study did not find codeine to be more dangerous than other opioids that have been studied less and may not be safer.[12-14]\n\n◉ Effects in Breastfed Infants\n\n\n                    Context: \n                    This excerpt provides detailed clinical guidance and observed effects related to maternal use of oral codeine during breastfeeding, emphasizing low-dose, short-term use and infant monitoring to reduce neonatal sedation risk. It highlights recommendations from professional organizations and summarizes studies on infant safety, situating this information within the broader context of codeine's safety, pharmacokinetics, and regulatory considerations documented in the full webpage.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_144", "document_index": 23, "latency_s": 1.202709400007734, "prompt_toks": 51534, "completion_toks": 75}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    ◉ Effects in Breastfed Infants\n\nCodeine was reported to be the possible cause of asymptomatic bradycardia 6 days following a single maternal 30 mg codeine dose in a week-old, term, exclusively breastfed infant.[21] This seems implausible.[13]\n\nFour probable cases of apnea associated with maternal codeine intake of 60 mg every 4 to 6 hours were reported in 4- to 6-day-old term and near-term breastfed infants. Apnea resolved 24 to 48 hours after withholding breast feeding and discontinuation of maternal codeine.[22]\n\n\n                    Context: \n                    This excerpt from the full document discusses the effects of maternal codeine use on breastfeeding infants, highlighting reports of asymptomatic bradycardia and apnea in newborns shortly after maternal intake. It is relevant to sections on drug safety, adverse effects, and pregnancy-related risks, providing specific case data on neonatal respiratory and cardiac responses linked to breastfeeding while using codeine.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_145", "document_index": 23, "latency_s": 1.7589123000070686, "prompt_toks": 51585, "completion_toks": 96}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    In a case-control study of 12 breastfed term newborns with unexplained episodes of apnea, bradycardia or cyanosis during the first week of life, maternal oral codeine use was determined to be the probable cause. A higher proportion of newborns with episodes, 83 vs 31%, had mothers using opiates, including codeine, for postpartum analgesia. The mean number of doses taken was also higher with mothers of case newborns taking a mean of 10 doses (range 4 to 22) vs. 5 doses (range 1 to 13) in the control group. There were no differences in other perinatal and demographic factors between cases and controls.[23] The authors recommended discontinuation of breastfeeding if infants of mothers taking opiate analgesics have unexplained negative cardiorespiratory symptoms.\n\n\n                    Context: \n                    This excerpt discusses research on the potential neonatal risks associated with maternal use of opioid analgesics like codeine during breastfeeding, highlighting a case-control study that links maternal codeine intake to episodes of apnea and bradycardia in newborns. It emphasizes the importance of monitoring and discontinuing breastfeeding if infants exhibit unexplained cardiorespiratory symptoms, making it relevant for understanding codeine safety, pharmacokinetics, and maternal-infant health considerations within the broader document.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_146", "document_index": 23, "latency_s": 1.792577699990943, "prompt_toks": 51565, "completion_toks": 109}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    No apnea, bradycardia, or color changes occurred in 11 healthy, term, 1- to 3-day-old newborn breastfed infants exposed to codeine in milk. Their mothers had taken an average of 4 doses of oral codeine 60 mg every 4 to 6 hours prior to breastfeeding.[18]\n\nIn one telephone follow-up study, 19% (5 of 26) of breastfeeding mothers taking multiple doses of codeine reported drowsiness in their infants. All infants were younger than 1 month. The authors added that the elimination half-life of codeine's metabolite, morphine, is prolonged in the newborn period which may explain why the adverse reaction was reported in only infants younger than 1 month.[24]\n\n\n                    Context: \n                    This excerpt summarizes clinical findings on neonatal safety related to maternal codeine use during breastfeeding, reporting no adverse effects such as apnea or bradycardia in healthy newborns exposed to maternal doses. It highlights that in one study, a small percentage of mothers reported infant drowsiness, especially in infants under 1 month, likely due to prolonged morphine half-life in neonates. This information is relevant for understanding safety considerations and pharmacokinetics of codeine in breastfeeding infants within the broader discussion of codeine pharmacology and toxicity.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_147", "document_index": 23, "latency_s": 1.3486134999984642, "prompt_toks": 51570, "completion_toks": 91}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    A large case-control study of 504 children with neuroblastoma found a statistically significant 2.4-fold association of the disease with maternal use of opioid agonists during pregnancy and lactation. This finding was largely attributable to a 3.4-fold association with maternal codeine use. Opioid exposure during lactation had a 3.5-fold association while codeine exposure had a 5.1-fold association. Because neuroblastoma is a sympathetic nervous system tumor arising from the progenitor cells of the sympathetic ganglia and adrenal medulla, and because codeine does cross the placenta and is transferred to milk, the authors of this study speculate that codeine's neuroendocrine effects could disrupt adrenal gland development in the fetus and neonate thus contributing to neuroblastoma.[25]\n\n\n                    Context: \n                    This excerpt discusses research linking maternal use of opioid agonists, especially codeine, during pregnancy and lactation to an increased risk of neuroblastoma in children. It highlights a significant 2.4-fold association in a case-control study, emphasizing the potential neuroendocrine disruption from transplacental and breastmilk transfer of codeine. This information is relevant to the document's comprehensive coverage of codeine's toxicity, safety, and developmental risks.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_148", "document_index": 23, "latency_s": 1.7748138000024483, "prompt_toks": 51644, "completion_toks": 89}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    A breastfed infant became increasingly sleepy and lethargic starting on day 7 of life. The infant developed gray skin and decreased milk intake on day 12 of life and died on day 13 of life. The infant's mother was taking acetaminophen with codeine prescribed for post-episiotomy pain at a codeine dose of 60 mg every 12 hours on days 1 and 2 postpartum, and 30 mg every 12 hours for 2 weeks (although the dose was later reported to be 30 mg every 6 hours[13]). The mother was found to be a ultrarapid metabolizer of codeine who excreted large amounts of morphine into her breastmilk.[18] The role that codeine and its pharmacogenetics played in the infant’s death has been questioned and the paper was retracted by two Canadian journals where the case was originally published.[2,13,26,27] The authors of the original case report later conducted a retrospective case-control study of 72 women who had taken codeine while breastfeeding found that 24% of the mothers reported decreased alertness in\n\n\n                    Context: \n                    This excerpt details a case of infant toxicity linked to maternal codeine use during breastfeeding, highlighting pharmacogenetic factors such as ultrarapid metabolism that can lead to fatal outcomes. It is relevant to the document's discussion of codeine safety, pharmacokinetics, and risks in vulnerable populations, emphasizing the role of genetic variability in adverse effects. Important details include maternal dosing, timing of infant symptoms, and the controversy surrounding the case's validity.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_149", "document_index": 23, "latency_s": 1.1396789000136778, "prompt_toks": 51611, "completion_toks": 80}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    of the original case report later conducted a retrospective case-control study of 72 women who had taken codeine while breastfeeding found that 24% of the mothers reported decreased alertness in their infants which improved after codeine or breastfeeding discontinuation. The affected infants were more likely to have visited an emergency room for symptoms such as lethargy, poor feeding or breathing difficulties. Mothers with affected infants took an average of 1.62 mg/kg daily or codeine compared to an average of 1.02 mg/kg daily in mothers of unaffected infants. The lowest maternal dose reported cause symptoms in the breastfed infant was 0.63 mg/kg daily. Usually the mothers of affected infants also had signs of central nervous system depression. Another woman was also an ultrarapid codeine metabolizer in addition to the first case reported. She took 120 mg of codeine daily and her infant was very drowsy and fed poorly and the mother was sedated, nauseated, dizzy, and weak during\n\n\n                    Context: \n                    This excerpt details a retrospective case-control study on maternal codeine use during breastfeeding, highlighting risks of infant central nervous system depression at doses as low as 0.63 mg/kg daily, especially in ultrarapid metabolizers. It is relevant for understanding drug safety, maternal dosing, and infant risk assessment in the context of opioid pharmacology, toxicity, and safety guidelines discussed throughout the full document.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_150", "document_index": 23, "latency_s": 1.7611294000089401, "prompt_toks": 51491, "completion_toks": 89}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    metabolizer in addition to the first case reported. She took 120 mg of codeine daily and her infant was very drowsy and fed poorly and the mother was sedated, nauseated, dizzy, and weak during codeine use. The mother transitioned to complete formula feeding by day 7 postpartum and noted a complete reversal of her infant's symptoms although she remained symptomatic.[28]\n\n\n                    Context: \n                    This excerpt details a case of mother-to-infant transfer of sedative effects during breastfeeding while the mother used high-dose codeine, highlighting pharmacogenetic factors like ultrarapid metabolizer status. It emphasizes the risks of maternal codeine use, including infant drowsiness and symptomatic reversal upon transitioning to formula, underlining the document's focus on overdose, toxicity, and safety concerns related to codeine's pharmacokinetics and genetics.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_151", "document_index": 23, "latency_s": 1.5802131000091322, "prompt_toks": 51505, "completion_toks": 86}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    A study compared the frequency of drowsiness in breastfed infants whose mothers took acetaminophen plus codeine to infants whose mothers took acetaminophen alone. Infants exposed to codeine had a 16.7% frequency of drowsiness compared to 0.5% of those exposed to acetaminophen alone. Mothers having infants with drowsiness took about 50% higher doses of codeine than those with no drowsiness.[29]\n\n\n                    Context: \n                    This excerpt discusses a clinical study on the impact of maternal codeine use during breastfeeding, highlighting the increased risk of infant drowsiness associated with higher maternal doses. It emphasizes the developmental and safety considerations of using opioids like codeine in lactating women, relevant to the overall document's comprehensive review of codeine’s pharmacology, toxicity, and safety warnings. This information is critical for understanding opioid exposure risks in neonatal care contexts.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_152", "document_index": 23, "latency_s": 1.7856343000021297, "prompt_toks": 51623, "completion_toks": 99}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    In a retrospective study, nursing mothers who were taking either codeine, oxycodone or acetaminophen for pain while breastfeeding were contacted by telephone to ascertain the degree of maternally perceived central nervous system (CNS) depression. Some of the mothers taking codeine had previously been reported in reference [28]. Mothers taking codeine reported signs of CNS depression in 17% (35/210) of their infants, while those taking acetaminophen reported infant CNS depression in only 0.5% (1/184) of their infants. Women who reported infant sedation were taking 1.4 mg/kg daily of oxycodone, and unaffected were taking 0.9 mg/kg daily. Affected infants had more hours of daily uninterrupted sleep than unaffected infants, and 4 of the affected infants had been taken to the emergency department for lethargy. Thirty of 35 mothers reported that infant sedation ceased with maternal codeine discontinuation. Mothers of affected infants were also more likely to experience lethargy and other\n\n\n                    Context: \n                    This excerpt details a retrospective study on maternal use of opioids, including codeine, during breastfeeding and its association with infant CNS depression. It highlights key findings such as the incidence of infant sedation linked to maternal opioid doses, the reversal upon discontinuation, and the relevance of maternal drug levels. This information is critical for understanding the safety and neurodevelopmental risks of maternal opioid use while breastfeeding within the broader review of codeine's pharmacology, safety profile, and its implications for neonatal health.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_153", "document_index": 23, "latency_s": 1.5605367999960436, "prompt_toks": 51510, "completion_toks": 80}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    for lethargy. Thirty of 35 mothers reported that infant sedation ceased with maternal codeine discontinuation. Mothers of affected infants were also more likely to experience lethargy and other side effects than mothers of unaffected infants. Mothers who took oxycodone reported a similar rate of infant sedation (20%) compared to codeine, but the groups were statistically different in parity and postmenstrual age (PMA), with the codeine group having a slightly higher PMA.[30]\n\n\n                    Context: \n                    This excerpt details studies on maternal use of opioids, specifically codeine and oxycodone, during breastfeeding and their effects on infant sedation and side effects. It highlights that maternal discontinuation of codeine can resolve infant sedation, and compares sedation rates between different opioids, emphasizing the significance of maternal medication management for breastfeeding safety within the larger discussion of codeine's clinical and toxicological profiles.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_154", "document_index": 23, "latency_s": 1.6007917999959318, "prompt_toks": 51616, "completion_toks": 75}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    A retrospective cohort study of women with publicly funded prescription coverage in the province of Ontario, Canada compared 7804 women who filled a codeine prescription within 7 days postpartum to 7804 who did not over a 10-year period. No difference was found in any adverse infant outcomes during the first 30 days of life between the two groups, including hospitalization for various causes.[31] However, study design problems appear to have limited this study, including a lack of knowledge of maternal codeine dosage ingested, timing of codeine ingestion, and extent of nursing.[32] In a similar, but larger study in Ontario, 17,037 mothers who filled a codeine prescription were matched on propensity score to an equal number of mothers who did not. Compared with infants born to mothers who were not prescribed an opioid, those born to mothers prescribed codeine were less likely to be admitted to hospital in the 30 days after the index date (hazard ratio 0.74). Admissions for and feeding\n\n\n                    Context: \n                    This excerpt summarizes key epidemiological studies from Ontario, Canada, evaluating maternal codeine prescriptions during postpartum and their impact on infant health outcomes. It highlights study design limitations, propensity score matching results, and comparative hospital admission rates for infants, providing critical context for assessing maternal opioid use and neonatal safety in the comprehensive review of codeine safety, toxicity, and regulatory considerations.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_155", "document_index": 23, "latency_s": 1.828357699996559, "prompt_toks": 51509, "completion_toks": 98}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    were not prescribed an opioid, those born to mothers prescribed codeine were less likely to be admitted to hospital in the 30 days after the index date (hazard ratio 0.74). Admissions for and feeding difficulties were less common among infants of mothers who filled a codeine prescription than among infants of mothers who did not fill a codeine prescription. No infant deaths occurred. Of note is that the median drug supply was for 3 days (IQR 2-4).[14]\n\n\n                    Context: \n                    This excerpt summarizes a study on the effects of maternal codeine prescriptions during breastfeeding, highlighting reduced infant hospital admissions and feeding difficulties when mothers used the medication for a median of 3 days. It is relevant to the document’s discussion of codeine’s safety during lactation, infant exposure risks, and pharmacogenetic considerations, providing specific data on maternal prescribing patterns and infant health outcomes. This information enhances understanding of the clinical implications of maternal codeine use and informs risk assessment related to breastfeeding safety.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_156", "document_index": 23, "latency_s": 1.1589305000088643, "prompt_toks": 51645, "completion_toks": 93}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    Six cases of CNS depression in infants breastfed by mothers taking codeine were reported over a 2-year period in Canada. Maternal dosages that were reported were in the range of 2 to 3 mg/kg daily. Infants were all 10 days of age or younger and responded favorably to discontinuation of nursing, discontinuation of maternal codeine or naloxone injection.[32]\n\nA 2-month-old breastfed (extent not stated) infant was noted by the mother to be somnolent and slept more than usual for 2 to 3 days. The baby's mother had a total of 4 or 5 tablets of acetaminophen 500 mg plus codeine 30 mg as needed for back pain for the prior 3 days. The mother discontinued the medication and breastfeeding. Under observation at an emergency room, the infant slowly recovered. A serum morphine level was not obtained.[33]\n\n◉ Effects on Lactation and Breastmilk\n\nNarcotics can increase serum prolactin.[34] However, the prolactin level in a mother with established lactation may not affect her ability to breastfeed.\n\n\n                    Context: \n                    This excerpt details cases of neonatal and infant CNS depression associated with maternal codeine use during breastfeeding, highlighting dosages of 2-3 mg/kg/day and infant outcomes. It underscores the risks of opioid transfer through breastmilk and the importance of monitoring and discontinuing narcotics if adverse effects occur. This information is crucial for understanding the safety, toxicity, and pharmacological considerations of codeine in nursing mothers within the broader context of its pharmacology and safety profile.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_157", "document_index": 23, "latency_s": 1.2709253999928478, "prompt_toks": 51463, "completion_toks": 70}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    ◉ Effects on Lactation and Breastmilk\n\nNarcotics can increase serum prolactin.[34] However, the prolactin level in a mother with established lactation may not affect her ability to breastfeed.\n\n◈ What is codeine?\n\n\n                    Context: \n                    This excerpt discusses the effects of codeine and other narcotics on lactation and breastmilk, including hormonal impacts, infant risks, and considerations during breastfeeding. It is part of the broader documentation on codeine’s pharmacology, safety, and clinical use, providing critical information on maternal and neonatal health considerations related to codeine exposure during lactation.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_158", "document_index": 23, "latency_s": 1.3089948999986518, "prompt_toks": 51603, "completion_toks": 71}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    Codeine is a medication that has been used to treat pain or cough. It belongs to a group of medications called opioids. Opioids are sometimes called narcotics. Some commonly used codeine products also contain other medications, such as acetaminophen. For more information about acetaminophen, please see the MotherToBaby fact sheet at https://mothertobaby.org/fact-sheets/acetaminophen-pregnancy/.Sometimes when people find out they are pregnant, they think about changing how they take their medication, or stopping their medication altogether. However, it is important to talk with your healthcare providers before making any changes to how you take this medication. Your healthcare providers can talk with you about the benefits of treating your condition and the risks of untreated illness during pregnancy.If you have been taking codeine regularly or have a dependency (also called opioid use disorder), you should not just stop taking your medication suddenly (also called “cold turkey”).\n\n\n                    Context: \n                    This excerpt provides an overview of the clinical use and pregnancy considerations related to codeine as an opioid medication, highlighting safety, potential risks during pregnancy, and the importance of medical guidance. It situates within the full document's comprehensive pharmacology, safety, and regulatory information about codeine, emphasizing its medical indications, dependence concerns, and advice for pregnant patients.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_159", "document_index": 23, "latency_s": 1.4833390999992844, "prompt_toks": 51492, "completion_toks": 82}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    pregnancy.If you have been taking codeine regularly or have a dependency (also called opioid use disorder), you should not just stop taking your medication suddenly (also called “cold turkey”). Stopping an opioid medication suddenly could cause you to go into withdrawal. It is not known how withdrawal might affect a pregnancy. It is suggested that any reduction in codeine be done slowly, and under the direction of your healthcare provider.\n\n\n                    Context: \n                    This excerpt provides guidance on managing codeine use during pregnancy, emphasizing the importance of gradual reduction under medical supervision to avoid withdrawal symptoms and potential pregnancy risks. It is relevant to the document's broader discussion of codeine's safety, toxicity, and effects during pregnancy and lactation. The section highlights the risks of sudden cessation in dependent or regular users, aligning with the overall focus on safe usage and clinical considerations.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_160", "document_index": 23, "latency_s": 1.125020699997549, "prompt_toks": 51524, "completion_toks": 75}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    ◈ I take codeine. Can it make it harder for me to get pregnant?\n\nA few studies have shown that use or misuse of opioids, including codeine, may cause changes to a person’s menstrual cycle (periods). This could make it harder to get pregnant.\n\n◈ Does taking codeine during pregnancy increase the chance of miscarriage?\n\nMiscarriage is common and can occur in any pregnancy for many reasons. It is not known if using codeine can increase the chance of miscarriage.\n\n◈ Does taking codeine increase the chance of birth defects?\n\n\n                    Context: \n                    This excerpt summarizes research findings on the reproductive risks associated with codeine use, addressing its potential impact on fertility, miscarriage, and birth defects. It is relevant within the broader document, which provides comprehensive information on codeine's pharmacology, safety, toxicity, and medical considerations. The content highlights current uncertainties and the need for further research on codeine's effects during pregnancy.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_161", "document_index": 23, "latency_s": 1.6253350000042701, "prompt_toks": 51582, "completion_toks": 70}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    ◈ Does taking codeine increase the chance of birth defects?\n\nEvery pregnancy starts out with a 3-5% chance of having a birth defect. This is called the background risk. It is not known if taking codeine during pregnancy increases the chance of birth defects above the background risk. A few studies looking at codeine use in pregnancy suggest a possible small increased chance of some birth defects, such as spina bifida (when the fetal spinal cord does not develop as usual) as well as problems with the intestines and/or heart problems. However, studies have not found a specific pattern of birth defects caused by codeine or opioid use in general. If there is an increased chance of birth defects with codeine use in pregnancy, it is likely to be small.\n\n◈ Does taking codeine in pregnancy increase the chance of other pregnancy-related problems?\n\n\n                    Context: \n                    This excerpt provides information on the potential risks associated with codeine use during pregnancy, including its unclear impact on birth defect likelihood and other pregnancy complications, and summarizes current research findings. It is relevant to the overall document's section on human toxicity, safety, and reproductive effects, aiding in targeted searches related to pregnancy outcomes and teratogenicity of opioids.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_162", "document_index": 23, "latency_s": 1.7072379000019282, "prompt_toks": 51580, "completion_toks": 85}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    ◈ Does taking codeine in pregnancy increase the chance of other pregnancy-related problems?\n\nStudies on the use of opioids during pregnancy have found an increased chance for pregnancy-related problems including poor growth of the baby, stillbirth, preterm delivery (birth before week 37), and the need for a C-section. This is more commonly reported in people who take opioids in higher doses or for longer than recommended by their healthcare providers (i.e., misuse or “abuse” opioids). Codeine might cause postpartum hemorrhage (heavy bleeding after delivery) for some people. Use of an opioid close to the time of delivery can result in withdrawal symptoms in the baby (see the section of this fact sheet on Neonatal Abstinence Syndrome).\n\n◈ Will my baby have withdrawal (Neonatal Abstinence Syndrome) if I continue to take codeine?\n\n\n                    Context: \n                    This chunk summarizes potential pregnancy-related risks and neonatal withdrawal (NAS) associated with maternal codeine use, emphasizing increased risks of fetal growth issues, preterm birth, postpartum hemorrhage, and neonatal symptoms if opioids are used near delivery. It is relevant to the document’s comprehensive review of codeine's safety, pharmacology, and maternal-child health impacts, providing evidence-based information for healthcare providers and pregnant women.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_163", "document_index": 23, "latency_s": 1.3673658999905456, "prompt_toks": 51590, "completion_toks": 87}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    ◈ Will my baby have withdrawal (Neonatal Abstinence Syndrome) if I continue to take codeine?\n\nNeonatal Abstinence Syndrome (NAS) is the term used to describe withdrawal symptoms in newborns from some medication(s) that a person takes during pregnancy. NAS symptoms with opioids can include trouble breathing, extreme drowsiness (sleepiness), poor feeding, irritability, sweating, tremors, vomiting and diarrhea. Most often, symptoms of NAS appear two days after birth and may last more than two weeks. The chance that NAS will occur depends on the length of time and/or the dose of opioid taken during pregnancy. If opioids were taken in pregnancy, it is important to let your baby’s healthcare providers know so that they can check for symptoms of NAS and provide the best care for your newborn.\n\n◈ Does taking codeine in pregnancy affect future behavior or learning for the child?\n\n\n                    Context: \n                    This excerpt addresses the potential effects of maternal codeine use during pregnancy on newborns, specifically regarding withdrawal symptoms (Neonatal Abstinence Syndrome) and long-term behavioral or learning impacts. It provides critical information for understanding fetal and neonatal risks associated with opioid exposure, relevant to sections on pregnancy, toxicity, and safety. Its detailed explanations on NAS symptoms and developmental concerns are key for clinicians and researchers seeking comprehensive maternal-infant safety data.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_164", "document_index": 23, "latency_s": 1.8100095999980113, "prompt_toks": 51591, "completion_toks": 67}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    ◈ Does taking codeine in pregnancy affect future behavior or learning for the child?\n\nSome studies on opioids as a general group have found more problems with learning and behavior in children exposed to opioids for a long period of time during pregnancy. Those studies have found an increased chance of developmental delay, trouble with memory, and autism-like features. However, it is hard to know if this is due to the medication exposure or other factors that can increase the chances of these problems.\n\n◈ What if I have been taking more codeine than recommended by my healthcare provider or have an opioid use disorder?\n\nTalk with your healthcare provider about your codeine use. People who are pregnant and take opioids in higher doses or for longer than recommended by their healthcare providers have an increased chance for issues such as poor fetal growth, stillbirth, preterm delivery, and the need for a C-section.\n\n◈ Codeine and breastfeeding:\n\n\n                    Context: \n                    This segment provides key information on potential long-term effects of prenatal opiate exposure, guidance for pregnant individuals taking higher-than-recommended doses, and considerations for breastfeeding with codeine use. It enhances the document's comprehensive coverage of clinical, safety, and reproductive health aspects related to codeine, aiding targeted searches on pregnancy and lactation safety.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_165", "document_index": 23, "latency_s": 1.6383024000097066, "prompt_toks": 51595, "completion_toks": 87}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    Codeine passes into breast milk. Some babies might have problems with the amount of medication in the breast milk. There are case reports of codeine use in breastfeeding that have described babies being very sleepy, having trouble latching on, having breathing problems, slower heart rate, and not getting enough oxygen. Other reports describe the use of codeine while breastfeeding without any problems in nursing babies.The United States Food and Drug Administration (FDA) recommends that codeine not be used during breastfeeding. Also, the product label for codeine recommends people who are breastfeeding not use this medication. But the benefits of using codeine may outweigh possible risks.If you are using codeine (or any opioid), talk to your healthcare provider about how to use the least amount for the shortest time and how to monitor (watch) your baby for any signs of concern. Contact the baby’s healthcare provider immediately if your baby has any problems such as increased sleepiness\n\n\n                    Context: \n                    This chunk discusses the safety and considerations of codeine use during breastfeeding, highlighting that it passes into breast milk and can cause adverse effects in infants, such as sleepiness and breathing problems. It references FDA recommendations and case reports, emphasizing the need for healthcare provider consultation and monitoring when using opioids like codeine in lactation. This information is relevant for users seeking detailed safety warnings and recommendations related to codeine's pharmacokinetics and risks.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_166", "document_index": 23, "latency_s": 1.5941293999931077, "prompt_toks": 51475, "completion_toks": 75}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    for the shortest time and how to monitor (watch) your baby for any signs of concern. Contact the baby’s healthcare provider immediately if your baby has any problems such as increased sleepiness (more than usual), trouble feeding, trouble breathing, or limpness. Be sure to talk to your healthcare provider about all your breastfeeding questions.\n\n\n                    Context: \n                    This excerpt belongs to the section on breastfeeding and infant safety, providing guidance on monitoring and managing potential adverse effects in infants exposed to codeine through maternal use. It emphasizes the importance of observing signs like increased sleepiness, feeding difficulties, or respiratory problems, and advises consulting healthcare providers for all breastfeeding-related concerns, aligning with the document's detailed safety and pharmacokinetic information.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_167", "document_index": 23, "latency_s": 1.3812916000024416, "prompt_toks": 51627, "completion_toks": 76}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    ◈ If a male takes codeine, could it affect fertility or increase the chance of birth defects?\n\nUse or misuse of opioids, including codeine, has been shown to lower male fertility (ability to get partner pregnant). In general, exposures that fathers or sperm donors have are unlikely to increase risks to a pregnancy. For more information, please see the MotherToBaby fact sheet Paternal Exposures at https://mothertobaby.org/fact-sheets/paternal-exposures-pregnancy/.\n\n13.1.8 Exposure Routes\n\nOral, Intramuscular. Well absorbed following oral administration with a bioavailability of approximately 90%. Maximum plasma concentration occurs 60 minutes post-administration. Food does not effect the rate or extent of absorption of codeine.\n\n13.1.9 Symptoms\n\nRespiratory depression, sedation and miosis and common symptoms of overdose. Other symptoms include nausea, vomiting, skeletal muscle flaccidity, bradycardia, hypotension, and cool, clammy skin. Apnea and death may ensue.\n\n\n                    Context: \n                    This excerpt details the potential reproductive effects of male opioid use, including codeine, highlighting possible impacts on fertility and birth defect risks, and provides information on exposure routes, overdose symptoms, and overdose management. It is relevant for understanding the pharmacological and toxicological profile of codeine, especially regarding reproductive safety, overdose symptoms, and routes of absorption, aiding research and clinical decision-making.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_168", "document_index": 23, "latency_s": 2.258793200002401, "prompt_toks": 51573, "completion_toks": 78}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    13.1.10 Adverse Effects\n\nSkin Sensitizer - An agent that can induce an allergic reaction in the skin.\n\nAsthma - Reversible bronchoconstriction (narrowing of bronchioles) initiated by the inhalation of irritating or allergenic agents.\n\nConstipation is one of the most common adverse effects of codeine. Most patients report some constipation following the initiation of therapy or increases in dose. With continued exposure, constipation remains a persistent harmful effect of the drug. Increased fluid intake and stool softeners are often recommended to patients to mitigate this unwanted effect. Nausea/vomiting is another common adverse effect, but it generally diminishes within days to weeks of continued codeine exposure. Anti-emetic therapies in both oral and rectal formulations are readily available for treatment.\n\n\n                    Context: \n                    This section details common adverse effects of codeine, including allergic skin reactions, bronchoconstriction in asthma, and gastrointestinal issues such as persistent constipation and nausea, noting that nausea typically diminishes over time and can be managed with anti-emetics. It provides critical information on side effect management and safety considerations relevant to codeine’s pharmacological profile within the comprehensive drug safety and toxicity document.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_169", "document_index": 23, "latency_s": 1.1025439000077313, "prompt_toks": 51575, "completion_toks": 83}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    Clouded mentation or sedation following codeine initiation tends to fade over time. However, during initiation or dosage adjustments, patients should be counseled by their prescribing clinician about the drug's ability to affect their cognitive state, especially if that patient intends to drive or operate heavy machinery while on the medication until tolerance develops to this adverse effect. When prescribed codeine, patients should also receive counsel regarding the risk associated with exposure to other mind-altering substances. The concomitant use of codeine with other known sedatives, such as alcohol or benzodiazepines, can significantly increase the risk of adverse and possibly dangerous effects. Naloxone availability can help as a specific antidote to reverse significant opioid overdose or CNS depression, even when these are secondary to concomitant use with other CNS depressing agents.\n\n\n                    Context: \n                    This excerpt discusses the potential central nervous system adverse effects of codeine, such as sedation and clouded mentation, highlighting the importance of patient counseling on tolerance development, driving risks, and interactions with sedatives or alcohol. It emphasizes safety precautions, overdose management with naloxone, and situates within the broader context of drug safety, toxicity, and clinical guidelines covered in the full chemical and pharmacological profile.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_170", "document_index": 23, "latency_s": 1.4081514999998035, "prompt_toks": 51510, "completion_toks": 58}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    Abuse, misuse, and addiction can occur, and patients should be appropriately counseled. Abrupt discontinuation in those who are physically dependent can lead to withdrawal reactions. Slow tapering (about 15% per week) is recommended for long-term users. Chronic use of controlled-released codeine is associated with hypogonadism and lower dehydroepiandrosterone sulfate levels. Patients have reported symptoms consistent with diminished sexual function, including decreased libido, fatigue, and/or impotence.\n\n\n                    Context: \n                    This excerpt discusses the risks of abuse, misuse, dependency, withdrawal, and long-term effects such as hypogonadism and sexual dysfunction associated with codeine, highlighting safety considerations within the broader detailed toxicity, pharmacology, and safety hazard information covered in the full webpage about codeine.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_171", "document_index": 23, "latency_s": 1.7132187000097474, "prompt_toks": 51536, "completion_toks": 88}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    Other common adverse effects include pruritis, urinary retention, hypersensitivity, blurred vision, bronchospasm, tremor, weakness, abdominal cramps, and pancreatitis. Patients with sleep apnea or other coexisting pulmonary disorders may be at a higher risk for respiratory depression, and doses must be initiated and titrated cautiously. When used in pregnancy, unfavorable newborn outcomes such as premature birth, low birth weight, hypoxic-ischemic brain injury, and neonatal death may occur. Newborns may also develop neonatal abstinence syndrome.\n\n13.1.11 Acute Effects\n\n13.1.12 Treatment\n\n\n                    Context: \n                    This excerpt summarizes common adverse effects, including pruritis, urinary retention, hypersensitivity, vision issues, bronchospasm, tremor, weakness, abdominal cramps, and pancreatitis, as well as risks in patients with sleep apnea or pulmonary conditions. It highlights safety considerations during pregnancy, such as risks of adverse newborn outcomes including neonatal abstinence syndrome. These details provide essential safety and toxicity information within the comprehensive drug profile.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_172", "document_index": 23, "latency_s": 0.9483611000032397, "prompt_toks": 51600, "completion_toks": 65}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    13.1.11 Acute Effects\n\n13.1.12 Treatment\n\nNaloxone antagonizes most effects of codeine. Protect the airway as Naloxone may induce vomiting. Naloxone has a shorter duration of action than codeine; repeated doses may be needed. Protect the patient's airway and support ventilation and perfusion. Meticulously monitor and maintain, within acceptable limits, the patient's vital signs, blood gases, serum electrolytes, etc. Absorption of drugs from the gastrointestinal tract may be decreased by giving activated charcoal, which in many cases, is more effective than emesis or lavage; consider charcoal instead of or in addition to gastric emptying. Repeated doses of charcoal over time may hasten elimination of some drugs that have been absorbed. Safeguard the patient's airway when employing gastric emptying or charcoal. (L1712)\n\n13.1.13 Interactions\n\n\n                    Context: \n                    This chunk details the acute effects of codeine overdose and its treatment protocols, including the use of naloxone, airway protection, and supportive care. It also highlights drug interactions that can influence codeine's toxicity and management. This information is critical for understanding emergency responses and pharmacological considerations in the comprehensive codeine profile.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_173", "document_index": 23, "latency_s": 1.8152155999996467, "prompt_toks": 51573, "completion_toks": 96}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    13.1.13 Interactions\n\nDrugs that depress CNS and respiratory function may have additive effects when combined with opioids. Withdrawal symptoms may be precipitated in dependent patients who are given naloxone or other opioid antagonists. Concomitant use of codeine and quinidine results in reduced analgesic effect because CYP2D6 inhibition prevents conversion of codeine to morphine. Other drugs that inhibit CYP2D6 may also produce this effect. Drugs that induce CYP2D6 and CYP3A may increase codeine conversion to morphine, with impaired analgesic control.\n\nDart, R.C. (ed). Medical Toxicology. Third Edition, Lippincott Williams & Wilkins. Philadelphia, PA. 2004., p. 761\n\n\n                    Context: \n                    This section discusses drug interactions affecting codeine’s pharmacodynamics, highlighting how agents that depress central nervous system and respiratory function can have additive effects with opioids, and how enzyme inhibitors like quinidine impair codeine's conversion to morphine via CYP2D6, influencing analgesic efficacy. This information is crucial for understanding risks and variations in codeine’s pharmacological effects, as emphasized in the overall document on chemical properties, safety, metabolism, and toxicity of codeine.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_174", "document_index": 23, "latency_s": 1.497067700009211, "prompt_toks": 51567, "completion_toks": 60}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    Dart, R.C. (ed). Medical Toxicology. Third Edition, Lippincott Williams & Wilkins. Philadelphia, PA. 2004., p. 761\n\nBecause opiate agonists may potentiate the effects of other CNS depressants including other opiate agonists, general anesthetics, tranquilizers, sedatives and hypnotics, and alcohol, opiate agonists should be used with great caution and in reduced dosage when used in conjunction with such drugs. Some tranquilizers, especially phenothiazines, may antagonize opiate agonist analgesia. /Opiate agonists/\n\nAmerican Society of Health-System Pharmacists 2016; Drug Information 2016. Bethesda, MD. 2016, p. 2202\n\n\n                    Context: \n                    This excerpt provides critical information on drug interactions and safety considerations for opiate agonists, emphasizing their potentiation of CNS depressants and possible antagonism by tranquilizers, and is relevant for understanding opioid safety and overdose prevention within the comprehensive chemical and pharmacological profile of codeine presented in the full document.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_175", "document_index": 23, "latency_s": 1.6204262999963248, "prompt_toks": 51611, "completion_toks": 87}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    American Society of Health-System Pharmacists 2016; Drug Information 2016. Bethesda, MD. 2016, p. 2202\n\nOpiate agonists may potentiate the effects of tricyclic antidepressants and monoamine oxidase (MAO) inhibitors, including procarbazine hydrochloride; therefore, opiate agonists should be used with great caution and in reduced dosage when used in conjunction with such drugs. Virtually all the reported incidents of opiate agonist interaction with MAO inhibitors have occurred in patients receiving meperidine. ... If an opiate agonist is required in patients receiving MAO inhibitors, a sensitivity test should be performed with small increments of morphine administered over a period of several hours while the patient is kept under close medical observation. /Opiate agonists/\n\nAmerican Society of Health-System Pharmacists 2016; Drug Information 2016. Bethesda, MD. 2016, p. 2202\n\n\n                    Context: \n                    This excerpt discusses the drug interactions and safety considerations for opiate agonists, emphasizing their potential to enhance the effects of tricyclic antidepressants and MAO inhibitors. It highlights the need for caution and dosage reduction when combining these drugs and advises performing sensitivity testing with morphine in patients on MAO inhibitors. This information is relevant for understanding opioid safety and interaction risks within the comprehensive pharmacology and toxicity data provided in the full document.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_176", "document_index": 23, "latency_s": 1.8348098999995273, "prompt_toks": 51660, "completion_toks": 89}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    American Society of Health-System Pharmacists 2016; Drug Information 2016. Bethesda, MD. 2016, p. 2202\n\nWithdrawal symptoms may occur in patients receiving opiate agonists concomitantly with opiate antagonists (e.g., naloxone, naltrexone) or opiate partial agonists (e.g., buprenorphine, butorphanol, nalbuphine, pentazocine). Partial agonists should not be administered in patients receiving opiate agonists as they may reduce the analgesic effect and/or precipitate withdrawal symptoms. /Opiate agonists/\n\nAmerican Society of Health-System Pharmacists 2016; Drug Information 2016. Bethesda, MD. 2016, p. 2202\n\nFor more Interactions (Complete) data for CODEINE (17 total), please visit the HSDB record page.\n\n13.1.14 Antidote and Emergency Treatment\n\nEmergency and supportive measures: Maintain an open airway and assist ventilation if necessary. Administer supplemental oxygen. Treat coma, seizures, hypotension, and noncardiogenic pulmonary edema if they occur. /Opiates and opioids/\n\n\n                    Context: \n                    This excerpt provides critical information on opioid withdrawal symptoms and emergency treatment protocols, specifically for patients receiving opiate agonists in combination with antagonists like naloxone or partial agonists such as buprenorphine. It is relevant for understanding drug interactions and overdose management within the comprehensive chemical safety and pharmacology data presented in the full document. Key details include the risk of precipitating withdrawal and recommended supportive measures like airway management and oxygen therapy.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_177", "document_index": 23, "latency_s": 1.0542264999967301, "prompt_toks": 51447, "completion_toks": 76}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    OLSON, K.R. (Ed). Poisoning and Drug Overdose, Sixth Edition. McGraw-Hill, New York, NY 2012, p. 312\n\n\n                    Context: \n                    This excerpt references the comprehensive toxicological and clinical information on codeine detailed in the full document, specifically from Olson's authoritative poisoning and overdose reference. It provides external validation and source attribution for the detailed data on codeine's toxicity, treatment, and safety profiles included within the overall webpage content. This citation enhances the document's credibility and aids in targeted searches for codeine overdose management.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_178", "document_index": 23, "latency_s": 1.4201990000001388, "prompt_toks": 51645, "completion_toks": 83}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    Specific drugs and antidotes: Naloxone is a specific opioid antagonist with no agonist properties of its own; large doses may be given safely. ... Caution: The duration of effect of naloxone (1-2 hours) is shorter than that of many opioids. Therefore, do not release a patient who has awakened after naloxone treatment until at least 3-4 hours has passed since the last dose of naloxone. In general, if naloxone was required to reverse opioid-induced coma, it is safer to admit the patient for at least 6-12 hours of observation. Nalmefene is an opioid antagonist with a longer duration of effect (3-5 hours). ... Caution: Although the duration of effect of nalmefene is longer than that of naloxone, it is still much shorter than that of methadone. If a methadone overdose is suspected, the patient should be observed for at least 8-12 hours after the last dose of nalmefene. Sodium bicarbonate may be effective for QRS-interval prolongation or hypotension associated with propoxyphene poisoning.\n\n\n                    Context: \n                    This section provides details on specific antidotes for opioid overdose, highlighting naloxone's role as a short-acting opioid antagonist and its administration precautions, including duration of effect and observation periods. It also discusses nalmefene as an alternative with a longer effect and briefly mentions sodium bicarbonate use in certain poisoning cases. This content is crucial for understanding emergency treatment protocols within the comprehensive opioid safety and toxicity management overview.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_179", "document_index": 23, "latency_s": 1.757763799992972, "prompt_toks": 51462, "completion_toks": 100}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    should be observed for at least 8-12 hours after the last dose of nalmefene. Sodium bicarbonate may be effective for QRS-interval prolongation or hypotension associated with propoxyphene poisoning. /Opiates and opioids/\n\n\n                    Context: \n                    This excerpt is from the section on antidote and emergency treatment of opiate and opioid poisoning, detailing post-treatment observation periods for drugs like nalmefene and related management of complications such as QRS prolongation or hypotension caused by toxins like propoxyphene. It emphasizes monitoring durations (8-12 hours) after nalmefene administration and mentions the potential use of sodium bicarbonate for specific cardiotoxic effects, highlighting critical first aid considerations within the comprehensive toxicity and treatment overview.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_180", "document_index": 23, "latency_s": 1.7886760999972466, "prompt_toks": 51656, "completion_toks": 86}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    OLSON, K.R. (Ed). Poisoning and Drug Overdose, Sixth Edition. McGraw-Hill, New York, NY 2012, p. 312\n\nDecontamination. Administer activated charcoal orally if conditions are appropriate. Gastric lavage is not necessary after small to moderate ingestions if activated charcoal can be given promptly. Consider whole-bowel irrigation after ingestion of sustained-release products (eg, MS-Contin, OxyContin). /Opiates and opioids/\n\nOLSON, K.R. (Ed). Poisoning and Drug Overdose, Sixth Edition. McGraw-Hill, New York, NY 2012, p. 312\n\nEnhanced elimination. Because of the very large volumes of distribution of the opioids and the availability of an effective antidotal treatment, there is no role for enhanced elimination procedures. /Opiates and opioids/\n\nOLSON, K.R. (Ed). Poisoning and Drug Overdose, Sixth Edition. McGraw-Hill, New York, NY 2012, p. 312\n\nFor more Antidote and Emergency Treatment (Complete) data for CODEINE (8 total), please visit the HSDB record page.\n\n\n                    Context: \n                    This excerpt summarizes key emergency management guidelines for opioid overdose, specifically indicating that activated charcoal is appropriate for decontamination after small to moderate ingestions, and that there is no role for enhanced elimination due to opioids' large volume of distribution. It references the full section on antidote and emergency treatment for codeine available on the HSDB record, emphasizing its relevance within the comprehensive chemical safety and toxicity profile outlined in the overall webpage content.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_181", "document_index": 23, "latency_s": 1.1519879000115907, "prompt_toks": 51448, "completion_toks": 54}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    For more Antidote and Emergency Treatment (Complete) data for CODEINE (8 total), please visit the HSDB record page.\n\n13.1.15 Human Toxicity Excerpts\n\n\n                    Context: \n                    This section provides detailed human toxicity information about codeine, including symptoms of overdose, adverse effects, and critical safety considerations. It is part of the comprehensive toxicity and safety data in the full document, and references the HSDB record for further detailed emergency and antidote information.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_182", "document_index": 23, "latency_s": 1.775727599990205, "prompt_toks": 51620, "completion_toks": 101}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    /HUMAN EXPOSURE STUDIES/ Correct diagnosis of genuine IgE-mediated opiate allergy poses a significant challenge, mainly because of uncertainties associated with opiate skin testing and the unavailability of drug-specific IgE (sIgE) assays. Recently, it has been suggested that sIgE to poppy seed extract and morphine would be reliable in the diagnosis of opiate allergy. However, given the high prevalence of sIgE antibodies to these compounds in an allergic population, the predictive value of these tests leaves significant doubts. This study aims at verifying the predictive value of positive poppy seed and morphine sIgE assays results. A total of 22 individuals with a positive sIgE to poppy seed or morphine were selected. All had controlled drug challenges with increasing doses of morphine and/or codeine. Of these, 18 patients had an additional basophil activation test (BAT) with morphine and codeine. None of the 22 patients demonstrated objective or subjective symptoms on provocation\n\n\n                    Context: \n                    This excerpt details recent human exposure studies evaluating diagnostic challenges in opioid allergy, specifically assessing the reliability of skin testing, drug-specific IgE assays, and basophil activation tests for morphine and poppy seed allergy, highlighting that positive sIgE results do not always correlate with clinical symptoms. It is relevant to the document's comprehensive review of opioid pharmacology, allergenicity, and safety considerations. Key data include the selective testing of 22 individuals, with no objective allergic reactions observed during provocation.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_183", "document_index": 23, "latency_s": 1.5990599000069778, "prompt_toks": 51590, "completion_toks": 87}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    and/or codeine. Of these, 18 patients had an additional basophil activation test (BAT) with morphine and codeine. None of the 22 patients demonstrated objective or subjective symptoms on provocation with morphine and/or codeine. Regarding BAT with morphine and codeine, expression of CD63 on basophils from 14 opiate tolerant individuals remained comparable to spontaneous expression by resting cells. The remaining 4 patients were classified as nonresponders. Positive sIgE results to poppy seed and morphine are not per se predictive for genuine opiate allergy and should not be used in isolation to diagnose morphine or codeine allergy. To avoid overdiagnosis, for the time being, we propose to supplement serological diagnosis with an oral provocation test. Whether BAT might help to discriminate between clinical reactivity and sensitization remains to be confirmed in larger collaborative studies.\n\n\n                    Context: \n                    This excerpt discusses the diagnostic evaluation of opiate allergy, highlighting that positive IgE tests to poppy seed and morphine are not definitive indicators of true allergy, and emphasizing the potential role of basophil activation tests (BAT) in differentiation. It is relevant for understanding the limitations of serological testing and the importance of oral provocation in allergy diagnosis within the broader context of medical, toxicological, and allergy-related information on codeine.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_184", "document_index": 23, "latency_s": 1.553866599992034, "prompt_toks": 51442, "completion_toks": 74}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    PMID:25956313\n\nVan Gasse AL et al; J Allergy Clin Immunol Pract 3 (3): 396-9 (2015)\n\n\n                    Context: \n                    This excerpt references a 2015 study by Van Gasse et al on opiate allergies, including codeine, contributing to the broader discussion of codeine’s safety, toxicity, and adverse reactions in the full document. It is relevant for understanding allergic responses and diagnostic considerations related to codeine use, complementing the comprehensive safety, toxicity, and pharmacological data provided.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_185", "document_index": 23, "latency_s": 2.40667470000335, "prompt_toks": 51603, "completion_toks": 82}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    /SIGNS AND SYMPTOMS/ The non-medical use of pharmaceutical opioids such as codeine is of increasing public health concern. The aim of the study was to describe codeine intoxication experiences amongst recreational drug users, as posted on public Internet forums. Internet searches were carried out by using the specific key word 'codeine' and in combination with 'experience', 'report', 'trip' and 'forum'. 96 Trip reports and 156 thread discussions relating to the sole use of codeine were analyzed using the empirical phenomenological psychological (EPP) method. Nine themes and 72 categories emerged. Narratives illustrated transitions between medical and non-medical use of codeine for dulling of emotional and/or physical pain, opiate withdrawal management and for intoxication. Codeine's appeal centered on access via family medicine cabinets, prescribers and pharmacies. Discussion and dissemination of indigenous harm reduction tactics included the learning to appreciate codeine's effect\n\n\n                    Context: \n                    This excerpt summarizes a study analyzing online reports of non-medical, recreational codeine use, highlighting themes of abuse, harm reduction, and user experiences. It provides insights into the social and behavioral aspects of codeine misuse, which are relevant for understanding drug abuse trends and public health risks discussed in the broader document. The section emphasizes patterns of intoxication, access issues, and harm reduction strategies documented from internet forums.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_186", "document_index": 23, "latency_s": 1.4709103000059258, "prompt_toks": 51587, "completion_toks": 96}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    centered on access via family medicine cabinets, prescribers and pharmacies. Discussion and dissemination of indigenous harm reduction tactics included the learning to appreciate codeine's effect via moderated use in optimal settings, avoidance of tolerance by use of informed dosing schedules, cold water extraction of codeine, and using codeine as an alternative to stronger opioids. Oral and rectal routes were favored, with awareness on forums of the harms of intravenous and subcutaneous injection. 250 mg was recommended to optimize recreational outcomes. Forum users describe potentiating practices and using over-the-counter medications to improve intoxication experiences and reduce unpleasant side effects. Dissociative effects, ability to ignore physical and emotional pain, codeine-induced synesthesia and altered states of consciousness were described. Overdose was characterized by anesthesia, severe chest and stomach pain, respiratory depression, panic and fear of death. Efforts to\n\n\n                    Context: \n                    This excerpt details user-reported harm reduction strategies and effects related to recreational codeine use, emphasizing methods such as moderation, extraction, and route preferences, alongside descriptions of intoxication experiences and overdose symptoms. It situates within the comprehensive webpage on codeine, highlighting both social practices and risks associated with non-medical use, relevant for toxicity, pharmacology, and abuse literature. Its focus on user discourse and harm minimization complements the scientific and safety information provided elsewhere in the document.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_187", "document_index": 23, "latency_s": 1.915865400005714, "prompt_toks": 51504, "completion_toks": 95}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    synesthesia and altered states of consciousness were described. Overdose was characterized by anesthesia, severe chest and stomach pain, respiratory depression, panic and fear of death. Efforts to ensure legitimate codeine use for pain and reduction of aberrant behaviors center on evidence based screening, risk minimization, prescription monitoring and specific treatment protocols. This study shows that internet drug forums drive communal know-how and indigenous harm reduction strategies, and warrant consideration as viable public health mechanisms for informing users.\n\n\n                    Context: \n                    This excerpt summarizes findings from human toxicity and overdose studies detailed in the document, highlighting symptoms like anesthesia, chest and stomach pain, respiratory depression, and psychological effects such as synesthesia and altered consciousness. It emphasizes the importance of evidence-based screening, risk management, and harm reduction strategies, including online forum insights, for public health and safe use of codeine. Its relevance lies in contextualizing adverse effects, overdose characteristics, and community-driven harm reduction approaches discussed throughout the full report.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_188", "document_index": 23, "latency_s": 1.6333360000135144, "prompt_toks": 51437, "completion_toks": 84}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    PMID:25052240\n\nVan Hout MC; Int J Drug Policy 26 (1): 67-77 (2015)\n\n\n                    Context: \n                    This excerpt references a key publication (PMID:25052240) by Van Hout (2015) on codeine intoxication experiences and harm reduction strategies, situating it within the comprehensive discussion of codeine’s pharmacology, safety, and toxicity in the full webpage content. It highlights the relevance of behavioral and forensic insights into codeine misuse, facilitating targeted literature searches and contextual understanding of abuse and overdose phenomena.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_189", "document_index": 23, "latency_s": 1.848535900004208, "prompt_toks": 51630, "completion_toks": 90}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    /SIGNS AND SYMPTOMS/ Hydrocodone has recently been reclassified as a Schedule II drug by the United States Drug Enforcement Administration and Food and Drug Administration in order to curtail prescription drug abuse. There is concern that analgesic substitutes, such as codeine, will not be as safe or effective. The purpose of this study is to compare the demographics, adverse events, and medical outcomes of patients who had unintentional hydrocodone or codeine exposures through the use of a state's poison center database. The Texas Poison Center Network's database was utilized to find all reported unintentional ingestions or adverse reactions of products containing codeine or hydrocodone. Comparisons were made between the two medications by calculating the rate ratios (RR) and 95% confidence intervals (CI). Children aged 5 years or younger were more exposed to codeine (51.6%). Hydrocodone exposures had more serious outcomes (11% vs. 9%; RR = 0.82; 95% CI 0.73-0.91) and had more nausea\n\n\n                    Context: \n                    This excerpt discusses adverse effects and safety considerations related to opioids, specifically comparing unintentional exposures to hydrocodone and codeine based on poison center data, highlighting differences in outcomes, age groups affected, and associated symptoms such as nausea. It is relevant to the document's comprehensive review of chemical safety, toxicity, and medical research on opioids like codeine. The data emphasizes patterns in accidental exposures and health risks, supporting the broader context of opioid safety assessment.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_190", "document_index": 23, "latency_s": 1.5789565999875776, "prompt_toks": 51708, "completion_toks": 85}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    intervals (CI). Children aged 5 years or younger were more exposed to codeine (51.6%). Hydrocodone exposures had more serious outcomes (11% vs. 9%; RR = 0.82; 95% CI 0.73-0.91) and had more nausea (7.1% vs. 2.8%; RR = 0.4; 95% CI 0.32-0.48) and vomiting (6.5% vs. 3.3%; RR = 0.51; 95% CI 0.43-0.62). Hydrocodone had a higher rate of intravenous fluids administration (2.4% vs. 1.7%; RR = 0.71; 95% CI 0.54-0.92) and antiemetics (0.4% vs. 0.1%; RR = 0.23; 95% CI 0.08-0.64). Codeine was more closely associated with dermal reactions and patients were given antihistamines (2.5% vs. 1.3%; RR = 1.88; 95% CI 1.46-2.41) more frequently. Cardiovascular side effects, ataxia, and headache occurred equally between the groups. Both drugs had a wide array of reported side effects, but the overall incidence of serious outcomes was low.\n\n\n                    Context: \n                    This excerpt summarizes a comparative analysis of adverse effects and outcomes associated with codeine and hydrocodone from a toxicology study. It highlights differences in serious outcomes, symptoms like nausea and vomiting, treatment interventions, and side effect profiles, providing relevant safety data within the broader context of drug toxicity, safety, and clinical effects detailed in the full document. The data is critical for understanding the relative risks and side effects of these opioids.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_191", "document_index": 23, "latency_s": 1.6738356999994721, "prompt_toks": 51637, "completion_toks": 84}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    PMID:26899518\n\nDay L et al; J Emerg Med pii: S0736-4679(16)00035-4 doi: 10.1016/j.jemermed.2016.01.023 (2016) (Epub ahead of print)\n\n/SIGNS AND SYMPTOMS/ Toxic doses of codeine may produce exhilaration, excitement, seizures, delirium, hypotension, miosis, slow pulse, tachycardia, narcosis, flushed facies, tinnitus, lassitude, muscular weakness, and circulatory collapse or respiratory paralysis. ... Respiratory arrest, coma, and death have occurred in young children receiving oral codeine doses of 5-12 mg/kg.\n\nAmerican Society of Health-System Pharmacists 2016; Drug Information 2016. Bethesda, MD. 2016, p. 2869\n\nFor more Human Toxicity Excerpts (Complete) data for CODEINE (16 total), please visit the HSDB record page.\n\n13.1.16 Non-Human Toxicity Excerpts\n\n\n                    Context: \n                    This excerpt summarizes human toxicity symptoms and fatal doses of codeine, highlighting adverse effects such as respiratory depression, seizures, and death in children at doses of 5-12 mg/kg. It is part of the comprehensive toxicity section in the full PubChem document, which details chemical safety, adverse effects, and related toxicological data. This information is crucial for understanding health risks of codeine exposure in medical and emergency contexts.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_192", "document_index": 23, "latency_s": 1.5688745000079507, "prompt_toks": 51673, "completion_toks": 105}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    For more Human Toxicity Excerpts (Complete) data for CODEINE (16 total), please visit the HSDB record page.\n\n13.1.16 Non-Human Toxicity Excerpts\n\n/LABORATORY ANIMALS: Developmental or Reproductive Toxicity/ ... Hamsters /injected with codeine/ on day 8 subcutaneously with 73 to 360 mg/kg ... /produced/ 6 to 8 percent cranioschisis in the offspring. No dose response was found and not a single malformation occurred in over 1400 saline injected controls.\n\nShepard, T.H. Catalog of Teratogenic Agents. 13th ed. Baltimore, MD: The Johns Hopkins University Press, 2010., p. 114\n\n/LABORATORY ANIMALS: Developmental or Reproductive Toxicity/ /A study of/ pregnant mice and hamsters ... /found at 150 mg/kg codeine/ an increase in meningoencephaloceles. No increase in defects was found in the mouse at doses up to 300 mg/kg.\n\nShepard, T.H. Catalog of Teratogenic Agents. 13th ed. Baltimore, MD: The Johns Hopkins University Press, 2010., p. 114\n\n\n                    Context: \n                    This excerpt summarizes non-human toxicity data for codeine's reproductive and developmental effects in laboratory animals, specifically noting cranioschisis in hamsters at doses between 73-360 mg/kg and meningoencephaloceles in pregnant mice and hamsters at 150 mg/kg. Its relevance lies in providing detailed teratogenicity findings, complementing the broader toxicological profile of codeine documented in the full document for research and regulatory purposes. These findings are critical for understanding potential reproductive risks associated with codeine exposure.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_193", "document_index": 23, "latency_s": 1.5235913000069559, "prompt_toks": 51548, "completion_toks": 101}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    Shepard, T.H. Catalog of Teratogenic Agents. 13th ed. Baltimore, MD: The Johns Hopkins University Press, 2010., p. 114\n\n/LABORATORY ANIMALS: Developmental or Reproductive Toxicity/ ... Hamsters and mice /were gavaged/ with up to 300 or 150 mg/kg /of codeine/ twice daily respectively. Decreased fetal weight was found at maternally toxic doses but no teratogenicity.\n\nShepard, T.H. Catalog of Teratogenic Agents. 13th ed. Baltimore, MD: The Johns Hopkins University Press, 2010., p. 114\n\n\n                    Context: \n                    This excerpt details reproductive toxicity data for codeine from Shepard's \"Catalog of Teratogenic Agents,\" highlighting animal studies in hamsters and mice where doses up to 300 or 150 mg/kg caused decreased fetal weight at maternally toxic levels without inducing teratogenic effects. It is relevant to the section on laboratory animal toxicity and supports the document's comprehensive review of codeine's adverse effects, especially regarding developmental risks. The source reference emphasizes the importance of dosage-related reproductive outcomes in toxicological assessment.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_194", "document_index": 23, "latency_s": 1.9870708000089508, "prompt_toks": 51642, "completion_toks": 89}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    /BEHAVIORAL STUDIES/ Chronic morphine therapy has been associated with paradoxically increased pain. Codeine is a widely used opioid, which is metabolized to morphine to elicit analgesia. Prolonged morphine exposure exacerbates pain by activating the innate immune toll-like receptor-4 (TLR4) in the central nervous system. In silico docking simulations indicate codeine also docks to MD2, an accessory protein for TLR4, suggesting potential to induce TLR4-dependent pain facilitation. We hypothesized codeine would cause TLR4-dependent hyperalgesia/allodynia that is disparate from its opioid receptor-dependent analgesic rank potency. Hyperalgesia and allodynia were assessed using hotplate and von Frey tests at days 0, 3 and 5 in mice receiving intraperitoneal equimolar codeine (21 mg kg(-1)), morphine (20 mg kg(-1)) or saline, twice daily. This experiment was repeated in animals with prior partial nerve injury and in TLR4 null mutant mice. Interventions with interleukin-1 receptor\n\n\n                    Context: \n                    This section details recent research on the neuroinflammatory mechanisms underlying opioid-induced hyperalgesia, highlighting codeine's potential to activate TLR4 and exacerbate pain sensitivity independently of its analgesic effects. It is relevant within the broader pharmacology and toxicity discussion, illustrating molecular pathways and behavioral effects associated with chronic opioid use. Key details include mouse models, dosing regimens, and intervention strategies targeting TLR4-mediated pain facilitation.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_195", "document_index": 23, "latency_s": 1.5499770000024, "prompt_toks": 51656, "completion_toks": 103}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    morphine (20 mg kg(-1)) or saline, twice daily. This experiment was repeated in animals with prior partial nerve injury and in TLR4 null mutant mice. Interventions with interleukin-1 receptor antagonist (IL-1RA) and glial-attenuating drug ibudilast were assessed. Analyses of glial activation markers (glial fibrillary acid protein and CD11b) in neuronal tissue were conducted at the completion of behavioral testing. Despite providing less acute analgesia (P=0.006), codeine induced similar hotplate hyperalgesia to equimolar morphine vs saline (-9.5 s, P<0.01 and -7.3 s, P<0.01, respectively), suggesting codeine does not rely upon conversion to morphine to increase pain sensitivity. This highlights the potential non-opioid receptor-dependent nature of codeine-enhanced pain sensitivity-although the involvement of other codeine metabolites cannot be ruled out. IL-1RA reversed codeine-induced hyperalgesia (P<0.001) and allodynia (P<0.001), and TLR4 knock-out protected against codeine-induced\n\n\n                    Context: \n                    This excerpt discusses preclinical research on the analgesic and hyperalgesic effects of codeine in animal models, highlighting that codeine's pain sensitivity may involve non-opioid pathways, such as TLR4 signaling and glial activation. It emphasizes that codeine-induced hyperalgesia is independent of its conversion to morphine and can be modulated by IL-1RA and TLR4 knockout, making it relevant for understanding the complex pharmacology and toxicity mechanisms detailed in this comprehensive chemical profile.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_196", "document_index": 23, "latency_s": 1.7853869999962626, "prompt_toks": 51506, "completion_toks": 92}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    the involvement of other codeine metabolites cannot be ruled out. IL-1RA reversed codeine-induced hyperalgesia (P<0.001) and allodynia (P<0.001), and TLR4 knock-out protected against codeine-induced changes in pain sensitivity. Glial attenuation with ibudilast reversed codeine-induced allodynia (P<0.001), and thus could be investigated further as potential treatment for codeine-induced pain enhancement.\n\n\n                    Context: \n                    This excerpt summarizes research on codeine's effects on pain sensitivity, highlighting the role of metabolites, immune signaling via TLR4, and the potential of glial modulators like ibudilast as treatments. It is relevant within the pharmacology and toxicology discussions, providing insight into non-opioid receptor mechanisms and potential therapies for codeine-induced hyperalgesia. This content enhances understanding of codeine's complex biological interactions and relevant experimental findings.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_197", "document_index": 23, "latency_s": 1.2517749999969965, "prompt_toks": 51677, "completion_toks": 94}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    PMID:25386959\n\nFull text: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4259992\n\nJohnson JL et al; Transl Psychiatry 4: e482 (2014)\n\nFor more Non-Human Toxicity Excerpts (Complete) data for CODEINE (8 total), please visit the HSDB record page.\n\n13.1.17 Human Toxicity Values\n\nIn adults, ingestion of 7 to 14 mg/kg may cause death. Much higher doses may be tolerated by chronic users. Ingestion of more than 1 mg/kg of codeine in children is capable of producing symptoms, and doses more than 5 mg/kg have caused respiratory arrest.\n\nDart, R.C. (ed). Medical Toxicology. Third Edition, Lippincott Williams & Wilkins. Philadelphia, PA. 2004., p. 761\n\nThe lethal dose is between 500 mg and 1 g.\n\nGossel, T.A., J.D. Bricker. Principles of Clinical Toxicology. 3rd ed. New York, NY: Raven Press, Ltd., 1994., p. 298\n\nToxic codeine blood concentration: 20-50 ug/dL; Lethal codeine blood concentration: > 60 ug/dL /From table/\n\n\n                    Context: \n                    This excerpt from Johnson JL et al.'s 2014 study provides critical human toxicity thresholds for codeine, noting that ingestion of 7-14 mg/kg can be fatal for adults, with blood concentrations exceeding 60 μg/dL being lethal. It supports the overall document's detailed pharmacology and toxicology profile of codeine, emphasizing overdose risk levels in humans. These data are essential for understanding safe dosage limits and toxicity management within the comprehensive chemical safety record.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_198", "document_index": 23, "latency_s": 1.0506278999964707, "prompt_toks": 51714, "completion_toks": 67}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    Toxic codeine blood concentration: 20-50 ug/dL; Lethal codeine blood concentration: > 60 ug/dL /From table/\n\nGossel, T.A., J.D. Bricker. Principles of Clinical Toxicology. 3rd ed. New York, NY: Raven Press, Ltd., 1994., p. 298\n\nTherapeutic codeine blood concentration: 1-12 ug/dL; Toxic codeine blood concentration: 20-50 ug/dL; Lethal codeine blood concentration: > 60 ug/dL /From table/\n\nGossel, T.A., J.D. Bricker. Principles of Clinical Toxicology. 3rd ed. New York, NY: Raven Press, Ltd., 1994., p. 298\n\n13.1.18 Non-Human Toxicity Values\n\nLD50 Rat oral 427 mg/kg\n\nLewis, R.J. Sr. (ed) Sax's Dangerous Properties of Industrial Materials. 11th Edition. Wiley-Interscience, Wiley & Sons, Inc. Hoboken, NJ. 2004., p. 980\n\nLD50 Rat ip 100 mg/kg\n\nLewis, R.J. Sr. (ed) Sax's Dangerous Properties of Industrial Materials. 11th Edition. Wiley-Interscience, Wiley & Sons, Inc. Hoboken, NJ. 2004., p. 980\n\nLD50 Rat sc 229 mg/kg\n\n\n                    Context: \n                    This section provides key toxicological thresholds and non-human toxicity data for codeine, including blood concentration ranges associated with therapeutic, toxic, and lethal effects in humans, as well as LD50 values in rats via various administration routes. It is essential for understanding codeine's toxicity profile within the comprehensive safety and toxicity overview of the full document.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_199", "document_index": 23, "latency_s": 1.4430686000123387, "prompt_toks": 51623, "completion_toks": 91}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    LD50 Rat ip 100 mg/kg\n\nLewis, R.J. Sr. (ed) Sax's Dangerous Properties of Industrial Materials. 11th Edition. Wiley-Interscience, Wiley & Sons, Inc. Hoboken, NJ. 2004., p. 980\n\nLD50 Rat sc 229 mg/kg\n\nLewis, R.J. Sr. (ed) Sax's Dangerous Properties of Industrial Materials. 11th Edition. Wiley-Interscience, Wiley & Sons, Inc. Hoboken, NJ. 2004., p. 980\n\nLD50 Rat iv 75 mg/kg\n\nLewis, R.J. Sr. (ed) Sax's Dangerous Properties of Industrial Materials. 11th Edition. Wiley-Interscience, Wiley & Sons, Inc. Hoboken, NJ. 2004., p. 980\n\nFor more Non-Human Toxicity Values (Complete) data for CODEINE (11 total), please visit the HSDB record page.\n\n13.1.19 Ongoing Test Status\n\n\n                    Context: \n                    This section provides specific non-human toxicity data for codeine, including rat LD50 values via different routes (ip 100 mg/kg, sc 229 mg/kg, iv 75 mg/kg), referencing Sax's Dangerous Properties of Industrial Materials. It is relevant for toxicity assessment and supports the comprehensive overview of codeine's safety profile detailed in the overall document. The note on additional toxicity data and ongoing test status indicates further resources are available for in-depth analysis.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_200", "document_index": 23, "latency_s": 1.4844460000022082, "prompt_toks": 51565, "completion_toks": 73}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    For more Non-Human Toxicity Values (Complete) data for CODEINE (11 total), please visit the HSDB record page.\n\n13.1.19 Ongoing Test Status\n\nEPA has released the Interactive Chemical Safety for Sustainability (iCSS) Dashboard. The iCSS Dashboard provides an interactive tool to explore rapid, automated (or in vitro high-throughput) chemical screening data generated by the Toxicity Forecaster (ToxCast) project and the federal Toxicity Testing in the 21st century (Tox21) collaboration. /The title compound was tested by ToxCast and/or Tox21 assays/[USEPA; ICSS Dashboard Application; Available from, as of December 17, 2015: http://actor.epa.gov/dashboard/]\n\n\n                    Context: \n                    This section provides updated information on ongoing toxicity testing status and data exploration tools related to codeine within the full PubChem compound profile. It highlights the EPA's release of the iCSS Dashboard for high-throughput chemical screening data, which is relevant for researchers accessing comprehensive non-human toxicity datasets for codeine. The content emphasizes recent advances and resources available for chemical safety assessment.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_201", "document_index": 23, "latency_s": 1.561663000000408, "prompt_toks": 51498, "completion_toks": 73}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    The following link will take the user to the National Toxicology Program (NTP) Test Agent Search Results page for codeine, which tabulates all of the Short-Term Toxicity, Long-term Carcinogenicity, and Organ Systems Toxicity studies performed with this chemical.[Available from: http://ntp.niehs.nih.gov/testing/status/agents/ts-11119-t.html]\n\n13.1.20 National Toxicology Program Studies\n\n\n                    Context: \n                    This excerpt references the comprehensive toxicology data compiled by the National Toxicology Program (NTP) on codeine, detailing various toxicity and carcinogenicity studies. It is relevant for understanding the substance's safety profile and is linked to the detailed NTP Test Agent Search Results page. This section enhances the document's coverage of codeine’s long-term toxicological evaluation.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_202", "document_index": 23, "latency_s": 1.7615469999873312, "prompt_toks": 51694, "completion_toks": 104}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    ... Male and female F344/N rats and B6C3Fl mice were given codeine (99% pure) in feed for ... 2 yr. ... 2 YEAR STUDY IN RATS: Groups of 60 male and 60 female F344/N rats were fed diets containing 0, 400, 800, or 1,600 ppm codeine for up to 106 wk. ... These exposure concentrations resulted in average daily doses of approximately 15, 30, and 70 mg codeine/kg body weight to males and 15, 40, and 80 mg/kg to females. 2 YEAR STUDY IN MICE: Groups of 60 male and 60 female B6C3Fl mice were fed diets containing 0, 750, 1,500, or 3,000 ppm codeine for up to 106 wk. ... These exposure concentrations resulted in average daily doses of approximately 100, 200, or 400 mg codeine/kg body weight to males and females. CONCLUSIONS: Under the conditions of these 2 yr feed studies, there was no evidence of carcinogenic activity of codeine in male or female F344/N rats exposed to 400, 800, or 1,600 ppm. There was no evidence of carcinogenic activity of codeine in male or female B6C3F1 mice exposed to\n\n\n                    Context: \n                    This excerpt summarizes a two-year carcinogenicity study of high-purity codeine in rats and mice, detailing dosage levels, exposure durations, and conclusions indicating no evidence of carcinogenic activity in both species at tested doses. It is part of the broader toxicology and safety assessment section of the full PubChem entry, providing critical data on long-term safety and carcinogenic risk related to codeine. The detailed dosing parameters and study outcomes are essential for understanding codeine’s carcinogenic potential in the overall chemical safety profile.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_203", "document_index": 23, "latency_s": 0.9873135999951046, "prompt_toks": 51478, "completion_toks": 66}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    of carcinogenic activity of codeine in male or female F344/N rats exposed to 400, 800, or 1,600 ppm. There was no evidence of carcinogenic activity of codeine in male or female B6C3F1 mice exposed to 750, 1,500, or 3,000 ppm.\n\n\n                    Context: \n                    This segment summarizes the core findings of the NTP two-year carcinogenicity studies on codeine, indicating no evidence of carcinogenic activity in both rats and mice at specified exposure levels. It is an essential part of the broader toxicity and safety evaluation presented in the document, highlighting the compound's carcinogenic risk assessment and regulatory considerations.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_204", "document_index": 23, "latency_s": 2.005435099999886, "prompt_toks": 51489, "completion_toks": 98}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    Toxicology & Carcinogenesis Studies of Codeine in F344/N Rats and B6C3F1 Mice (Feed Studies). Technical Report Series No. 455 (1996) NIH Publication No. 96-3360 U.S. Department of Health and Human Services, National Toxicology Program, National Institute of Environmental Health Sciences, Research Triangle Park, NC 27709\n\n\n                    Context: \n                    This excerpt summarizes the 1996 NTP carcinogenicity and toxicity study of codeine in rats and mice, providing official findings on its safety profile, carcinogenic potential, and dosage effects. It is a key reference within the comprehensive toxicity and safety data section of the full webpage, relevant for researchers assessing codeine's long-term health risks and regulatory status. The detailed study results support the overall information on codeine’s toxicity, carcinogenicity, and dosage considerations presented in the document.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_205", "document_index": 23, "latency_s": 1.3665215999935754, "prompt_toks": 51642, "completion_toks": 87}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    Codeine (COD), a widely used narcotic analgesic, was evaluated for potential developmental toxicity in timed-pregnant CD-1 mice (28-38 confirmed pregnancies per group). Codeine (COD) (0, 75, 150 or 300 mg/kg, bid) in distilled water was administered by gavage (po) throughout major organogenesis (gestational days (gd) 6 through 15). No notable maternal toxicity was observed at the lowest dose (75 mg/kg, bid). Among the animals exposed to 150 mg COD/kg. Only 1 nonpregnant female died whereas, the pregnant females exhibited neither mortality nor clinical signs of toxicity. A decreasing trend for corrected maternal weight gain was observed with a significant reduction at 300 mg/kg. Among the high-dose females, mortality reached 19% (7 of 37) and relative liver weight increased. No evidence of embryo/fetal toxicity was observed at the lowest dose (75 mg/kg, bid). ... At 150 and 300 mg/kg, the cumulative index of intrauterine mortality (e.g., resorptions plus late fetal deaths expressed as\n\n\n                    Context: \n                    This excerpt summarizes a developmental toxicity study of codeine (COD) in pregnant mice, detailing dose-related effects such as maternal weight decline and intrauterine mortality at higher doses. It provides specific data on dosage, maternal and embryo/fetal outcomes, and toxicity observations, making it relevant for understanding codeine's teratogenic assessment within the comprehensive drug safety profile. This information aids in evaluating codeine's reproductive safety and toxicological thresholds.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_206", "document_index": 23, "latency_s": 2.0721658999973442, "prompt_toks": 51620, "completion_toks": 92}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    embryo/fetal toxicity was observed at the lowest dose (75 mg/kg, bid). ... At 150 and 300 mg/kg, the cumulative index of intrauterine mortality (e.g., resorptions plus late fetal deaths expressed as a percentage of implants per litter) exhibited a doserelated increasing trend, due to a significant increase in resorptions in the 300 mg/kg group as compared to the vehicle control group. Among live litters, the number of live fetuses per litter and the percentage of male fetuses per litter did not differ across treatment groups. The incidence of major malformations was low (less than or equal to 1.16% malformed fetuses per litter) in all dose groups, and the average percent malformed fetuses per litter did not differ statistically across groups. The percent females malformed per litter exhibited a significant increasing trend, but no individual COD-treated group was above the vehicle control for this endpoint. In summary, the lowest dose (75 mg/kg, bid) was a no observed effect level\n\n\n                    Context: \n                    This excerpt summarizes developmental toxicity findings from a toxicology study of codeine, indicating embryo/fetal effects at the lowest dose of 75 mg/kg administered twice daily. It highlights dose-related increases in intrauterine mortality and malformations, while noting no significant differences in live fetuses or gender distribution across doses. As part of the broader toxicology and safety evaluation in the document, it provides key details on reproductive and developmental risks associated with codeine exposure.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_207", "document_index": 23, "latency_s": 1.7708317000069655, "prompt_toks": 51622, "completion_toks": 110}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    a significant increasing trend, but no individual COD-treated group was above the vehicle control for this endpoint. In summary, the lowest dose (75 mg/kg, bid) was a no observed effect level (NOEL) for all indices of maternal and embryo/fetal toxicity. Reduced fetal body weight was observed at 150 mg/kg, bid, in the absence of significant treatment-related toxicity among pregnant females. Relative to codeine use in a clinical context, 150 mg/kg, bid is 100 times higher than the estimated clinical intake per dose and 33 times higher than the estimated clinical intake per day (e.g., 1.5 mg/kg per dose and 9 mg/kg/day ). Codeine exposure during gestation failed to increase the incidence of major fetal malformations even at the highest dose (300 mg/kg, bid) which produced a significant increase in the percentage of resorptions per litter. The 300 mg/kg dose was also associated with a significant decrease in average fetal body weight per litter, and 19% mortality among pregnant females.\n\n\n                    Context: \n                    This excerpt summarizes findings from toxicity studies on codeine administered to pregnant animals, highlighting dose-related effects such as reduced fetal weight and increased litter resorptions at higher doses. It emphasizes that the no observed effect level (75 mg/kg, bid) is well above typical human clinical doses, and that even at the highest tested dose (300 mg/kg, bid), there was no increased incidence of major fetal malformations, though fetal weight and maternal mortality were affected. This information is crucial for understanding codeine’s developmental toxicity profile in toxicological assessments.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_208", "document_index": 23, "latency_s": 1.7011854000011226, "prompt_toks": 51512, "completion_toks": 92}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    Department of Health & Human Services/National Institute of Environmental Health Sciences, National Toxicology Program; Codeine (CAS No. 76-57-3) Administered to CD-1 Mice on Gestational Days 6 Through 15, NTP Study No. TER90057 (April 7, 1987) Available from, as of March 8, 2016: https://ntp.niehs.nih.gov/testing/types/dev/abstracts/pages/ter90057/index.html\n\n\n                    Context: \n                    This chunk details a specific reproductive toxicity study of codeine (CAS 76-57-3) conducted on CD-1 mice during gestational days 6 to 15, published by the National Toxicology Program of the NIEHS. It is part of the broader toxicity and developmental data section, providing critical information on codeine's reproductive safety profile, relevant for researchers and regulatory assessments. The reference link facilitates access to detailed study results and protocol information.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_209", "document_index": 23, "latency_s": 1.559136199997738, "prompt_toks": 51645, "completion_toks": 78}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    Codeine (COD), a widely used narcotic analgesic, was evaluated for potential developmental toxicity in timed-pregnant LVG hamsters. Codeine was dissolved in distilled water to provide doses of 0, 10, 50, or 150 mg/kg and administered by gavage twice daily (bid) on gestational days (gd) 5 through 13. A positive control study was performed concurrently with the teratology study. Diethylene glycol dimethyl ether (DYNE), the positive control compound, was administered by gavage at a dose of 400 mg/kg, twice daily. Maternal viability was not affected by codeine through the dosing period (gd 5 through 13) to sacrifice on gd 14. The predominant clinical sign of toxicity occurring during treatment was weight loss ( greater than or equal to 2.5 g/day) which was mainly exhibited by dams administered 50 and 150 mg/kg, twice daily. Maternal body weight showed a decreasing trend with treatment on gd 8, 11 and 14, and at the high dose was significantly below the control level on gd 11 and 14.\n\n\n                    Context: \n                    This excerpt summarizes a developmental toxicity study of codeine in pregnant LVG hamsters, detailing dosing regimens, maternal viability outcomes, toxicity signs such as weight loss, and effects on maternal body weight at different gestational days. It is relevant within the broader document as part of toxicity and safety assessments, highlighting codeine's potential teratogenic effects and dose-dependent maternal toxicity during pregnancy.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_210", "document_index": 23, "latency_s": 1.7085746000084328, "prompt_toks": 51617, "completion_toks": 90}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    50 and 150 mg/kg, twice daily. Maternal body weight showed a decreasing trend with treatment on gd 8, 11 and 14, and at the high dose was significantly below the control level on gd 11 and 14. Maternal weight gain (gestation, treatment and corrected) and gravid uterine weight exhibited downward trends with treatment. With the exception of corrected weight gain, the values determined for the high dose group were significantly below control values. Relative liver weight (% body weight) exhibited an increasing trend with treatment and was significantly greater than control at 150 mg/kg, twice daily. Embryo/fetal toxicity occurred in a dose dependent manner. At 10 mg codeine/kg, twice daily, there were no effects on any of the parameters that indicate changes in embryo/fetal viability or growth. The incidence of resorption per litter showed an increasing trend with treatment and at the high dose (37.9%) was significantly greater than the control level (10.5%). Late fetal death occurred\n\n\n                    Context: \n                    This excerpt summarizes findings from developmental toxicity studies of codeine in animal models, highlighting dose-dependent effects on maternal weight, relative liver weight, and embryo/fetal viability, including increased resorptions at higher doses and no effects at lower doses. It provides detailed data on toxic doses, maternal and fetal outcomes, and dose-response relationships, making it relevant for understanding codeine’s reproductive toxicity profile within the broader pharmacological and toxicological information in the document.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_211", "document_index": 23, "latency_s": 1.692453799987561, "prompt_toks": 51630, "completion_toks": 124}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    The incidence of resorption per litter showed an increasing trend with treatment and at the high dose (37.9%) was significantly greater than the control level (10.5%). Late fetal death occurred only in the 150 mg/kg, twice daily, dose group at a rate of 1.0% per litter which was significantly greater than the control level (0.0%). The number of live fetuses per litter and their sex ratio were not affected by the codeine treatment. The body weights of fetuses from dams exposed to 50 and 150 mg/kg, twice daily, were significantly lower than control weights. The incidence of malformations per litter showed an increasing trend with treatment which ranged from 0.9% for control to 4.6% for the high dose group. When analyzed by malformation type per litter, i.e. external, visceral or skeletal, no obvious dose-related trends were identified. There was a nonstatistically significant increase in % malformations at the 150 mg/kg, twice daily, dose with meningoencephalocele the predominant\n\n\n                    Context: \n                    This excerpt details the developmental toxicity findings from a 2-year study assessing codeine's effects in animal models, highlighting increased fetal resorption (37.9% vs. 10.5% in controls), late fetal deaths, lower fetal weights, and a dose-related increase in malformations (up to 4.6%), including a non-significant rise in meningoencephalocele at high doses. It situates within the section discussing reproductive and developmental toxicology, emphasizing dose-dependent adverse fetal outcomes. These findings are key for understanding codeine’s teratogenic potential and risk profile in regulatory assessments.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_212", "document_index": 23, "latency_s": 1.5342878000083147, "prompt_toks": 51628, "completion_toks": 75}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    no obvious dose-related trends were identified. There was a nonstatistically significant increase in % malformations at the 150 mg/kg, twice daily, dose with meningoencephalocele the predominant observation. Gestational exposure of dams to DYME (400 mg/kg, twice daily, by mouth) produced a wide range of defects at an overall malformation incidence of 33% per litter (1% for control) (DYME results, see Appendix VII). In conclusion, embryo/fetal development of the LVG hamster was sensitive to codeine administered at a maternally nontoxic dose of 50 mg/kg, twice daily. At that dose, fetal body weight was significantly reduced while all parameters of maternal toxicity indicated no effect. The no observed effect level (NOEL) for codeine-induced developmental toxicity was 10 mg/kg, twice daily. Maternal toxicity was demonstrated in the 150 mg/kg, twice daily, group by significant changes in body and organ weights. The NOEL for codeine-induced maternal toxicity was 50 mg/kg, twice daily.\n\n\n                    Context: \n                    This excerpt summarizes findings from developmental toxicity studies of codeine in LVG hamsters and related compounds, highlighting dose-dependent effects on fetal weight and malformation incidence. It details the maternal and fetal NOEL levels, toxicity parameters, and specific birth defects observed at higher doses, situating these results within a comprehensive review of codeine's toxicological profile presented in the full document.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_213", "document_index": 23, "latency_s": 1.1870221999997739, "prompt_toks": 51639, "completion_toks": 94}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    Department of Health & Human Services/National Institute of Environmental Health Sciences, National Toxicology Program; Codeine (CAS No. 76-57-3) in LVG Hamsters on Gestational Days 5 through 13, NTP Study No. TER90058 (September 15, 1987) Available from, as of March 8, 2016: https://ntp.niehs.nih.gov/testing/types/dev/abstracts/pages/ter90058/index.html\n\n13.1.21 Populations at Special Risk\n\nCodeine, the reference compound with which other antitussives are compared ... is effective orally for acute cough associated with a variety of diseases & irritants. Codeine is more effective than dextromethorphan for severe acute cough. ... Codeine is not recommended for children less than 2 years.\n\nAmerican Conference of Governmental Industrial Hygienists. Threshold Limit Values (TLVs) for Chemical Substances and Physical Agents and Biological Exposure Indices (BEIs) for 1995-1996. Cincinnati, OH: ACGIH, 1995., p. 421\n\n\n                    Context: \n                    This excerpt provides specific information on populations at increased risk of adverse effects from codeine exposure, highlighting its efficacy for severe cough and contraindication for children under 2 years. It references a 1987 study on developmental toxicity in LVG hamsters and cites authoritative guidelines from the 1995 ACGIH TLVs, making it relevant for understanding health risks, regulatory standards, and special populations in the broader context of chemical safety and toxicology of codeine.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_214", "document_index": 23, "latency_s": 1.5859695999970427, "prompt_toks": 51640, "completion_toks": 101}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    In patients with asthma or pulmonary emphysema, the indiscriminate use of antitussives may precipitate respiratory insufficiency resulting from increased viscosity of bronchial secretions and suppression of cough reflex.\n\nAmerican Society of Health-System Pharmacists 2016; Drug Information 2016. Bethesda, MD. 2016, p. 2868\n\nCodeine should be used with caution in nursing women who are known or suspected ultrarapid metabolizers of cytochrome P-450 (CYP) 2D6 substrates.\n\nAmerican Society of Health-System Pharmacists 2016; Drug Information 2016. Bethesda, MD. 2016, p. 2205\n\nChildren with obstructive sleep apnea receiving codeine for the management of postoperative pain following tonsillectomy and/or adenoidectomy, who also have evidence of ultrarapid metabolism of CYP2D6 substrates, are at increased risk of respiratory depression.\n\nAmerican Society of Health-System Pharmacists 2016; Drug Information 2016. Bethesda, MD. 2016, p. 2205\n\n\n                    Context: \n                    This excerpt highlights key safety considerations for codeine, emphasizing risks in patients with respiratory conditions, those who are ultrarapid CYP2D6 metabolizers, and children with sleep apnea. It is relevant to the full document's sections on drug warnings, safety hazards, and special populations, providing critical information on contraindications and risk management for codeine use. The details include respiratory insufficiency risks, caution in nursing women, and increased danger for children with obstructive sleep apnea.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_215", "document_index": 23, "latency_s": 1.069145400004345, "prompt_toks": 51502, "completion_toks": 63}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    American Society of Health-System Pharmacists 2016; Drug Information 2016. Bethesda, MD. 2016, p. 2205\n\nFor more Populations at Special Risk (Complete) data for CODEINE (14 total), please visit the HSDB record page.\n\n13.1.22 Protein Binding\n\n7-25% bound to plasma proteins.\n\n13.2 Ecological Information\n\n13.2.1 Environmental Fate / Exposure Summary\n\n\n                    Context: \n                    This excerpt from section 13.1.22 provides specific data on protein binding of codeine, indicating 7-25% plasma protein binding, and begins the ecological information section starting with environmental fate and exposure summary details. It is relevant for locating pharmacokinetic and environmental impact data within the comprehensive full document.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_216", "document_index": 23, "latency_s": 1.884549700000207, "prompt_toks": 51623, "completion_toks": 94}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    Codeine's production and administration as human and veterinary analgesic and as a substance of abuse may result in its release to the environment through various waste streams. Codeine occurs naturally in poppies. If released to air, an estimated vapor pressure of 5.5X10-9 mm Hg at 25 °C indicates codeine will exist solely in the particulate phase in the atmosphere. Particulate-phase codeine will be removed from the atmosphere by wet and dry deposition. Codeine is affected by light and, therefore, may be susceptible to direct photolysis by sunlight. If released to soil, codeine is expected to have low mobility based upon an estimated Koc of 700. The pKa of codeine is 8.21, indicating that this compound will exist almost entirely in the cation form in the environment and cations generally adsorb more strongly to soils containing organic carbon and clay than their neutral counterparts. Volatilization from moist soil is not expected because the compound exists as a cation and cations do\n\n\n                    Context: \n                    This fragment discusses the environmental fate, dispersion, and physicochemical properties of codeine, highlighting its natural occurrence, volatility, persistence, and mobility in soil and water systems. It is relevant within the larger document as it details the environmental behavior and risks associated with codeine released through waste streams, supporting assessments of its environmental impact and stability. Key details include vapor pressure, photolysis susceptibility, low soil mobility due to cationic form, and adsorption characteristics.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_217", "document_index": 23, "latency_s": 0.9758395999961067, "prompt_toks": 51615, "completion_toks": 75}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    adsorb more strongly to soils containing organic carbon and clay than their neutral counterparts. Volatilization from moist soil is not expected because the compound exists as a cation and cations do not volatilize. Biodegradation data in soil or water were not available. If released into water, codeine is expected to adsorb to suspended solids and sediment based upon the estimated Koc. The pKa indicates codeine will exist almost entirely in the cation form at pH values of 5 to 9 and, therefore, volatilization from water surfaces is not expected to be an important fate process. An estimated BCF of 3 suggests the potential for bioconcentration in aquatic organisms is low. Hydrolysis is not expected to be an important environmental fate process since this compound lacks functional groups that hydrolyze under environmental conditions (pH 5 to 9). Occupational exposure to codeine may occur through inhalation and dermal contact with this compound at workplaces where codeine is produced or\n\n\n                    Context: \n                    This excerpt details the environmental fate and mobility of codeine, including adsorption to soils and sediments, volatilization potential based on pKa, bioconcentration risk indicated by BCF, and lack of hydrolysis. It is relevant for environmental risk assessment and contextualizes codeine's environmental behavior within the comprehensive toxicity and safety information provided in the full document.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_218", "document_index": 23, "latency_s": 1.2722551000042586, "prompt_toks": 51506, "completion_toks": 75}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    hydrolyze under environmental conditions (pH 5 to 9). Occupational exposure to codeine may occur through inhalation and dermal contact with this compound at workplaces where codeine is produced or used. Monitoring data indicate that the general population may be exposed to codeine via ingestion of contaminated drinking water and poppy seeds. The general public is also likely to be exposed to codeine via ingestion and dermal contact with medications containing codeine during direct medical treatment. (SRC)\n\n\n                    Context: \n                    This excerpt summarizes environmental fate and human exposure routes for codeine, highlighting its hydrolysis under environmental pH conditions and potential occupational and general population exposure through inhalation, dermal contact, contaminated water, poppy seeds, and medical use. It contextualizes the chemical's environmental behavior and exposure risks discussed throughout the comprehensive toxicity, environmental, and safety data in the full document.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_219", "document_index": 23, "latency_s": 1.2568297999969218, "prompt_toks": 51655, "completion_toks": 86}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    13.2.2 Natural Pollution Sources\n\nCodeine occurs naturally in poppies, specifically in latex from the opium poppy (Papaver somniferum)(1).\n\n(1) USDA; Dr. Duke's Phytochemical and Ethnobotanical Databases. Codeine. Washington, DC: US Dept Agric, Agric Res Service. Available from, as of Mar 3, 2016: https://phytochem.nal.usda.gov/phytochem/search\n\nMorphine is obtained from opium, which itself is obtained from the milky exudate of incised unripe seed capsules of the poppy plant, Papaver somniferum, indigenous to Asia Minor. The alkaloids of opium include phenanthrenes (morphine, codeine, thebaine) and benzyl isoquinolines (papaverine, noscapine).\n\nEllenhorn, M.J. and D.G. Barceloux. Medical Toxicology - Diagnosis and Treatment of Human Poisoning. New York, NY: Elsevier Science Publishing Co., Inc. 1988., p. 710\n\n13.2.3 Artificial Pollution Sources\n\n\n                    Context: \n                    This section details the natural and anthropogenic sources of codeine in the environment. It explains that codeine is naturally found in poppies, specifically in latex from Papaver somniferum, and notes that morphine is also derived from opium obtained from the same plant. The segment highlights the distinction between natural pollutions from poppies and artificial pollution sources related to human activity, offering critical environmental context for chemical source identification.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_220", "document_index": 23, "latency_s": 1.534358600009, "prompt_toks": 51502, "completion_toks": 73}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    13.2.3 Artificial Pollution Sources\n\nCodeine's production and administration as a human and veterinary analgesic and as a substance of abuse(1) may result in its release to the environment through various waste streams(SRC).\n\n(1) O'Neil MJ, ed; The Merck Index. 15th eds., Cambridge, UK: Royal Society of Chemistry, p. 439 (2013)\n\n13.2.4 Environmental Fate\n\n\n                    Context: \n                    This excerpt details the environmental impact of codeine, specifically its sources of environmental pollution and its environmental fate. It highlights how codeine's use in medicine and abuse can lead to release into the environment and discusses its behavior and degradation pathways in soil, water, and the atmosphere. This information is essential for environmental risk assessment and related safety evaluations within the comprehensive chemical profile.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_221", "document_index": 23, "latency_s": 1.7282527999923332, "prompt_toks": 51652, "completion_toks": 105}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    (1) O'Neil MJ, ed; The Merck Index. 15th eds., Cambridge, UK: Royal Society of Chemistry, p. 439 (2013)\n\n13.2.4 Environmental Fate\n\nTERRESTRIAL FATE: Based on a classification scheme(1), an estimated Koc value of 700(SRC), determined from a structure estimation method(2), indicates that codeine is expected to have low mobility in soil(SRC). The pKa of codeine is 8.21(3), indicating that this compound will exist almost entirely in the cation form in the environment and cations generally adsorb more strongly to soils containing organic carbon and clay than their neutral counterparts(4). Volatilization from moist soil is not expected because the compound exists as a cation and cations do not volatilize. Codeine is not expected to volatilize from dry soil surfaces(SRC) based upon an estimated vapor pressure of 5.5X10-9 mm Hg at 25 °C(SRC), determined from a fragment constant method(2). Biodegradation data in soil were not available(SRC, 2016).\n\n\n                    Context: \n                    This excerpt provides detailed information on the environmental fate of codeine, including its terrestrial mobility, soil adsorption, and volatilization potential, referencing scientific classification schemes and estimations. It is relevant for environmental risk assessment, highlighting that codeine has low soil mobility and is unlikely to volatilize, with specific parameters such as Koc value of 700 and pKa of 8.21. The references and technical details support comprehensive ecological hazard evaluation within the broader drug safety and environmental impact analyses in the document.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_222", "document_index": 23, "latency_s": 1.6650528000027407, "prompt_toks": 51580, "completion_toks": 83}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    (1) Swann RL et al; Res Rev 85: 17-28 (1983)\n\n(2) US EPA; Estimation Program Interface (EPI) Suite. Ver. 4.1. Nov, 2012. Available from, as of Mar 3, 2016: https://www2.epa.gov/tsca-screening-tools\n\n(3) Haynes WM, ed; CRC Handbook of Chemistry and Physics. 95th ed,. Boca Raton, FL: CRC Press LLC, p 5-103, 2014-2015\n\n(4) Doucette WJ; pp. 141-188 in Handbook of Property Estimation Methods for Chemicals. Boethling RS, Mackay D, eds. Boca Raton, FL: Lewis Publ (2000)\n\n\n                    Context: \n                    This excerpt lists key references related to chemical property estimation and environmental data sources for codeine, including studies on property estimation methods, EPA tools, and chemical physics handbooks. It provides essential source citations that support the detailed chemical, physical, and environmental information included throughout the full webpage, aiding researchers in data validation and cross-referencing. The references are directly relevant for understanding codeine's environmental fate and property calculations.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_223", "document_index": 23, "latency_s": 1.6002242999966256, "prompt_toks": 51657, "completion_toks": 86}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    (4) Doucette WJ; pp. 141-188 in Handbook of Property Estimation Methods for Chemicals. Boethling RS, Mackay D, eds. Boca Raton, FL: Lewis Publ (2000)\n\nAQUATIC FATE: Based on a classification scheme(1), an estimated Koc value of 700(SRC), determined from a structure estimation method(2), indicates that codeine is expected to adsorb to suspended solids and sediment(SRC). A pKa of 8.21(3) indicates codeine will exist almost entirely in the cation form at pH values of 5 to 9 and, therefore, volatilization from water surfaces is not expected to be an important fate process(SRC). According to a classification scheme(4), an estimated BCF of 3(SRC), from its log Kow of 1.19(5) and a regression-derived equation(2), suggests the potential for bioconcentration in aquatic organisms is low(SRC). Biodegradation data in water were not available(SRC, 2016).\n\n(1) Swann RL et al; Res Rev 85: 17-28 (1983)\n\n\n                    Context: \n                    This excerpt provides detailed environmental fate data for codeine, including estimates of its adsorption, volatilization, bioconcentration potential, and biodegradation in aquatic systems. It references various classification schemes and scientific studies, situating this information within the comprehensive analysis of chemical behavior, environmental impact, and property estimation methodologies presented in the full document. This information is critical for environmental risk assessment and regulatory considerations related to codeine.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_224", "document_index": 23, "latency_s": 1.5642875999910757, "prompt_toks": 51708, "completion_toks": 69}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    (1) Swann RL et al; Res Rev 85: 17-28 (1983)\n\n(2) US EPA; Estimation Program Interface (EPI) Suite. Ver. 4.1. Nov, 2012. Available from, as of Mar 3, 2016: https://www2.epa.gov/tsca-screening-tools\n\n(3) Haynes WM, ed; CRC Handbook of Chemistry and Physics. 95th ed,. Boca Raton, FL: CRC Press LLC, p 5-103, 2014-2015\n\n(4) Franke C et al; Chemosphere 29: 1501-14 (1994)\n\n(5) Avdeef A et al; J Med Chem 39: 4377-81 (1996)\n\nATMOSPHERIC FATE: According to a model of gas/particle partitioning of semivolatile organic compounds in the atmosphere(1), codeine, which has an estimated vapor pressure of 5.5X10-9 mm Hg at 25 °C(SRC), determined from a fragment constant method(2), is expected to exist solely in the particulate phase in the ambient atmosphere. Particulate-phase codeine may be removed from the air by wet and dry deposition(SRC). Codeine is affected by light(4) and, therefore, may be susceptible to direct photolysis by sunlight(SRC).\n\n\n                    Context: \n                    This excerpt summarizes the atmospheric fate of codeine, detailing its predicted phase in the environment, removal mechanisms, and photolysis susceptibility based on vapor pressure and modeling data. It references key sources on environmental modeling and chemical properties, relevant for environmental risk assessment within the comprehensive chemical profile. The information enhances understanding of codeine's environmental behavior and persistence.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_225", "document_index": 23, "latency_s": 1.1249755000026198, "prompt_toks": 51711, "completion_toks": 78}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    (1) Bidleman TF; Environ Sci Technol 22: 361-367 (1988)\n\n(2) US EPA; Estimation Program Interface (EPI) Suite. Ver. 4.1. Nov, 2012. Available from, as of Mar 3, 2016: https://www2.epa.gov/tsca-screening-tools\n\n(3) Meylan WM, Howard PH; Chemosphere 26: 2293-99 (1993)\n\n(4) Lewis RJ Sr; Hawley's Condensed Chemical Dictionary. 15th ed., New York, NY: John Wiley & Sons, Inc. p. 318 (2007)\n\n13.2.5 Environmental Abiotic Degradation\n\nCodeine is not expected to undergo hydrolysis in the environment due to the lack of functional groups that hydrolyze under environmental conditions(1). Codeine is affected by light(2) and, therefore, may be susceptible to direct photolysis by sunlight(SRC).\n\n(1) Lyman WJ et al; Handbook of Chemical Property Estimation Methods. Washington, DC: Amer Chem Soc pp. 7-4, 7-5 (1990)\n\n(2) Lewis RJ Sr; Hawley's Condensed Chemical Dictionary. 15th ed., New York, NY: John Wiley & Sons, Inc. p. 318 (2007)\n\n13.2.6 Environmental Bioconcentration\n\n\n                    Context: \n                    This excerpt discusses the environmental fate of codeine, covering its abiotic degradation and bioconcentration potential. It includes references to key studies and emphasizes that codeine does not hydrolyze in the environment but is affected by light, making it susceptible to photolysis, and has a low bioconcentration factor. These details are relevant for environmental risk assessments within the comprehensive chemical data overview.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_226", "document_index": 23, "latency_s": 1.0848810000024969, "prompt_toks": 51638, "completion_toks": 71}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    (2) Lewis RJ Sr; Hawley's Condensed Chemical Dictionary. 15th ed., New York, NY: John Wiley & Sons, Inc. p. 318 (2007)\n\n13.2.6 Environmental Bioconcentration\n\nAn estimated BCF of 3 was calculated in fish for codeine(SRC), using a log Kow of 1.19(1) and a regression-derived equation(1). According to a classification scheme(2), this BCF suggests the potential for bioconcentration in aquatic organisms is low(SRC).\n\n(1) Avdeef A et al; J Med Chem 39: 4377-81 (1996)\n\n(2) US EPA; Estimation Program Interface (EPI) Suite. Ver. 4.1. Nov, 2012. Available from, as of Mar 3, 2016: https://www2.epa.gov/tsca-screening-tools\n\n(3) Franke C et al; Chemosphere 29: 1501-14 (1994)\n\n13.2.7 Soil Adsorption / Mobility\n\n\n                    Context: \n                    This section summarizes environmental fate data for codeine, focusing on bioconcentration and soil mobility. It provides calculated bioconcentration factors indicating low potential for bioaccumulation in aquatic organisms and details on soil adsorption and mobility, highlighting low soil mobility based on estimated Koc values. These details are vital for understanding codeine's environmental persistence and contamination risks.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_227", "document_index": 23, "latency_s": 1.842355699991458, "prompt_toks": 51639, "completion_toks": 96}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    (3) Franke C et al; Chemosphere 29: 1501-14 (1994)\n\n13.2.7 Soil Adsorption / Mobility\n\nUsing a structure estimation method based on molecular connectivity indices(1), the Koc of codeine can be estimated to be 700(SRC). According to a classification scheme(2), this estimated Koc value suggests that codeine is expected to have low mobility in soil. The pKa of codeine is 8.21(3), indicating that this compound will exist almost entirely in the cation form in the environment and cations generally adsorb more strongly to soils containing organic carbon and clay than their neutral counterparts(4). Sorption isotherms of 2.1 and 14.1 for codeine, present at 50 ng/mL, were measured using river sediments at pH 6.5-6.6 from the Burgen and Dausenau rivers, respectively, Switzerland. The log Koc values of 2.4 and 2.5 correspond to Koc values of 251 and 315, respectively(5).\n\n\n                    Context: \n                    This section provides detailed environmental fate information for codeine, focusing on its soil adsorption and mobility characteristics. It discusses estimation methods for soil affinity (Koc estimated at 700), the compound's behavior in soil based on pKa (8.21), and measured sorption isotherms with log Koc values around 2.4–2.5. This data is relevant for understanding codeine's environmental persistence and transport in soil environments within the comprehensive chemical safety profile.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_228", "document_index": 23, "latency_s": 2.467105100004119, "prompt_toks": 51715, "completion_toks": 91}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    (1) US EPA; Estimation Program Interface (EPI) Suite. Ver. 4.1. Nov, 2012. Available from, as of Mar 3, 2016: https://www2.epa.gov/tsca-screening-tools\n\n(2) Swann RL et al; Res Rev 85: 17-28 (1983)\n\n(3) Haynes WM, ed; CRC Handbook of Chemistry and Physics. 95th ed,. Boca Raton, FL: CRC Press LLC, p 5-103, 2014-2015(4) Doucette WJ; pp. 141-188 in Handbook of Property Estimation Methods for Chemicals. Boethling RS, Mackay D, eds. Boca Raton, FL: Lewis Publ (2000)\n\n(4) Stein K et al; Environ Sci Technol 42: 6415-23 (2008)\n\n13.2.8 Volatilization from Water / Soil\n\nA pKa of 8.21 indicates codeine will exist almost entirely in the cation form at pH values of 5 to 9 and, therefore, volatilization from water surfaces is not expected to be an important fate process. Codeine is not expected to volatilize from dry soil surfaces(SRC) based upon an estimated vapor pressure of 5.5X10-9 mm Hg(SRC), determined from a fragment constant method(2).\n\n\n                    Context: \n                    This excerpt summarizes research on codeine's environmental fate, specifically its volatility and behavior in water and soil systems, supported by key literature references and EPA estimation methods. It highlights that due to its chemical properties, codeine is unlikely to volatilize from water surfaces or dry soil, with specific parameters like pKa and vapor pressure influencing its environmental mobility. This information is critical for understanding codeine's environmental persistence and pollution potential within comprehensive chemical hazard assessments.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_229", "document_index": 23, "latency_s": 1.5211043000017526, "prompt_toks": 51604, "completion_toks": 57}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    (1) Haynes WM, ed; CRC Handbook of Chemistry and Physics. 95th ed,. Boca Raton, FL: CRC Press LLC, p 5-103, 2014-2015\n\n(2) US EPA; Estimation Program Interface (EPI) Suite. Ver. 4.1. Nov, 2012. Available from, as of Mar 3, 2016: https://www2.epa.gov/tsca-screening-tools\n\n13.2.9 Environmental Water Concentrations\n\nGROUNDWATER: Codeine was below the method detection limit = 1.0 ng/L in 30 of 31 freshwater samples, which included alluvial groundwater and wells, from Missouri and Mississippi collected during the winter. It was below the detection limit in samples collected during the summer(1).\n\n(1) Wang C et al; Water Res 45(4): 1818-28 (2011)\n\n\n                    Context: \n                    This paragraph summarizes environmental water concentration data for codeine, highlighting its detection limits in groundwater samples from Missouri and Mississippi. It references EPA water quality estimation tools and specifies that codeine was generally below detectable levels in freshwater samples, emphasizing environmental presence and monitoring relevance within the overall chemical profile.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_230", "document_index": 23, "latency_s": 1.4702140000008512, "prompt_toks": 51630, "completion_toks": 82}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    DRINKING WATER: Codeine was present in 0.16% of 1231 samples of groundwater used for public drinking-water supply in California, surveyed as part of the California Groundwater Ambient Monitoring and Assessment Program Priority Basin Project, 2004-2010. The maximum concentration reported was 0.214 ug/L(1). Codeine was not detected in seventy samples of drinking water from Spanish cities, 15 from 7 other European countries, three from Japan and nine from seven different Latin American countries, surveyed between fall 2008 and summer 2009(2). Codeine was not detected in grab tap water samples from five main drinking water supply areas in the Madrid region of Spain, sampled from October 25 to 30, 2007(3). Codeine was below the method detection limit = 1.0 ng/L in 30 of 31 freshwater samples from Missouri and Mississippi collected during the winter. The concentration ranged from 3.0-3.7 ng/L positive unspecified river site. It was below the detection limit in samples collected during the\n\n\n                    Context: \n                    This section provides data on environmental and public water exposure to codeine, highlighting its detection in groundwater and surface water samples across different regions. It details maximum concentration levels found in California, Spain, and the US, emphasizing the typically low and infrequent presence of codeine in drinking water supplies. This information is relevant for understanding environmental exposure risks in the context of the broader chemical safety and toxicity profile of codeine.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_231", "document_index": 23, "latency_s": 1.0491949999995995, "prompt_toks": 51452, "completion_toks": 77}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    from Missouri and Mississippi collected during the winter. The concentration ranged from 3.0-3.7 ng/L positive unspecified river site. It was below the detection limit in samples collected during the summer(4).\n\n\n                    Context: \n                    This segment reports environmental monitoring data on trace levels of codeine in water samples from Missouri and Mississippi during winter, with concentrations between 3.0-3.7 ng/L at an unspecified river site. It highlights seasonal variations, noting that such low-level detections were below the detection limit in summer samples, illustrating the fluctuating presence and environmental persistence of codeine addressed throughout the document.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_232", "document_index": 23, "latency_s": 1.720215699999244, "prompt_toks": 51516, "completion_toks": 78}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    (1) Fram MS, Belitz K; Sci Total Environ 409(18): 3409-17 (2011)\n\n(2) Rosa Boleda M et al; Chemosphere 84(11): 1601-7 (2011)\n\n(3) Valcarcel Y et al; Chemosphere 82(7): 1062-71 (2011)\n\n(4) Wang C et al; Water Res 45(4): 1818-28 (2011)\n\n\n                    Context: \n                    This section lists academic references from 2011 related to environmental and water research studies on substances such as codeine and pharmaceuticals, providing sources for data on environmental fate, contamination, and water quality assessments found within the broader context of chemical environmental behavior and toxicity information detailed in the full document. These references support the environmental fate and ecological impact data of codeine included in the comprehensive chemical profile.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_233", "document_index": 23, "latency_s": 1.1639696000056574, "prompt_toks": 51659, "completion_toks": 78}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    SURFACE WATER: Codeine is one of the top 61 most frequently studied pharmaceuticals in freshwater ecosystems. Worldwide, codeine has a mean detection frequency of 64.4% with a median concentration of 49.6 ng/L (max 1000.0 ng/L)(1). Maximum codeine concentrations ranged from 5.4 to 15 ng/L in 7 water samples collected offshore from 2 wastewater treatment plants in Milwaukee, WI on Lake Michigan(2). Codeine was detected at concentrations of 53.6, 39.6, 26.5 ng/L and below the quantitation limit in water samples from the Somes River, Transylvania, Romania; samples were collected 3km downstream from wastewater treatment plants. The corresponding loads were 93, 77 and 56 g/day, respectively(3). Codeine is one of the most frequently detected pain killers in surface water in South Wales, UK(4). Codeine was present in 5 of 11 samples at an average concentration of 40.4 ng/L (96.9 ng/L max) in samples from the Guadalquivir River in the province of Jaen, South East Spain. It was not detected in\n\n\n                    Context: \n                    This excerpt provides detailed information on the environmental occurrence and concentrations of codeine in surface water samples worldwide, including specific detection frequencies, median and maximum concentrations, and geographic locations such as Lake Michigan, Romania, and Spain. It highlights codeine’s prevalence in freshwater ecosystems and its potential environmental impact, making it a critical data point within the comprehensive chemical safety and environmental profile included in the full document.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_234", "document_index": 23, "latency_s": 1.9718453999958, "prompt_toks": 51676, "completion_toks": 71}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    was present in 5 of 11 samples at an average concentration of 40.4 ng/L (96.9 ng/L max) in samples from the Guadalquivir River in the province of Jaen, South East Spain. It was not detected in associated wetland samples(5). The compound was detected at 194-693, 470-501, 377-501 and 35-50 ng/L in the Jarama, Manzanares, Guadarrama, Henares and Tagus rivers, respectively, located in the Madrid region of Spain. The median concentration was 424 ng/L; sampling was conducted in October 2007(6). Codeine was below the method detection limit = 1.0 ng/L in 30 of 31 freshwater samples from Missouri and Mississippi collected during the winter. The concentration ranged from 3.0-3.7 ng/L positive unspecified river site. It was below the detection limit in samples collected during the summer(7). Codeine concentrations were reported as 0.16, 0.010 and 0.08 ug/L in sewage outfall 0.493, 59.8 and 1054.8 km, respectively, downstream from sewage outfall on Wascana Creek, Regina, Saskatchewan, Canada.\n\n\n                    Context: \n                    This section summarizes environmental data on codeine concentrations in various water bodies, including river and sewage samples in Spain, Missouri, Mississippi, and Canada, highlighting detection frequencies, concentration ranges, and sampling locations. It underscores codeine's presence in environmental water sources relevant for pollutant monitoring and water quality assessment within the broader context of chemical environmental fate and exposure data.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_235", "document_index": 23, "latency_s": 1.6789138000021921, "prompt_toks": 51496, "completion_toks": 90}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    concentrations were reported as 0.16, 0.010 and 0.08 ug/L in sewage outfall 0.493, 59.8 and 1054.8 km, respectively, downstream from sewage outfall on Wascana Creek, Regina, Saskatchewan, Canada. Sampling was conducted during winter 2005 through spring 2007; method detection limit = 0.05 ug/L(8).\n\n\n                    Context: \n                    This excerpt provides environmental concentration data for codeine detected in water samples downstream from a sewage outfall on Wascana Creek, Regina, Saskatchewan, Canada, between 2005 and 2007. The reported levels ranged from 0.16 to 1054.8 μg/L at various distances, with a method detection limit of 0.05 μg/L, highlighting potential environmental exposure and water contamination concerns discussed in the broader document.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_236", "document_index": 23, "latency_s": 1.1071040999959223, "prompt_toks": 51616, "completion_toks": 91}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    (1) Hughes SR et al; Environ Sci Technol 47: 661-77 (2013)\n\n(2) Blair BD et al; Chemosphere 93(9): 2116-23 (2013)\n\n(3) Moldovan Z; Chemosphere 64: 1808-17 (2006)\n\n(4) Kasprzyk-Hordern B et al; Water Res 42(13): 3498-518 (2008)\n\n(5) Robles-Molina J et al; Sci Total Environ 479-480: 247-57 (2014)\n\n(6) Valcarcel Y et al; Chemosphere 82(7): 1062-71 (2011)\n\n(7) Wang C et al; Water Res 45(4): 1818-28 (2011)\n\n(8) Waiser MJ et al; Environ Toxicol Chem 30(2): 508-19 (2011)\n\n\n                    Context: \n                    This section lists key references from scientific studies (2011-2014) that investigate the environmental presence, occurrence, and analysis of pharmaceuticals like codeine in water systems, including detection in wastewater, surface water, and sediments. It provides essential citations for research on drug environmental fate and pollution levels, complementing the document's coverage of chemical environmental behavior and analytical methods. These references are relevant for understanding environmental monitoring and contaminant distribution of codeine.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_237", "document_index": 23, "latency_s": 0.9619961999997031, "prompt_toks": 51578, "completion_toks": 59}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    SURFACE WATER: The U.S. Geological Survey and the National Park Service conducted a reconnaissance study to investigate the occurrence of selected human-health pharmaceutical compounds in water samples collected from Lake Mead on the Colorado River and Las Vegas Wash, a waterway used to transport treated wastewater from the Las Vegas metropolitan area to Lake Mead. Current research indicates many of these compounds can bioaccumulate and may adversely affect aquatic organisms by disrupting physiological processes, impairing reproductive functions, increasing cancer rates, contributing to the development of antibiotic-resistant strains of bacteria, and acting in undesirable ways when mixed with other substances. These compounds may be present in effluent because a high percentage of prescription and non-prescription drugs used for human-health purposes are excreted from the body as a mixture of parent compounds and degraded metabolite compounds; also, they can be released to the\n\n\n                    Context: \n                    This excerpt discusses the presence and environmental impact of pharmaceuticals like codeine in surface water sources, highlighting studies by the U.S. Geological Survey and the National Park Service on lake water contamination and bioaccumulation risks, relevant to the document's focus on chemical safety, environmental fate, and toxicity.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_238", "document_index": 23, "latency_s": 1.992814700002782, "prompt_toks": 51633, "completion_toks": 104}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    prescription and non-prescription drugs used for human-health purposes are excreted from the body as a mixture of parent compounds and degraded metabolite compounds; also, they can be released to the environment when unused products are discarded by way of toilets, sinks, and trash in landfills. Thirteen of 33 targeted compounds were detected in at least one water sample collected between October 2000 and August 2001. All concentrations were less than or equal to 0.20 micrograms per liter. The most frequently detected compounds in samples from Las Vegas Wash were caffeine, carbamazepine (used to treat epilepsy), cotinine (a metabolite of nicotine), and dehydronifedipine (a metabolite of the antianginal Procardia). Less frequently detected compounds in samples collected from Las Vegas Wash were antibiotics (clarithromycin, erythromycin, sulfamethoxazole, and trimethoprim), acetaminophen (an analgesic and anti-inflammatory), cimetidine (used to treat ulcers), codeine (a narcotic and\n\n\n                    Context: \n                    This excerpt highlights the environmental occurrence and detection levels of pharmaceuticals, including codeine, in water samples collected between 2000 and 2001, emphasizing how human-use drugs are excreted and discarded into waterways. It provides specific data on detected concentrations, common compounds such as caffeine and carbamazepine, and the prevalence of antibiotics and analgesics like acetaminophen. This information relates to the document's focus on the environmental fate, detection, and analytical methods for compounds like codeine.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_239", "document_index": 23, "latency_s": 1.2011191000055987, "prompt_toks": 51575, "completion_toks": 90}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    were antibiotics (clarithromycin, erythromycin, sulfamethoxazole, and trimethoprim), acetaminophen (an analgesic and anti-inflammatory), cimetidine (used to treat ulcers), codeine (a narcotic and analgesic), diltiazem (an antihypertensive), and 1,7-dimethylxanthine (a metabolite of caffeine). Fewer compounds were detected in samples collected from Lake Mead than from Las Vegas Wash. Caffeine was detected in all samples collected from Lake Mead. Other compounds detected in samples collected from Lake Mead were acetaminophen, carbamazepine, cotinine, 1,7-dimethylxanthine, and sulfamethoxazole(1).\n\n\n                    Context: \n                    This excerpt details environmental monitoring data on pharmaceutical contamination in water samples, highlighting the detection of compounds like codeine, acetaminophen, and other drugs in Lake Mead and Las Vegas Wash. It emphasizes frequently found substances such as caffeine and sulfamethoxazole, providing context for the broader discussion of water quality, drug persistence, and environmental exposure in the full document. These findings are relevant for understanding environmental occurrence and risks associated with pharmaceutical residues.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_240", "document_index": 23, "latency_s": 1.6500562000001082, "prompt_toks": 51673, "completion_toks": 68}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    (1) Boyd RA; Furlong T; Human-Health Pharmaceutical Compounds in Lake Mead, Nevada and Arizona and Las Vegas Wash, Nevada, October 200 - August 2001. Washington, DC: US Dept Int, US Geol Surv. USGS Open-File Report 02-385. Available from, as of Jun 13, 2106: https://pubs.usgs.gov/of/2002/ofr02385/abstract.html\n\n13.2.10 Effluent Concentrations\n\nA maximum codeine concentration of 11 ng/L was reported in effluent samples collected from 2 wastewater treatment plants in Milwaukee, WI on Lake Michigan(1).\n\n(1) Blair BD et al; Chemosphere 93(9): 2116-23 (2013)\n\n13.2.11 Sediment / Soil Concentrations\n\nSEDIMENT: Codeine was present at below the detection limit of 3.6 ng/g in sediments collected offshore from a wastewater treatment plant in Milwaukee, WI on Lake Michigan. A sediment sample in the immediate vicinity of another plant outflow contained codeine at 4 ng/g(1).\n\n(1) Blair BD et al; Chemosphere 93(9): 2116-23 (2013)\n\n\n                    Context: \n                    This excerpt summarizes environmental concentrations of codeine in water and sediment samples from Lake Michigan, highlighting maximum effluent levels (11 ng/L) and sediment detection limits (below 3.6 ng/g). It references study data relevant for environmental risk assessment, situating chemical occurrence data within the broader scientific and toxicological information provided in the document.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_241", "document_index": 23, "latency_s": 1.7412051999999676, "prompt_toks": 51715, "completion_toks": 94}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    (1) Blair BD et al; Chemosphere 93(9): 2116-23 (2013)\n\nSOIL: Codeine was not detected in soil samples from 3 sites (city hall, golf course, reclaimed water facility) in a medium-sized city in the Front Range of Colorado following irrigation with reclaimed water from May through September 2003. Codeine concentrations in the irrigation effluent were 58.7, not detected and 27.9 ng/L on May 14, July 16 and September 16, 2003(1).\n\n(1) Kinney CA et al; Environ Toxicol Chem 25(2): 317-26 (2006)\n\n13.2.12 Food Survey Values\n\nThe codeine concentration in poppy seeds (Papaver somniferum L.) ranges from 0.8 to 57.1 mg/kg(1).\n\nPMID:16848508\n\n(1) Sproll C et al; J Agric Food Chem 54: 5292-98 (2006)\n\n13.2.13 Plant Concentrations\n\nCodeine concentrations in plants(1).\n\nGenus species\n\nFamily\n\nCommon name\n\nPart\n\nLow/High concn (ppm)\n\nGenus species\n\nArgemone mexicana\n\nFamily\n\nPapaveraceae\n\nCommon name\n\nPrickly Poppy\n\nPart\n\nPlant\n\nLow/High concn (ppm)\n\nnot reported\n\nGenus species\n\n\n                    Context: \n                    This excerpt provides environmental and botanical data on codeine, detailing its absence in Colorado soil samples following irrigation with reclaimed water and its concentration range in poppy seeds (0.8-57.1 mg/kg). It also lists plant species, such as Argemone mexicana and Papaver somniferum, that naturally contain codeine in varying concentrations. This information is relevant for understanding environmental presence, source plants, and potential exposure pathways covered throughout the full document.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_242", "document_index": 23, "latency_s": 1.2483643000014126, "prompt_toks": 51745, "completion_toks": 108}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    Family\n\nCommon name\n\nPart\n\nLow/High concn (ppm)\n\nGenus species\n\nArgemone mexicana\n\nFamily\n\nPapaveraceae\n\nCommon name\n\nPrickly Poppy\n\nPart\n\nPlant\n\nLow/High concn (ppm)\n\nnot reported\n\nGenus species\n\nEschscholzia californica\n\nFamily\n\nPapaveraceae\n\nCommon name\n\nCalifornia Poppy\n\nPart\n\nPlant\n\nLow/High concn (ppm)\n\nnot reported\n\nGenus species\n\nPapaver somniferum\n\nFamily\n\nPapaveraceae\n\nCommon name\n\nOpium Poppy, Poppyseed Poppy\n\nPart\n\nPlant\n\nLow/High concn (ppm)\n\nnot reported\n\nGenus species\n\nPapver somniferum\n\nFamily\n\nPapaveraceae\n\nCommon name\n\nOpium Poppy, Poppyseed Poppy\n\nPart\n\nRoot\n\nLow/High concn (ppm)\n\n100.0/200.0\n\nGenus species\n\nPapaver somniferum\n\nFamily\n\nPapaveraceae\n\nCommon name\n\nOpium Poppy, Poppyseed Poppy\n\nPart\n\nInflorescence\n\nLow/High concn (ppm)\n\nnot reported\n\nGenus species\n\nPapaver somniferum\n\nFamily\n\nPapaveraceae\n\nCommon name\n\nOpium Poppy, Poppyseed Poppy\n\nPart\n\nShoot\n\nLow/High concn (ppm)\n\n/14.0\n\nGenus species\n\nPapaver somniferum\n\nFamily\n\nPapaveraceae\n\nCommon name\n\n\n                    Context: \n                    This section details the occurrence and concentration range of various Papaveraceae family plants, including Opium Poppy (Papaver somniferum), California Poppy (Eschscholzia californica), and Prickly Poppy (Argemone mexicana), highlighting their parts such as root, inflorescence, and shoot, with reported low/high concentrations in ppm. It provides key botanical and chemical source information relevant to understanding the plant origins of the compound, situating it within chemical and pharmacological context.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_243", "document_index": 23, "latency_s": 1.506951499992283, "prompt_toks": 51781, "completion_toks": 87}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    Papaver somniferum\n\nFamily\n\nPapaveraceae\n\nCommon name\n\nOpium Poppy, Poppyseed Poppy\n\nPart\n\nShoot\n\nLow/High concn (ppm)\n\n/14.0\n\nGenus species\n\nPapaver somniferum\n\nFamily\n\nPapaveraceae\n\nCommon name\n\nOpium Poppy, Poppyseed Poppy\n\nPart\n\nStem\n\nLow/High concn (ppm)\n\n10.0/300.0\n\nGenus species\n\nPapver somniferum\n\nFamily\n\nPapaveraceae\n\nCommon name\n\nOpium Poppy, Poppyseed Poppy\n\nPart\n\nResin, Exudate, Sap\n\nLow/High concn (ppm)\n\n/34700.0\n\nGenus species\n\nPapaver somniferum\n\nFamily\n\nPapaveraceae\n\nCommon name\n\nOpium Poppy, Poppyseed Poppy\n\nPart\n\nLatex Exudate\n\nLow/High concn (ppm)\n\n5000.0/40000.0\n\nGenus species\n\nPapaver somniferum\n\nFamily\n\nPapaveraceae\n\nCommon name\n\nOpium Poppy, Poppyseed Poppy\n\nPart\n\nStem\n\nLow/High concn (ppm)\n\n/100.0\n\nGenus species\n\nPapaver somniferum\n\nFamily\n\nPapaveraceae\n\nCommon name\n\nOpium Poppy, Poppyseed Poppy\n\nPart\n\nTissue Culture\n\nLow/High concn (ppm)\n\n34.0/200.0\n\nGenus species\n\nPapaver somniferum\n\nFamily\n\nPapaveraceae\n\nCommon name\n\nOpium Poppy, Poppyseed Poppy\n\nPart\n\nSeed\n\n\n                    Context: \n                    This excerpt details the concentration ranges of various parts of Papaver somniferum (opium poppy), including shoot, stem, resin, latex, tissue culture, and seed, in parts per million (ppm). It is relevant to the overall document as it provides specific botanical and chemical source data crucial for understanding the natural occurrence and extraction of codeine and related alkaloids from this plant species, supported by detailed quantitative values.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_244", "document_index": 23, "latency_s": 1.1674670000065817, "prompt_toks": 51763, "completion_toks": 102}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    Opium Poppy, Poppyseed Poppy\n\nPart\n\nTissue Culture\n\nLow/High concn (ppm)\n\n34.0/200.0\n\nGenus species\n\nPapaver somniferum\n\nFamily\n\nPapaveraceae\n\nCommon name\n\nOpium Poppy, Poppyseed Poppy\n\nPart\n\nSeed\n\nLow/High concn (ppm)\n\n0.1/440.0\n\nGenus species\n\nPapaver somniferum\n\nFamily\n\nPapaveraceae\n\nCommon name\n\nOpium Poppy, Poppyseed Poppy\n\nPart\n\nFruit\n\nLow/High concn (ppm)\n\n400.0/1320.0\n\nGenus species\n\nPapver bracteatum\n\nFamily\n\nPapaveraceae\n\nCommon name\n\nGiant Scarlet Poppy\n\nPart\n\nPlant\n\nLow/High concn (ppm)\n\nnot reported\n\nGenus species\n\nPapaver somniferum\n\nFamily\n\nPapaveraceae\n\nCommon name\n\nOpium Poppy, Poppyseed Poppy\n\nPart\n\nLeaf\n\nLow/High concn (ppm)\n\n60.0/430.0\n\nGenus species\n\nPapaver somniferum\n\nFamily\n\nPapaveraceae\n\nCommon name\n\nOpium Poppy, Poppyseed Poppy\n\nPart\n\nHypocotyl\n\nLow/High concn (ppm)\n\nnot reported\n\nGenus species\n\nPapaver somniferum\n\nFamily\n\nPapaveraceae\n\nCommon name\n\nOpium Poppy, Poppyseed Poppy\n\nPart\n\nGum\n\nLow/High concn (ppm)\n\n/35000.0\n\n\n                    Context: \n                    This section details the concentration ranges of opioids, specifically morphine, in various parts of the opium poppy (Papaver somniferum) and related species, including tissue culture, seed, fruit, leaf, hypocotyl, and gum. The reported low and high ppm values highlight the variability in alkaloid content across plant parts and cultivation conditions, providing essential data for understanding the natural occurrence and extraction relevance of opiates within the overall chemical profile of papaver species documented in this comprehensive resource.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_245", "document_index": 23, "latency_s": 1.800006100005703, "prompt_toks": 51627, "completion_toks": 93}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    Part\n\nHypocotyl\n\nLow/High concn (ppm)\n\nnot reported\n\nGenus species\n\nPapaver somniferum\n\nFamily\n\nPapaveraceae\n\nCommon name\n\nOpium Poppy, Poppyseed Poppy\n\nPart\n\nGum\n\nLow/High concn (ppm)\n\n/35000.0\n\n(1) USDA; Dr. Duke's Phytochemical and Ethnobotanical Databases. Codeine. Washington, DC: US Dept Agric, Agric Res Service. Available from, as of Mar 3, 2016: https://phytochem.nal.usda.gov/phytochem/search\n\n13.2.14 Milk Concentrations\n\nCodeine passes into breast milk.\n\nEllenhorn, M.J. and D.G. Barceloux. Medical Toxicology - Diagnosis and Treatment of Human Poisoning. New York, NY: Elsevier Science Publishing Co., Inc. 1988., p. 731\n\n13.2.15 Probable Routes of Human Exposure\n\n\n                    Context: \n                    This chunk provides specific data on the concentration of codeine in the gum part of Papaver somniferum (opium poppy) at 35,000 ppm, its natural occurrence in the plant, and its passage into breast milk. It is relevant for understanding the source, plant concentration, and human exposure pathways of codeine, situating plant-derived levels and transfer into milk within the comprehensive chemical, biological, and toxicity profile detailed in the full document.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_246", "document_index": 23, "latency_s": 1.0847657999984222, "prompt_toks": 51580, "completion_toks": 85}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    13.2.15 Probable Routes of Human Exposure\n\nNIOSH (NOES Survey 1981-1983) has statistically estimated that 908 workers (563 of these are female) were potentially exposed to codeine in the US(1). Occupational exposure to codeine may occur through inhalation and dermal contact with this compound at workplaces where codeine is produced or used. Monitoring data indicate that the general population may be exposed to codeine via ingestion of contaminated drinking water and poppy seeds. This is a controlled substance (opiate) listed in the U.S. Code of Federal Regulations, Title 21 Parts 329.1 and 1308.12 (1995). The general public is also likely to be exposed to codeine via ingestion and dermal contact with medications containing codeine during direct medical treatment(SRC).\n\n\n                    Context: \n                    This excerpt details the primary routes of human exposure to codeine, highlighting occupational inhalation and dermal contact risks for workers, as well as environmental and medical exposure pathways for the general population through contaminated water, poppy seeds, and medications. It is relevant to sections discussing codeine toxicity, pharmacology, and safety, providing critical information on exposure sources and regulatory classification. Key details include estimated worker exposure numbers and regulatory references.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_247", "document_index": 23, "latency_s": 1.600277699995786, "prompt_toks": 51665, "completion_toks": 70}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    (1) NIOSH; NOES. National Occupational Exposure Survey conducted from 1981-1983. Estimated numbers of employees potentially exposed to specific agents by 2-digit standard industrial classification (SIC). Available from, as of Mar 3, 2016: https://www.cdc.gov/noes/noes1/agtindex.html\n\n(2) O'Neil MJ, ed; The Merck Index. 15th eds., Cambridge, UK: Royal Society of Chemistry, p. 439 (2013)\n\n13.2.16 Average Daily Intake\n\nA derived acceptable daily intake of codeine in the United States has been reported as 2 mcg/kg/day(1).\n\n(1) Schwab BW et al; Regul Toxicol Pharmacol 42: 296-312 (2005)\n\n14 Associated Disorders and Diseases\n\nAssociated Occupational Diseases with Exposure to the Compound\n\nContact dermatitis, allergic [Category: Skin Disease]\n\nAsthma, occupational [Category: Airway Disease]\n\n15 Literature\n\n15.1 Consolidated References\n\n15.2 NLM Curated PubMed Citations\n\n15.3 Springer Nature References\n\n15.4 Thieme References\n\n15.5 Wiley References\n\n15.6 Nature Journal References\n\n\n                    Context: \n                    This excerpt provides toxicity and exposure-related references, including occupational exposure estimates, regulatory assessments, and literature sources, relevant to understanding codeine's health risks. It details occupational disease categories such as contact dermatitis and asthma, along with authoritative citations on daily intake and research references, serving as a key resource for toxicity and risk evaluation within the comprehensive chemical profile.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_248", "document_index": 23, "latency_s": 1.5961160000006203, "prompt_toks": 51690, "completion_toks": 86}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    15 Literature\n\n15.1 Consolidated References\n\n15.2 NLM Curated PubMed Citations\n\n15.3 Springer Nature References\n\n15.4 Thieme References\n\n15.5 Wiley References\n\n15.6 Nature Journal References\n\nHagel et al. Dioxygenases catalyze the O-demethylation steps of morphine biosynthesis in opium poppy. Nature Chemical Biology, doi: 10.1038/nchembio.317, published online 14 March 2010 http://www.nature.com/naturechemicalbiology\n\nDastmalchi et al. Neopinone isomerase is involved in codeine and morphine biosynthesis in opium poppy. Nature Chemical Biology, doi: 10.1038/s41589-019-0247-0, published online 18 March 2019\n\n15.7 Chemical Co-Occurrences in Literature\n\n15.8 Chemical-Gene Co-Occurrences in Literature\n\n15.9 Chemical-Disease Co-Occurrences in Literature\n\n16 Patents\n\nUS8062667\n\nUS8790700\n\nUS9066942\n\nUS6383471\n\nUS6248363\n\nUS9107921\n\n16.1 Depositor-Supplied Patent Identifiers\n\nLink to all deposited patent identifiers\n\n16.2 WIPO PATENTSCOPE\n\nPatents are available for this chemical structure:\n\n\n                    Context: \n                    This section provides a curated list of recent scientific literature, references, and patent identifiers related to codeine, including key studies on its biosynthesis pathway and associated research articles in prominent journals. It enhances the overall document by facilitating targeted literature and patent searches for researchers interested in codeine’s biochemical mechanisms and intellectual property status. The details include references to influential studies, literature categories, and patent numbers, supporting in-depth research and patent analysis.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_249", "document_index": 23, "latency_s": 1.6594713999947999, "prompt_toks": 51710, "completion_toks": 103}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    US6383471\n\nUS6248363\n\nUS9107921\n\n16.1 Depositor-Supplied Patent Identifiers\n\nLink to all deposited patent identifiers\n\n16.2 WIPO PATENTSCOPE\n\nPatents are available for this chemical structure:\n\nhttps://patentscope.wipo.int/search/en/result.jsf?inchikey=OROGSEYTTFOCAN-DNJOTXNNSA-N\n\n16.3 FDA Orange Book Patents\n\n16.4 Chemical Co-Occurrences in Patents\n\n16.5 Chemical-Disease Co-Occurrences in Patents\n\n16.6 Chemical-Gene Co-Occurrences in Patents\n\n17 Interactions and Pathways\n\n17.1 Chemical-Target Interactions\n\n17.2 Drug-Drug Interactions\n\n17.3 Drug-Food Interactions\n\nAvoid alcohol.\n\nTake with food. Food reduces irritation.\n\n17.4 Pathways\n\n18 Biological Test Results\n\n18.1 BioAssay Results\n\n19 Taxonomy\n\n20 Classification\n\n20.1 MeSH Tree\n\n20.2 NCI Thesaurus Tree\n\n20.3 ChEBI Ontology\n\n20.4 KEGG: Phytochemical Compounds\n\n20.5 KEGG: ATC\n\n20.6 KEGG: Risk Category of Japanese OTC Drugs\n\n20.7 KEGG: Drug Groups\n\n20.8 WHO ATC Classification System\n\n20.9 FDA Pharm Classes\n\n20.10 ChemIDplus\n\n\n                    Context: \n                    This section provides comprehensive patent-related identifiers and patent database links for codeine, including depositor-supplied patent IDs, WIPO PATENTSCOPE URL, and references to FDA Orange Book patents. It also outlines key interactions, pathways, and classification information such as chemical-target interactions, drug-food interactions, and taxonomic and classification hierarchies relevant to codeine, supporting advanced patent and biochemical research within the full chemical profile. These details enhance the document’s utility for patent searching, chemical interactions, and regulatory classification.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_250", "document_index": 23, "latency_s": 1.5131768999999622, "prompt_toks": 51683, "completion_toks": 77}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    20.5 KEGG: ATC\n\n20.6 KEGG: Risk Category of Japanese OTC Drugs\n\n20.7 KEGG: Drug Groups\n\n20.8 WHO ATC Classification System\n\n20.9 FDA Pharm Classes\n\n20.10 ChemIDplus\n\n20.11 CAMEO Chemicals\n\n20.12 IUPHAR / BPS Guide to PHARMACOLOGY Target Classification\n\n20.13 ChEMBL Target Tree\n\n20.14 UN GHS Classification\n\n20.15 EPA CPDat Classification\n\n20.16 Drug Enforcement Administration (DEA) Classification\n\n20.17 NORMAN Suspect List Exchange Classification\n\n20.18 CCSBase Classification\n\n20.19 EPA DSSTox Classification\n\n20.20 LOTUS Tree\n\n20.21 MolGenie Organic Chemistry Ontology\n\n20.22 Chemicals in PubChem from Regulatory Sources\n\n21 Information Sources\n\nAustralian Industrial Chemicals Introduction Scheme (AICIS)\n\nLICENSE\n\nhttps://www.industrialchemicals.gov.au/copyright\n\nMorphinan-6-ol, 7,8-didehydro-4,5-epoxy-3-methoxy-17-methyl-, (5.alpha.,6.alpha.)-\n\nhttps://services.industrialchemicals.gov.au/search-assessments/\n\nCAMEO Chemicals\n\nLICENSE\n\n\n                    Context: \n                    This chunk lists various chemical classification systems, regulatory classifications, and authoritative resources such as KEGG, WHO ATC, FDA Pharm Classes, and others, spanning sections 20.5 to 21 of the full document. It provides links and licensing information relevant to chemical, pharmacological, and regulatory categorization of codeine, supporting classification and regulatory research within the comprehensive chemical database.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_251", "document_index": 23, "latency_s": 1.1008287999866297, "prompt_toks": 51659, "completion_toks": 83}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    Morphinan-6-ol, 7,8-didehydro-4,5-epoxy-3-methoxy-17-methyl-, (5.alpha.,6.alpha.)-\n\nhttps://services.industrialchemicals.gov.au/search-assessments/\n\nCAMEO Chemicals\n\nLICENSE\n\nCAMEO Chemicals and all other CAMEO products are available at no charge to those organizations and individuals (recipients) responsible for the safe handling of chemicals. However, some of the chemical data itself is subject to the copyright restrictions of the companies or organizations that provided the data.\n\nhttps://cameochemicals.noaa.gov/help/reference/terms_and_conditions.htm?d_f=false\n\nCODEINE\n\nhttps://cameochemicals.noaa.gov/chemical/20046\n\nCAMEO Chemical Reactivity Classification\n\nhttps://cameochemicals.noaa.gov/browse/react\n\nCAS Common Chemistry\n\nLICENSE\n\nThe data from CAS Common Chemistry is provided under a CC-BY-NC 4.0 license, unless otherwise stated.\n\nhttps://creativecommons.org/licenses/by-nc/4.0/\n\nCodeine\n\nhttps://commonchemistry.cas.org/detail?cas_rn=76-57-3\n\nChemIDplus\n\nLICENSE\n\n\n                    Context: \n                    This segment provides chemical identifiers, licensing information, and classification details for codeine, including its IUPAC name, CAS number, and registry links. It enhances the overall document's searchability by consolidating chemical data, regulatory data, and data source licenses relevant to codeine's chemical classification and safe handling. These details are crucial for precise chemical identification, regulatory compliance, and data sourcing in research and safety assessments.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_252", "document_index": 23, "latency_s": 1.031101699991268, "prompt_toks": 51657, "completion_toks": 95}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    https://creativecommons.org/licenses/by-nc/4.0/\n\nCodeine\n\nhttps://commonchemistry.cas.org/detail?cas_rn=76-57-3\n\nChemIDplus\n\nLICENSE\n\nhttps://www.nlm.nih.gov/copyright.html\n\nCodeine [INN:BAN]\n\nhttps://pubchem.ncbi.nlm.nih.gov/substance/?source=chemidplus&sourceid=0000076573\n\nChemIDplus Chemical Information Classification\n\nhttps://pubchem.ncbi.nlm.nih.gov/source/chemidplus\n\nDrugBank\n\nLICENSE\n\nCreative Common's Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/legalcode)\n\nhttps://www.drugbank.ca/legal/terms_of_use\n\nCodeine\n\nhttps://www.drugbank.ca/drugs/DB00318\n\nEPA DSSTox\n\nLICENSE\n\nhttps://www.epa.gov/privacy/privacy-act-laws-policies-and-resources\n\nCodeine\n\nhttps://comptox.epa.gov/dashboard/DTXSID2020341\n\nCompTox Chemicals Dashboard Chemical Lists\n\nhttps://comptox.epa.gov/dashboard/chemical-lists/\n\nEuropean Chemicals Agency (ECHA)\n\nLICENSE\n\n\n                    Context: \n                    This chunk provides licensing, external resource links, and identifier references for codeine from sources like Creative Commons, CAS, ChemIDplus, DrugBank, EPA DSSTox, and ECHA. It complements the full webpage's comprehensive chemical and pharmacological data by offering legal and database access details, enhancing resource retrieval and verification for researchers. Its relevance lies in documenting codeine’s licensing and cross-referenced identifiers crucial for legal, intellectual property, and data integration purposes.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_253", "document_index": 23, "latency_s": 1.4208451000013156, "prompt_toks": 51608, "completion_toks": 71}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    Codeine\n\nhttps://comptox.epa.gov/dashboard/DTXSID2020341\n\nCompTox Chemicals Dashboard Chemical Lists\n\nhttps://comptox.epa.gov/dashboard/chemical-lists/\n\nEuropean Chemicals Agency (ECHA)\n\nLICENSE\n\nUse of the information, documents and data from the ECHA website is subject to the terms and conditions of this Legal Notice, and subject to other binding limitations provided for under applicable law, the information, documents and data made available on the ECHA website may be reproduced, distributed and/or used, totally or in part, for non-commercial purposes provided that ECHA is acknowledged as the source: \"Source: European Chemicals Agency, http://echa.europa.eu/\". Such acknowledgement must be included in each copy of the material. ECHA permits and encourages organisations and individuals to create links to the ECHA website under the following cumulative conditions: Links can only be made to webpages that provide a link to the Legal Notice page.\n\n\n                    Context: \n                    This chunk provides references and licensing information related to chemical data sources for codeine, including links to the CompTox Chemicals Dashboard and the European Chemicals Agency (ECHA). It details legal restrictions on data use, acknowledgment requirements, and source attribution, which are relevant for researchers and professionals seeking authoritative, licensed chemical information within the comprehensive PubChem summary.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_254", "document_index": 23, "latency_s": 1.008849799996824, "prompt_toks": 51671, "completion_toks": 65}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    https://echa.europa.eu/web/guest/legal-notice\n\nCodeine\n\nhttps://chem.echa.europa.eu/100.000.882\n\nCodeine (EC: 200-969-1)\n\nhttps://echa.europa.eu/information-on-chemicals/cl-inventory-database/-/discli/details/108769\n\nCodeine monohydrate (EC: 641-609-7)\n\nhttps://echa.europa.eu/information-on-chemicals/cl-inventory-database/-/discli/details/174359\n\nFDA Global Substance Registration System (GSRS)\n\nLICENSE\n\nUnless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug Administration as the source is appreciated but not required.\n\nhttps://www.fda.gov/about-fda/about-website/website-policies#linking\n\nCODEINE ANHYDROUS\n\nhttps://gsrs.ncats.nih.gov/ginas/app/beta/substances/UX6OWY2V7J\n\nHazardous Substances Data Bank (HSDB)\n\nLICENSE\n\n\n                    Context: \n                    This chunk provides regulatory and identification information for codeine, including links to EU chemical registry entries, FDA public domain licensing policies, and specific substance identifiers such as EC numbers and source URLs. It is relevant for legal, safety, and standardized data referencing within the comprehensive PubChem homepage, supporting regulatory compliance and cross-referencing.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_255", "document_index": 23, "latency_s": 1.273253300008946, "prompt_toks": 51644, "completion_toks": 76}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    CODEINE ANHYDROUS\n\nhttps://gsrs.ncats.nih.gov/ginas/app/beta/substances/UX6OWY2V7J\n\nHazardous Substances Data Bank (HSDB)\n\nLICENSE\n\nhttps://www.nlm.nih.gov/web_policies.html\n\nCODEINE\n\nhttps://pubchem.ncbi.nlm.nih.gov/source/hsdb/3043\n\nHuman Metabolome Database (HMDB)\n\nLICENSE\n\nHMDB is offered to the public as a freely available resource. Use and re-distribution of the data, in whole or in part, for commercial purposes requires explicit permission of the authors and explicit acknowledgment of the source material (HMDB) and the original publication (see the HMDB citing page). We ask that users who download significant portions of the database cite the HMDB paper in any resulting publications.\n\nhttp://www.hmdb.ca/citing\n\nCodeine\n\nhttp://www.hmdb.ca/metabolites/HMDB0004995\n\nHMDB0004995_msms_2226588\n\nhttps://hmdb.ca/metabolites/HMDB0004995#spectra\n\nNew Zealand Environmental Protection Authority (EPA)\n\nLICENSE\n\n\n                    Context: \n                    This chunk provides alternative identifiers and licensing information for codeine, including links to the GSRS, HSDB, HMDB, and New Zealand EPA databases. It complements the comprehensive chemical and safety data in the full document, aiding researchers seeking database-specific resources and licensing details for codeine. It is relevant for tracing codeine's regulatory, metabolic, and toxicological data sources.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_256", "document_index": 23, "latency_s": 1.6232984000089345, "prompt_toks": 51637, "completion_toks": 98}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    Codeine\n\nhttp://www.hmdb.ca/metabolites/HMDB0004995\n\nHMDB0004995_msms_2226588\n\nhttps://hmdb.ca/metabolites/HMDB0004995#spectra\n\nNew Zealand Environmental Protection Authority (EPA)\n\nLICENSE\n\nThis work is licensed under the Creative Commons Attribution-ShareAlike 4.0 International licence.\n\nhttps://www.epa.govt.nz/about-this-site/general-copyright-statement/\n\nCodeine\n\nhttps://www.epa.govt.nz/industry-areas/hazardous-substances/guidance-for-importers-and-manufacturers/hazardous-substances-databases/\n\nBindingDB\n\nLICENSE\n\nAll data curated by BindingDB staff are provided under the Creative Commons Attribution 3.0 License (https://creativecommons.org/licenses/by/3.0/us/).\n\nhttps://www.bindingdb.org/rwd/bind/info.jsp\n\n(-)-Codeine\n\nhttps://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50019351\n\nComparative Toxicogenomics Database (CTD)\n\nLICENSE\n\n\n                    Context: \n                    This chunk provides additional references and licensing information related to codeine, including links to the Human Metabolome Database (HMDB), Environmental Protection Authority (EPA), BindingDB, and the Comparative Toxicogenomics Database (CTD). It complements the comprehensive chemical, pharmacological, and safety data within the full webpage, emphasizing data sources, licensing terms, and metabolite spectra relevant for research and regulatory purposes. This information enhances the document's utility for scientific data retrieval and legal compliance.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_257", "document_index": 23, "latency_s": 1.2420822999993106, "prompt_toks": 51614, "completion_toks": 80}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    https://www.bindingdb.org/rwd/bind/info.jsp\n\n(-)-Codeine\n\nhttps://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50019351\n\nComparative Toxicogenomics Database (CTD)\n\nLICENSE\n\nIt is to be used only for research and educational purposes. Any reproduction or use for commercial purpose is prohibited without the prior express written permission of NC State University.\n\nhttp://ctdbase.org/about/legal.jsp\n\nCodeine\n\nhttps://ctdbase.org/detail.go?type=chem&acc=D003061\n\nDrug Gene Interaction database (DGIdb)\n\nLICENSE\n\nThe data used in DGIdb is all open access and where possible made available as raw data dumps in the downloads section.\n\nhttp://www.dgidb.org/downloads\n\nCODEINE ANHYDROUS\n\nhttps://www.dgidb.org/drugs/rxcui:1545976\n\nIUPHAR/BPS Guide to PHARMACOLOGY\n\nLICENSE\n\n\n                    Context: \n                    This content provides additional links and licensing information related to drug interaction, toxicogenomics, and chemical databases for codeine, complementing the main PubChem drug profile. It includes references to BindingDB, CTD, DGIdb, and IUPHAR, which are important resources for drug-gene interactions and toxicology research relevant to the overall detailed chemical and pharmacological profile of codeine.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_258", "document_index": 23, "latency_s": 1.3239064999943366, "prompt_toks": 51634, "completion_toks": 91}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    http://www.dgidb.org/downloads\n\nCODEINE ANHYDROUS\n\nhttps://www.dgidb.org/drugs/rxcui:1545976\n\nIUPHAR/BPS Guide to PHARMACOLOGY\n\nLICENSE\n\nThe Guide to PHARMACOLOGY database is licensed under the Open Data Commons Open Database License (ODbL) https://opendatacommons.org/licenses/odbl/. Its contents are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License (http://creativecommons.org/licenses/by-sa/4.0/)\n\nhttps://www.guidetopharmacology.org/about.jsp#license\n\ncodeine\n\nhttps://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1673\n\nGuide to Pharmacology Target Classification\n\nhttps://www.guidetopharmacology.org/targets.jsp\n\nTherapeutic Target Database (TTD)\n\nCodeine\n\nhttps://idrblab.net/ttd/data/drug/details/D03DIG\n\nToxin and Toxin Target Database (T3DB)\n\nLICENSE\n\n\n                    Context: \n                    This chunk provides references and licensing information for key pharmacological and chemical databases related to codeine, including DrugBank, Guide to PHARMACOLOGY, TTD, and T3DB. It details licensing terms, database URLs, and identifiers, serving as an essential resource for database cross-referencing within the comprehensive chemical and pharmacological data on pubchem webpage. This information enhances search retrieval by linking codeine to authoritative data sources and licensing details.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_259", "document_index": 23, "latency_s": 1.7073209999944083, "prompt_toks": 51617, "completion_toks": 78}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    https://www.guidetopharmacology.org/targets.jsp\n\nTherapeutic Target Database (TTD)\n\nCodeine\n\nhttps://idrblab.net/ttd/data/drug/details/D03DIG\n\nToxin and Toxin Target Database (T3DB)\n\nLICENSE\n\nT3DB is offered to the public as a freely available resource. Use and re-distribution of the data, in whole or in part, for commercial purposes requires explicit permission of the authors and explicit acknowledgment of the source material (T3DB) and the original publication.\n\nhttp://www.t3db.ca/downloads\n\nCodeine\n\nhttp://www.t3db.ca/toxins/T3D2749\n\nChEBI\n\nCodeine\n\nhttps://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:16714\n\nChEBI Ontology\n\nhttp://www.ebi.ac.uk/chebi/userManualForward.do#ChEBI%20Ontology\n\nDrug Enforcement Administration (DEA)\n\nLICENSE\n\n\n                    Context: \n                    This chunk provides specific references and links to key pharmacological and toxicological databases related to codeine, including the Therapeutic Target Database, T3DB, ChEBI, and DEA classifications. It complements the broader document's comprehensive overview of codeine by highlighting relevant online resources for target information, toxin data, chemical ontology, and regulatory details, essential for research and regulatory search queries.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_260", "document_index": 23, "latency_s": 1.5657343000057153, "prompt_toks": 51568, "completion_toks": 63}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    Codeine\n\nhttps://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:16714\n\nChEBI Ontology\n\nhttp://www.ebi.ac.uk/chebi/userManualForward.do#ChEBI%20Ontology\n\nDrug Enforcement Administration (DEA)\n\nLICENSE\n\nUnless otherwise indicated, information on Department of Justice websites is in the public domain and may be copied and distributed without permission. Citation of the Department of Justice as source of the information is appreciated, as appropriate.\n\nhttps://www.justice.gov/legalpolicies\n\nCodeine\n\nhttps://www.deadiversion.usdoj.gov/schedules/\n\nDEA Drug and Chemical Classification\n\nhttps://www.dea.gov/drug-information/drug-scheduling\n\nFDA Pharm Classes\n\nLICENSE\n\n\n                    Context: \n                    This chunk provides official classification and regulatory links for codeine, including its ChEBI ID, ontology, DEA scheduling information, and FDA pharmacological classes. It is part of the comprehensive chemical profile, supporting regulatory and classification data crucial for research, safety assessment, and legal compliance within the full PubChem compound documentation.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_261", "document_index": 23, "latency_s": 1.4794344999972964, "prompt_toks": 51645, "completion_toks": 68}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    Codeine\n\nhttps://www.deadiversion.usdoj.gov/schedules/\n\nDEA Drug and Chemical Classification\n\nhttps://www.dea.gov/drug-information/drug-scheduling\n\nFDA Pharm Classes\n\nLICENSE\n\nUnless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug Administration as the source is appreciated but not required.\n\nhttps://www.fda.gov/about-fda/about-website/website-policies#linking\n\nCODEINE ANHYDROUS\n\nhttps://dailymed.nlm.nih.gov/dailymed/browse-drug-classes.cfm\n\nFDA Pharmacological Classification\n\nhttps://www.fda.gov/industry/structured-product-labeling-resources/pharmacologic-class\n\nLiverTox\n\nLICENSE\n\nhttps://www.nlm.nih.gov/copyright.html\n\nCodeine\n\nhttps://www.ncbi.nlm.nih.gov/books/n/livertox/Codeine/\n\nLOTUS - the natural products occurrence database\n\nLICENSE\n\n\n                    Context: \n                    This excerpt provides key regulatory and classification information for codeine, including DEA drug scheduling, FDA drug classes, legal licensing, and safety resources. It complements the comprehensive chemical, pharmacological, and toxicological data in the full webpage, serving as an essential reference for regulatory status and legal categorization of codeine within the overall chemical profile.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_262", "document_index": 23, "latency_s": 1.7104160000017146, "prompt_toks": 51673, "completion_toks": 92}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    LiverTox\n\nLICENSE\n\nhttps://www.nlm.nih.gov/copyright.html\n\nCodeine\n\nhttps://www.ncbi.nlm.nih.gov/books/n/livertox/Codeine/\n\nLOTUS - the natural products occurrence database\n\nLICENSE\n\nThe code for LOTUS is released under the GNU General Public License v3.0.\n\nhttps://lotus.nprod.net/\n\nCodeine\n\nhttps://www.wikidata.org/wiki/Q174723\n\nLOTUS Tree\n\nhttps://lotus.naturalproducts.net/\n\nNCI Thesaurus (NCIt)\n\nLICENSE\n\nUnless otherwise indicated, all text within NCI products is free of copyright and may be reused without our permission. Credit the National Cancer Institute as the source.\n\nhttps://www.cancer.gov/policies/copyright-reuse\n\nhttps://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C383\n\nhttps://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C77284\n\nNCI Thesaurus\n\nhttps://ncit.nci.nih.gov\n\nOpen Targets\n\nLICENSE\n\nDatasets generated by the Open Targets Platform are freely available for download.\n\n\n                    Context: \n                    This excerpt provides licensing and source information related to key databases and resources associated with codeine, including LiverTox, LOTUS, NCI Thesaurus, and Open Targets. It supplements the comprehensive chemical and pharmacological data on codeine presented earlier, emphasizing data provenance, licensing terms, and linked resources relevant for research and regulatory purposes. This contextualizes the usage rights and data sources supporting the overall scientific and regulatory profile of codeine in the document.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_263", "document_index": 23, "latency_s": 1.327622099997825, "prompt_toks": 51686, "completion_toks": 76}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    NCI Thesaurus\n\nhttps://ncit.nci.nih.gov\n\nOpen Targets\n\nLICENSE\n\nDatasets generated by the Open Targets Platform are freely available for download.\n\nhttps://platform-docs.opentargets.org/licence\n\nCODEINE\n\nhttps://platform.opentargets.org/drug/CHEMBL485\n\nCCSbase\n\nCCSbase Classification\n\nhttps://ccsbase.net/\n\nNORMAN Suspect List Exchange\n\nLICENSE\n\nData: CC-BY 4.0; Code (hosted by ECI, LCSB): Artistic-2.0\n\nhttps://creativecommons.org/licenses/by/4.0/\n\nCODEINE\n\nNORMAN Suspect List Exchange Classification\n\nhttps://www.norman-network.com/nds/SLE/\n\nChEMBL\n\nLICENSE\n\nAccess to the web interface of ChEMBL is made under the EBI's Terms of Use (http://www.ebi.ac.uk/Information/termsofuse.html). The ChEMBL data is made available on a Creative Commons Attribution-Share Alike 3.0 Unported License (http://creativecommons.org/licenses/by-sa/3.0/).\n\nhttp://www.ebi.ac.uk/Information/termsofuse.html\n\nhttps://www.ebi.ac.uk/chembl/explore/compound/CHEMBL485\n\nChEMBL Protein Target Tree\n\n\n                    Context: \n                    This segment lists key chemical and pharmacological resources related to codeine, including the NCI Thesaurus, Open Targets, CCSbase, NORMAN Suspect List Exchange, and ChEMBL, with associated licensing details and URLs. It provides essential external database references important for research, regulatory, and data integration purposes, enhancing the document's comprehensive resource coverage on codeine.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_264", "document_index": 23, "latency_s": 1.301486800002749, "prompt_toks": 51589, "completion_toks": 74}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    http://www.ebi.ac.uk/Information/termsofuse.html\n\nhttps://www.ebi.ac.uk/chembl/explore/compound/CHEMBL485\n\nChEMBL Protein Target Tree\n\nhttps://www.ebi.ac.uk/chembl/g/#browse/targets\n\nIUPAC Digitized pKa Dataset\n\nCodeine\n\nhttps://github.com/IUPAC/Dissociation-Constants\n\nClinicalTrials.gov\n\nLICENSE\n\nThe ClinicalTrials.gov data carry an international copyright outside the United States and its Territories or Possessions. Some ClinicalTrials.gov data may be subject to the copyright of third parties; you should consult these entities for any additional terms of use.\n\nhttps://clinicaltrials.gov/ct2/about-site/terms-conditions#Use\n\nhttps://clinicaltrials.gov/\n\nHaz-Map, Information on Hazardous Chemicals and Occupational Diseases\n\nLICENSE\n\n\n                    Context: \n                    This chunk provides key external resources and licensing information related to chemical and biomedical data sources associated with codeine, including links to the ChEMBL compound and target databases, IUPAC pKa datasets, clinical trial regulations, and occupational hazard information. These references complement the comprehensive chemical, pharmacological, and regulatory data presented in the full webpage, aiding research and data retrieval.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_265", "document_index": 23, "latency_s": 1.2081190000026254, "prompt_toks": 51622, "completion_toks": 82}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    https://clinicaltrials.gov/ct2/about-site/terms-conditions#Use\n\nhttps://clinicaltrials.gov/\n\nHaz-Map, Information on Hazardous Chemicals and Occupational Diseases\n\nLICENSE\n\nCopyright (c) 2022 Haz-Map(R). All rights reserved. Unless otherwise indicated, all materials from Haz-Map are copyrighted by Haz-Map(R). No part of these materials, either text or image may be used for any purpose other than for personal use. Therefore, reproduction, modification, storage in a retrieval system or retransmission, in any form or by any means, electronic, mechanical or otherwise, for reasons other than personal use, is strictly prohibited without prior written permission.\n\nhttps://haz-map.com/About\n\nCodeine\n\nhttps://haz-map.com/Agents/1272\n\nCrystallography Open Database (COD)\n\nLICENSE\n\nAll data in the COD and the database itself are dedicated to the public domain and licensed under the CC0 License. Users of the data should acknowledge the original authors of the structural data.\n\n\n                    Context: \n                    This segment provides licensing and usage information for external chemical and clinical trial databases, such as ClinicalTrials.gov, Haz-Map, and the Crystallography Open Database. It details legal terms, restrictions, and acknowledgments relevant to data sources associated with codeine and related substances, supporting the webpage's comprehensive references and resource citations. This information is crucial for researchers accessing external datasets and ensuring proper usage rights.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_266", "document_index": 23, "latency_s": 1.2123861000000034, "prompt_toks": 51632, "completion_toks": 79}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    All data in the COD and the database itself are dedicated to the public domain and licensed under the CC0 License. Users of the data should acknowledge the original authors of the structural data.\n\nhttps://creativecommons.org/publicdomain/zero/1.0/\n\nhttps://www.crystallography.net/cod/5000074.html\n\nThe Cambridge Structural Database\n\nhttps://www.ccdc.cam.ac.uk/structures/Search?Ccdcid=643258\n\nDailyMed\n\nLICENSE\n\nhttps://www.nlm.nih.gov/copyright.html\n\nCODEINE\n\nhttps://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=CODEINE\n\nDrug Induced Liver Injury Rank (DILIrank) Dataset\n\nLICENSE\n\nUnless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug Administration as the source is appreciated but not required.\n\n\n                    Context: \n                    This chunk provides information on the public domain status, licensing, and authoritative sources related to chemical structural data, crystallography, and drug datasets for codeine. It references the CC0 license, the Cambridge Structural Database, DailyMed, and the FDA’s Drug Induced Liver Injury Rank dataset, emphasizing open access and licensing details relevant for researchers and data users within the comprehensive PubChem page.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_267", "document_index": 23, "latency_s": 2.736665599994012, "prompt_toks": 51639, "completion_toks": 69}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    https://www.fda.gov/about-fda/about-website/website-policies#linking\n\ncodeine\n\nhttps://www.fda.gov/science-research/liver-toxicity-knowledge-base-ltkb/drug-induced-liver-injury-rank-dilirank-dataset\n\nStatPearls\n\nLICENSE\n\nThis book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.\n\nCodeine\n\nhttps://www.ncbi.nlm.nih.gov/books/n/statpearls/article-19677/\n\nDrugs and Lactation Database (LactMed)\n\nLICENSE\n\nhttps://www.nlm.nih.gov/copyright.html\n\nCodeine\n\nhttps://www.ncbi.nlm.nih.gov/books/n/lactmed/LM347/\n\nMother To Baby Fact Sheets\n\nLICENSE\n\n\n                    Context: \n                    This chunk provides references to authoritative sources on codeine-related liver toxicity, drug information distribution, and lactation safety, complementing the full document's comprehensive overview of codeine’s pharmacology, safety, and regulatory status. It includes links to FDA policies, clinical reference books, and licensing information, highlighting key information for regulatory and clinical research contexts.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_268", "document_index": 23, "latency_s": 1.2205653999990318, "prompt_toks": 51651, "completion_toks": 91}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    Drugs and Lactation Database (LactMed)\n\nLICENSE\n\nhttps://www.nlm.nih.gov/copyright.html\n\nCodeine\n\nhttps://www.ncbi.nlm.nih.gov/books/n/lactmed/LM347/\n\nMother To Baby Fact Sheets\n\nLICENSE\n\nCopyright by OTIS. This work is available under the Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported license (CC BY-NC-ND 3.0).\n\nhttps://www.ncbi.nlm.nih.gov/books/about/copyright/\n\ncodeine\n\nhttps://www.ncbi.nlm.nih.gov/books/n/mtb/codeine-en/\n\nDrugs@FDA\n\nLICENSE\n\nUnless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug Administration as the source is appreciated but not required.\n\nhttps://www.fda.gov/about-fda/about-website/website-policies#linking\n\nCODEINE POLISTIREX\n\nhttps://www.accessdata.fda.gov/scripts/cder/daf/\n\n\n                    Context: \n                    This section provides references and licensing information related to the use of codeine in lactation and drug information resources, including the Drugs and Lactation Database (LactMed), Mother To Baby Fact Sheets, and FDA content. It is relevant for understanding regulations, safety, and guidance on codeine use during breastfeeding, intersecting with the broader comprehensive data on codeine's chemical properties, pharmacology, toxicity, and legal status presented in the full document.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_269", "document_index": 23, "latency_s": 1.0837673000060022, "prompt_toks": 51641, "completion_toks": 77}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    https://www.fda.gov/about-fda/about-website/website-policies#linking\n\nCODEINE POLISTIREX\n\nhttps://www.accessdata.fda.gov/scripts/cder/daf/\n\nWHO Model Lists of Essential Medicines\n\nLICENSE\n\nPermission from WHO is not required for the use of WHO materials issued under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Intergovernmental Organization (CC BY-NC-SA 3.0 IGO) license.\n\nhttps://www.who.int/about/policies/publishing/copyright\n\nCodeine\n\nhttps://list.essentialmeds.org/medicines/16\n\nEPA Chemical and Products Database (CPDat)\n\nLICENSE\n\nhttps://www.epa.gov/privacy/privacy-act-laws-policies-and-resources\n\nhttps://comptox.epa.gov/dashboard/DTXSID2020341#exposure\n\nEPA CPDat Classification\n\nhttps://www.epa.gov/chemical-research/chemical-and-products-database-cpdat\n\nEU Clinical Trials Register\n\nhttps://www.clinicaltrialsregister.eu/\n\nFDA Orange Book\n\nLICENSE\n\n\n                    Context: \n                    This chunk provides regulatory and licensing information related to codeine, including links to FDA, WHO, and EPA databases, licensing conditions, and essential medicine listings. It situates the document’s comprehensive overview of codeine's chemical, safety, and pharmacological data within the context of regulatory classifications and international guidelines, supporting search efforts focused on legal, licensing, and official standards for this compound.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_270", "document_index": 23, "latency_s": 1.0931386000011116, "prompt_toks": 51594, "completion_toks": 68}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    EPA CPDat Classification\n\nhttps://www.epa.gov/chemical-research/chemical-and-products-database-cpdat\n\nEU Clinical Trials Register\n\nhttps://www.clinicaltrialsregister.eu/\n\nFDA Orange Book\n\nLICENSE\n\nUnless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug Administration as the source is appreciated but not required.\n\nhttps://www.fda.gov/about-fda/about-website/website-policies#linking\n\nCODEINE POLISTIREX\n\nhttps://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book\n\nFooDB\n\nLICENSE\n\n\n                    Context: \n                    This chunk provides references to regulatory and research databases related to codeine, including the EPA CPDat Classification, the EU Clinical Trials Register, and the FDA Orange Book. These references are part of the comprehensive chemical profile, supporting regulatory, safety, and pharmacological research, and enhance searchability for regulatory status and approval information within the overall document.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_271", "document_index": 23, "latency_s": 1.5065896000014618, "prompt_toks": 51673, "completion_toks": 71}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    CODEINE POLISTIREX\n\nhttps://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book\n\nFooDB\n\nLICENSE\n\nFooDB is offered to the public as a freely available resource. Use and re-distribution of the data, in whole or in part, for commercial purposes requires explicit permission of the authors and explicit acknowledgment of the source material (FooDB) and the original publication.\n\nhttps://foodb.ca/about\n\nCodeine\n\nhttps://foodb.ca/compounds/FDB012162\n\nUSGS Health-Based Screening Levels for Evaluating Water-Quality Data\n\nLICENSE\n\nhttps://www.usgs.gov/legal\n\nCodeine\n\nhttps://water.usgs.gov/water-resources/hbsl/index.html\n\nSpectraBase\n\nCODEINE\n\nhttps://spectrabase.com/spectrum/DtBoV1cDYUq\n\nCodeine\n\nhttps://spectrabase.com/spectrum/95AZyScFOep\n\nCodeine\n\nhttps://spectrabase.com/spectrum/JLOIGGpiMdl\n\nJapan Chemical Substance Dictionary (Nikkaji)\n\nhttp://jglobal.jst.go.jp/en/redirect?Nikkaji_No=J4.178E\n\nKEGG\n\nLICENSE\n\n\n                    Context: \n                    This chunk provides references and external links related to the chemical data, regulatory information, spectral databases, and resources for codeine, complementing the comprehensive pharmacological and safety data in the full webpage. It enhances searchability for codeine’s regulatory status, chemical property databases, spectral profiles, and classification systems, supporting precise information retrieval for research and regulatory purposes.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_272", "document_index": 23, "latency_s": 1.080080799991265, "prompt_toks": 51685, "completion_toks": 83}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    Codeine\n\nhttps://spectrabase.com/spectrum/JLOIGGpiMdl\n\nJapan Chemical Substance Dictionary (Nikkaji)\n\nhttp://jglobal.jst.go.jp/en/redirect?Nikkaji_No=J4.178E\n\nKEGG\n\nLICENSE\n\nAcademic users may freely use the KEGG website. Non-academic use of KEGG generally requires a commercial license\n\nhttps://www.kegg.jp/kegg/legal.html\n\nhttps://www.kegg.jp/entry/C06174\n\nPhytochemical compounds\n\nhttp://www.genome.jp/kegg-bin/get_htext?br08003.keg\n\nAnatomical Therapeutic Chemical (ATC) classification\n\nhttp://www.genome.jp/kegg-bin/get_htext?br08303.keg\n\nRisk category of Japanese OTC drugs\n\nhttp://www.genome.jp/kegg-bin/get_htext?br08312.keg\n\nDrug Groups\n\nhttp://www.genome.jp/kegg-bin/get_htext?br08330.keg\n\nNatural Product Activity and Species Source (NPASS)\n\nCodeine\n\nhttps://bidd.group/NPASS/compound.php?compoundID=NPC43069\n\nMassBank Europe\n\nLICENSE\n\nhttps://github.com/MassBank/MassBank-web/blob/main/MassBank-Project/LICENSE.txt\n\nCodeine\n\n\n                    Context: \n                    This chunk provides additional identifiers and resources related to codeine, including spectral databases (SpectraBase), chemical dictionaries (Japan Nikkaji), pathway and classification links (KEGG), natural product sources (NPASS), and licensing information (MassBank Europe). It complements the main document's comprehensive overview by listing external data sources, licensing terms, and chemical pathway references essential for detailed chemical and pharmacological research.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_273", "document_index": 23, "latency_s": 2.084058799999184, "prompt_toks": 51673, "completion_toks": 86}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    Codeine\n\nhttps://bidd.group/NPASS/compound.php?compoundID=NPC43069\n\nMassBank Europe\n\nLICENSE\n\nhttps://github.com/MassBank/MassBank-web/blob/main/MassBank-Project/LICENSE.txt\n\nCodeine\n\nhttps://massbank.eu/MassBank/Result.jsp?inchikey=OROGSEYTTFOCAN-DNJOTXNNSA-N\n\nMassBank of North America (MoNA)\n\nLICENSE\n\nThe content of the MoNA database is licensed under CC BY 4.0.\n\nhttps://mona.fiehnlab.ucdavis.edu/documentation/license\n\nCodeine\n\nhttps://mona.fiehnlab.ucdavis.edu/spectra/browse?query=exists(compound.metaData.name:%27InChIKey%27%20and%20compound.metaData.value:%27OROGSEYTTFOCAN-DNJOTXNNSA-N%27)\n\nMetabolomics Workbench\n\nCodeine\n\nhttps://www.metabolomicsworkbench.org/data/StructureData.php?RegNo=42703\n\nNature Chemical Biology\n\nhttps://pubchem.ncbi.nlm.nih.gov/substance/87544102\n\nhttps://pubchem.ncbi.nlm.nih.gov/substance/381131012\n\nNLM RxNorm Terminology\n\nLICENSE\n\n\n                    Context: \n                    This excerpt lists electronic databases and spectral resources related to codeine, including MassBank Europe, MassBank of North America (MoNA), and Metabolomics Workbench, along with their licensing information. Its relevance to the comprehensive document lies in providing access points to spectral and metabolomics data essential for chemical identification, analytical validation, and research applications involving codeine within the broader scope of chemical, pharmacological, and toxicological information.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_274", "document_index": 23, "latency_s": 1.6687647999933688, "prompt_toks": 51606, "completion_toks": 62}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    Nature Chemical Biology\n\nhttps://pubchem.ncbi.nlm.nih.gov/substance/87544102\n\nhttps://pubchem.ncbi.nlm.nih.gov/substance/381131012\n\nNLM RxNorm Terminology\n\nLICENSE\n\nThe RxNorm Terminology is created by the National Library of Medicine (NLM) and is in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from NLM. Credit to the U.S. National Library of Medicine as the source is appreciated but not required. The full RxNorm dataset requires a free license.\n\nhttps://www.nlm.nih.gov/research/umls/rxnorm/docs/termsofservice.html\n\ncodeine\n\nhttps://rxnav.nlm.nih.gov/id/rxnorm/2670\n\ncodeine anhydrous\n\nhttps://rxnav.nlm.nih.gov/id/rxnorm/1545976\n\nWHO Anatomical Therapeutic Chemical (ATC) Classification\n\nLICENSE\n\n\n                    Context: \n                    This excerpt lists references to scientific literature, specifically highlighting \"Nature Chemical Biology\" with related PubChem substances links, and details about the NLM RxNorm terminology and licensing information. It provides context on authoritative data sources and licensing terms relevant to chemical and drug information within the comprehensive PubChem drug profile for codeine.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_275", "document_index": 23, "latency_s": 1.054980400003842, "prompt_toks": 51669, "completion_toks": 78}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    codeine\n\nhttps://rxnav.nlm.nih.gov/id/rxnorm/2670\n\ncodeine anhydrous\n\nhttps://rxnav.nlm.nih.gov/id/rxnorm/1545976\n\nWHO Anatomical Therapeutic Chemical (ATC) Classification\n\nLICENSE\n\nUse of all or parts of the material requires reference to the WHO Collaborating Centre for Drug Statistics Methodology. Copying and distribution for commercial purposes is not allowed. Changing or manipulating the material is not allowed.\n\nhttps://www.whocc.no/copyright_disclaimer/\n\nCodeine\n\nhttps://www.whocc.no/atc_ddd_index/?code=R05DA04\n\nEPA CPDat Classification\n\nhttps://www.whocc.no/atc_ddd_index/\n\nNTP Technical Reports\n\nLICENSE\n\nhttps://ntp.niehs.nih.gov/support/policies\n\nCodeine\n\nhttps://ntp.niehs.nih.gov/data/tr\n\nPharmGKB\n\nLICENSE\n\nPharmGKB data are subject to the Creative Commons Attribution-ShareALike 4.0 license (https://creativecommons.org/licenses/by-sa/4.0/).\n\nhttps://www.pharmgkb.org/page/policies\n\ncodeine\n\nhttps://www.pharmgkb.org/chemical/PA449088\n\nPharos\n\nLICENSE\n\n\n                    Context: \n                    This chunk provides key identifiers, classifications, and licensing information for codeine, including links to RxNorm, WHO ATC, EPA CPDat, NTP, PharmGKB, and Pharos, emphasizing regulatory and licensing details relevant for research, clinical use, and data licensing. It serves as a reference for standardized coding and legal usage within the comprehensive chemical profile presented in the full webpage.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_276", "document_index": 23, "latency_s": 1.076184799996554, "prompt_toks": 51674, "completion_toks": 86}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    https://www.pharmgkb.org/page/policies\n\ncodeine\n\nhttps://www.pharmgkb.org/chemical/PA449088\n\nPharos\n\nLICENSE\n\nData accessed from Pharos and TCRD is publicly available from the primary sources listed above. Please respect their individual licenses regarding proper use and redistribution.\n\nhttps://pharos.nih.gov/about\n\ncodeine\n\nhttps://pharos.nih.gov/ligands/MFTT55MXH58M\n\nSpringer Nature\n\nhttps://pubchem.ncbi.nlm.nih.gov/substance/341140652\n\nSpringerMaterials\n\nCodein\n\nhttps://materials.springer.com/substanceprofile/docs/smsid_zfckxypvvfpbwwxn\n\nThieme Chemistry\n\nLICENSE\n\nThe Thieme Chemistry contribution within PubChem is provided under a CC-BY-NC-ND 4.0 license, unless otherwise stated.\n\nhttps://creativecommons.org/licenses/by-nc-nd/4.0/\n\nhttps://pubchem.ncbi.nlm.nih.gov/substance/376580179\n\nhttps://pubchem.ncbi.nlm.nih.gov/substance/376425967\n\nWikidata\n\nLICENSE\n\nCCZero\n\nhttps://creativecommons.org/publicdomain/zero/1.0/\n\ncodeine\n\nhttps://www.wikidata.org/wiki/Q174723\n\nWikipedia\n\n\n                    Context: \n                    This excerpt lists external data sources, licenses, and reference links related to codeine, including identifiers from PharmGKB, Pharos, Springer Nature, Thieme Chemistry, Wikidata, Wikipedia, and other databases. It provides supplementary resource information essential for comprehensive chemical, pharmacological, and genetic data retrieval within the broader PubChem drug profile documentation. These details enhance search accuracy by connecting codeine to authoritative external references and licensing terms.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_277", "document_index": 23, "latency_s": 1.6789092999970308, "prompt_toks": 51677, "completion_toks": 78}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    https://pubchem.ncbi.nlm.nih.gov/substance/376425967\n\nWikidata\n\nLICENSE\n\nCCZero\n\nhttps://creativecommons.org/publicdomain/zero/1.0/\n\ncodeine\n\nhttps://www.wikidata.org/wiki/Q174723\n\nWikipedia\n\nCodeine\n\nhttps://en.wikipedia.org/wiki/Codeine\n\nWiley\n\nhttps://pubchem.ncbi.nlm.nih.gov/substance/386264683\n\nMedical Subject Headings (MeSH)\n\nLICENSE\n\nWorks produced by the U.S. government are not subject to copyright protection in the United States. Any such works found on National Library of Medicine (NLM) Web sites may be freely used or reproduced without permission in the U.S.\n\nhttps://www.nlm.nih.gov/copyright.html\n\nCodeine\n\nhttps://www.ncbi.nlm.nih.gov/mesh/68003061\n\nMeSH Tree\n\nhttp://www.nlm.nih.gov/mesh/meshhome.html\n\nAntitussive Agents\n\nhttps://www.ncbi.nlm.nih.gov/mesh/68000996\n\nNarcotics\n\nhttps://www.ncbi.nlm.nih.gov/mesh/68009294\n\nAnalgesics, Opioid\n\nhttps://www.ncbi.nlm.nih.gov/mesh/68000701\n\nPubChem\n\nhttps://pubchem.ncbi.nlm.nih.gov\n\nGHS Classification (UNECE)\n\nGHS Classification\n\n\n                    Context: \n                    This chunk provides key identifiers and legal/license information for codeine, referencing authoritative sources such as Wikidata, Wikipedia, and the U.S. National Library of Medicine, within the comprehensive PubChem compound data document. It highlights relevant databases, licensing terms, and links to related classification systems like MeSH and GHS, supporting efficient retrieval of legal, licensing, and classification details for codeine.\n                "}
{"metadata": {"source": "pubchem", "title": "Codeine | C18H21NO3 | CID 5284371 - PubChem", "description": "Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284371", "drug": "Codeine", "cid": 5284371, "char_count": 196538, "word_count": 26595, "doc_id": "doc_23", "num_chunks": 279, "chunk_id": "23::chunk_278", "document_index": 23, "latency_s": 1.4556909999955678, "prompt_toks": 51580, "completion_toks": 77}, "content": "Drug: Codeine | cid: 5284371\nSource: pubchem | Source description: Codeine | C18H21NO3 | CID 5284371 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    https://www.ncbi.nlm.nih.gov/mesh/68009294\n\nAnalgesics, Opioid\n\nhttps://www.ncbi.nlm.nih.gov/mesh/68000701\n\nPubChem\n\nhttps://pubchem.ncbi.nlm.nih.gov\n\nGHS Classification (UNECE)\n\nGHS Classification\n\nhttp://www.unece.org/trans/danger/publi/ghs/ghs_welcome_e.html\n\nMolGenie\n\nLICENSE\n\nCC-BY 4.0\n\nhttps://creativecommons.org/licenses/by/4.0/\n\nMolGenie Organic Chemistry Ontology\n\nhttps://github.com/MolGenie/ontology/\n\nPATENTSCOPE (WIPO)\n\nSID 403034822\n\nhttps://pubchem.ncbi.nlm.nih.gov/substance/403034822\n\nNCBI\n\nhttps://www.ncbi.nlm.nih.gov/projects/linkout\n\n\n                    Context: \n                    This excerpt provides key classification and licensing information for the opioid analgesic class, including PubChem links, UNECE GHS classification, and the CC-BY 4.0 license from MolGenie. It situates within the broader document's references to chemical classifications, licensing terms, and patent identifiers, supporting comprehensive search and retrieval related to opioid drugs and their regulatory status.\n                "}
